alpha-aminopyridine has been researched along with roflumilast in 473 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 92 (19.45) | 29.6817 |
| 2010's | 288 (60.89) | 24.3611 |
| 2020's | 93 (19.66) | 2.80 |
| Authors | Studies |
|---|---|
| Hatzelmann, A; Schudt, C | 1 |
| Barsig, J; Beume, R; Bundschuh, DS; Eltze, M; Hatzelmann, A; Wollin, L | 1 |
| Bethke, T; Feuring, M; Hörmann, K; Kusma, M; Neuhäuser, M; Schmidt, BM; Stuck, BA; Timmer, WE; Wehling, M | 1 |
| Amin, S; Jeffrey, AM; Krzeminski, J; Luo, FQ; Williams, GM; Zech, K | 1 |
| Bethke, T; Birraux, G; Hatzelmann, A; Leclerc, V; Neuhäuser, M; Timmer, W; Wurst, W | 1 |
| Baraniuk, JN; Tai, CF | 1 |
| Fitzgerald, M; Sturton, G | 1 |
| Giembycz, MA | 1 |
| Reid, P | 1 |
| Beume, R; Foster, PS; Herbert, C; Kumar, RK; Thomas, PS; Webb, DC; Wollin, L; Yang, M | 1 |
| Draheim, R; Egerland, U; Rundfeldt, C | 1 |
| Dai, YR; Xia, XD; Xu, ZJ | 1 |
| Adachi, K; Harada, D; Manabe, H; Ohmori, K; Ohshima, E | 1 |
| Vignola, AM | 1 |
| Banner, KH; Trevethick, MA | 1 |
| Boswell-Smith, V; Jones, NA; Lever, R; Page, CP | 1 |
| Belleguic, C; Cupif, JF; David, M; Depince, A; Gouault, N; Martin-Chouly, CA; Pinel, B | 1 |
| Hanania, NA; Soto, FJ | 1 |
| Chung, C; Dubé, D; Friesen, RW; Huang, Z; Kwok, E; Laliberté, F; Liu, S; Tota, MR; Veilleux, A; Young, A; Zhang, L | 1 |
| Cortijo, J; Morcillo, EJ; Sanz, MJ | 1 |
| Beume, R; Lucattelli, M; Lungarella, G; Martorana, PA; Wollin, L | 1 |
| Bardin, PG; Bredenbröker, D; Leichtl, S; Schmid-Wirlitsch, C; Strydom, K; van Schalkwyk, E; Venter, L; Williams, Z | 1 |
| Cheon, HG; Heo, JY; Kwak, HJ; Nam, JY; Song, JS; Yang, SD | 1 |
| Beume, R; Bundschuh, DS; Marx, D; Wohlsen, A; Wollin, L | 1 |
| Bergmann, JF | 1 |
| Eller, P; Pechlaner, C | 1 |
| Morice, AH | 1 |
| Vassiliou, V | 1 |
| Bhowmik, A; Boyd, AE; Rajakulasingam, K | 1 |
| Burnet, M; Guse, JH; Gutke, HJ; Khobzaoui, M; Renukappa-Gutke, T | 1 |
| Adler, LM; Albrecht, A; Aubier, M; Bousquet, J; Bredenbröker, D; Harnest, U; Hofbauer, P; Izquierdo, JL; Kroemer, B; Rost, KD; Sastre, J | 1 |
| Christie, P | 1 |
| Cheon, HG; Kwak, HJ; No, ZS; Song, JH; Song, JS; Yang, SD | 1 |
| Beume, R; Marx, D; Wohlsen, A; Wollin, L | 1 |
| Afzal, S; Banner, KH; Growcott, EJ; Ren, X; Spink, KG; Wharton, J | 1 |
| Fan Chung, K | 1 |
| Doggrell, SA | 1 |
| Antoniu, SA | 3 |
| Lipworth, B | 1 |
| Bateman, ED; Bredenbröker, D; Harnest, U; Hofbauer, P; Izquierdo, JL; Leichtl, S; Magyar, P; Schmid-Wirlitsch, C | 1 |
| Gagnon, JM; Karish, SB | 1 |
| Husfeld, C; Ji, YH; Klein, U; Linnevers, C; McCluskie, K; Thomas, GR; Yang, A | 1 |
| Boswell-Smith, V; Page, CP | 1 |
| Black, JL; Boustany, S; Burgess, JK; Cox, N; Ge, Q; Johnson, PR; Moir, LM; Oliver, BG; Poniris, MH | 1 |
| Bardin, PG; Bredenbroker, D; Leichtl, S; Louw, C; Schmid-Wirlitsch, C; Venter, L; Williams, Z | 1 |
| Blume, H; Erb, KA; Hermann, R; Knoerzer, D; Lahu, G; Nassr, N; Reutter, F; Schug, B; von Richter, O; Zech, K | 1 |
| Bethke, TD; Hauns, B; Hauschke, D; Hermann, R; Herzog, R; Hünnemeyer, A; Zech, K | 1 |
| Bethke, TD; David, M; Giessmann, T; Hauns, B; Hauschke, D; Hermann, R; Lahu, G; Siegmund, W; Weinbrenner, A; Westphal, K; Zech, K | 1 |
| Bethke, TD; Böhmer, GM; David, M; Fux, R; Gleiter, CH; Hauns, B; Hermann, R; Knoerzer, D; Mörike, K; Wurst, W | 1 |
| Aggarwal, N; Arya, R; Bora, RS; Dastidar, S; Gupta, D; Malik, R; Ray, A; Saini, KS; Singh, V | 1 |
| Hermann, R; Hünnemeyer, A; Knoerzer, D; Lahu, G; Nassr, N; Reutter, F; von Richter, O; Zech, K | 1 |
| Abraham, WM; Claveau, D; Dias, R; Dubé, D; Gallant, M; Girard, Y; Goetghebeur, P; Huang, Z; Jones, T; Lacombe, P; Laliberte, F; Liu, S; Macdonald, D; Mancini, JA; Ng, K; Nicholson, DW; Otu, F; Styhler, A; Turner, MJ; Young, RN; Zhang, L | 1 |
| Bredenbroeker, D; Calverley, PM; Fabbri, LM; McIvor, A; Sanchez-Toril, F; Teichmann, P | 1 |
| de Mey, C; Hermann, R; Herzog, R; Knoerzer, D; Lahu, G; Nassr, N; Péterfai, E; Zech, K | 1 |
| Bethke, TD; Bredenbröker, D; Gauw, SA; Grootendorst, DC; Hiemstra, PS; Hospers, JJ; Rabe, KF; Sterk, PJ; Verhoosel, RM | 1 |
| Hermann, R; Herzog, R; Huennemeyer, A; Lahu, G; von Richter, O; Zech, K | 1 |
| Celly, C; Chapman, RW; House, A; Hunter, JC; Jones, H; Lamca, J; Phillips, JE; Prelusky, D; Richard, J; Ting, P | 1 |
| Caeser, M; Calverley, PM; Lindemann, M; Rutten-van Mölken, MP; van Nooten, FE | 1 |
| Bethke, TD; Giessmann, T; Hauns, B; Hermann, R; Lahu, G; Reutter, F; Siegmund, W; Weinbrenner, A; Westphal, K; Zech, K | 1 |
| Chaves, J; Lerner, A; Makkinje, A; Meyers, JA; Taverna, J | 1 |
| Burgbacher, B; Cerdá-Nicolás, M; Cortijo, J; Hatzelmann, A; Issekutz, AC; Klar, J; Morcillo, EJ; Sanz, MJ; Schatton, E; Schudt, C; Taha, MA; Tenor, H | 1 |
| Barone, FC; Barton, ME; Kikkawa, H; Kinoshita, M; Kuratani, K; Legos, JJ; Shimamura, M; White, RF | 1 |
| Cui, X; Wang, D | 1 |
| Boswell-Smith, V; Spina, D | 1 |
| Choi, HE; Chung, KS; Kwak, HJ; Lim, HJ; Park, HY; Park, KM | 1 |
| Foster, PS; Herbert, C; Hettiaratchi, A; Kumar, RK; Thomas, PS; Webb, DC | 1 |
| Bredenbroeker, D; Hermann, R; Hohlfeld, JM; Krug, N; Lavae-Mokhtari, M; Mueller, M; Schaumann, F; Schoenfeld, K | 1 |
| Douglas, GJ; Evans, SM; Fidock, MD; Hincks, JS; Lamb, DJ; Perros-Huguet, C; Sreckovic, S; Ulrich, K; Walsh, R; Wetterstrand, EM; Yeadon, M | 1 |
| Field, SK | 1 |
| Erb, KJ; Göggel, R; Werner-Klein, M; Westhof, A | 1 |
| Boichot, E; Cayron-Elizondo, V; Gillon, JY; Guénon, I; Lagente, V; Le Quément, C; Valença, S | 1 |
| Abdel-Rahman, SM; Bethke, TD; Gleason, MC; Herzog, R; Kearns, GL; Lahu, G; Neville, KA; Szefler, SJ; Zech, K | 1 |
| Harada, D; Ikeda, Y; Kobayashi, K; Manabe, H; Nosaka, Y | 1 |
| Angell, TD; Ballantine, SP; Cook, CM; Cooper, AW; Dawson, J; Delves, CJ; Hamblin, JN; Jones, PS; Lindvall, M; Lucas, FS; Mitchell, CJ; Neu, MY; Ranshaw, LE; Solanke, YE; Somers, DO; Wiseman, JO | 1 |
| Beume, R; De Cunto, G; Lucattelli, M; Lungarella, G; Lunghi, B; Martorana, PA | 1 |
| Hermann, R; Herzog, R; Huennemeyer, A; Lahu, G; McCracken, N; von Richter, O; Zech, K | 1 |
| Tatlicioğlu, T | 1 |
| Cerdá-Nicolás, M; Cortijo, J; Hatzelmann, A; Iranzo, A; Mata, M; Milara, X; Morcillo, EJ; Ruiz-Saurí, A; Tenor, H | 1 |
| Beume, R; Braun, A; Hoymann, HG; Korolewitz, R; Krug, N; Muller, M; Wollin, L | 1 |
| Ahn, Y; Ertl, RF; Fredriksson, K; Holz, O; Kamio, K; Kawasaki, S; Kobayashi, T; Liu, X; Magnussen, H; Rennard, SI; Skold, CM; Sugiura, H; Togo, S; Wang, X | 1 |
| Böhmer, GM; Gleiter, CH; Hermann, R; Hünnemeyer, A; Lahu, G; Nassr, N; Templin, S; Wenger, M | 1 |
| Elmlinger, M; Hermann, R; Herzog, R; Huennemeyer, A; Lahu, G; McCracken, N; Zech, K | 1 |
| Adnot, S; Eddahibi, S; Hatzelmann, A; Izikki, M; Klar, J; Marx, D; Raffestin, B; Tenor, H; Zadigue, P | 1 |
| Ball, D; Barnette, MS; Capper-Spudich, EA; Davis, TG; Ferrari, L; Knowles, RG; Kou, JP; Lucas, FS; Nials, AT; Peterson, JJ; Podolin, PL; Solanke, YE; Williamson, RA; Wiseman, J; Wren, P | 1 |
| Gauvreau, G; O'Byrne, PM | 1 |
| Calverley, PM; Fabbri, LM; Goehring, UM; Kristiansen, S; Martinez, FJ; Rabe, KF | 1 |
| Brose, M; Bundschuh, DS; Calverley, PM; Fabbri, LM; Izquierdo-Alonso, JL; Martinez, FJ; Rabe, KF | 1 |
| Bosch, DG; Case, SR; Chu, HW; Ge, XN; Martin, RJ; Minor, MN | 1 |
| Gavaldà, A; Lehner, MD; Pagès, L | 1 |
| Duffy, K; Hermann, R; Herzog, R; Huennemeyer, A; Koch, M; Lahu, G; Nassr, N; von Richter, O; Zech, K | 1 |
| Cazzola, M; Matera, MG; Picciolo, S | 1 |
| Wedzicha, JA | 1 |
| Beume, R; Hirrle, A; Marx, D; Tenor, H; Wohlsen, A | 1 |
| Conti, AA; Dilaghi, B; Modesti, PA; Nozzoli, C | 1 |
| Adnot, S; Beume, R; Hatzelmann, A; Lungarella, G; Morcillo, EJ; Sanjar, S; Schudt, C; Tenor, H | 1 |
| Giembycz, MA; Gross, NJ; Rennard, SI | 1 |
| Elmlinger, M; Herzog, R; Hinder, M; Huennemeyer, A; Lahu, G; Nassr, N; Ruth, P | 1 |
| Böhmer, GM; Gleiter, CH; Lahu, G; Mörike, K; Nassr, N; Walz, A | 1 |
| Gillissen, A; Häussermann, A | 1 |
| Rabe, KF | 2 |
| Bahra, P; Banner, KH; Dale, N; Freeman, MS; Hardaker, EL; Poll, C; Raza, F | 1 |
| Kreutzkamp, B | 1 |
| Sanford, M | 1 |
| Field, SK; Giembycz, MA | 1 |
| Diletti, E; Elmlinger, M; Facius, A; Hünnemeyer, A; Lahu, G; McCracken, N; Ruth, P; Zech, K | 1 |
| Cazzola, M | 1 |
| Colbatzky, F; Göggel, R; Nickolaus, P; Peter, D | 1 |
| Beghé, B; Fabbri, LM; Kirkpatrick, P; Yasothan, U | 1 |
| Calverley, PM; Ulrik, CS | 1 |
| Bethke, TD; Huennemeyer, A; Lahu, G; Lemmer, B | 1 |
| Chisholm, A; Crockett, A; Jones, R; Price, D; Ryan, D | 1 |
| Bethke, TD; Lahu, G | 1 |
| Aparicio, J; Izquierdo, JL | 1 |
| Diamant, Z; Spina, D | 1 |
| Bethke, TD; Eckermann, G; Lahu, G; Nassr, N | 1 |
| Bredenbröker, D; Calverley, PM; Goehring, UM; Martinez, FJ; Rennard, SI | 1 |
| Cheon, HG; Cho, YS; Heo, JY | 1 |
| Iwata, M; Kobayashi, M; Kubo, S; Ohtsu, Y; Shimizu, Y; Takahashi, K | 1 |
| Cortijo Gimeno, J; Morcillo Sánchez, E | 1 |
| Izquierdo Alonso, JL | 3 |
| Agustí, A | 1 |
| Cortijo Gimeno, J | 1 |
| Martínez, FJ | 1 |
| Rochat, T | 1 |
| Chazan, RC | 1 |
| Dunkern, T; Hatzelmann, A; Selige, J | 1 |
| Black, PN; Chong, J; Leung, B; Poole, P | 1 |
| Bredenbröker, D; Huennemeyer, A; Lahu, G; Nassr, N | 1 |
| Almagro Mena, P | 1 |
| Bethke, TD; Lahu, G; McCracken, N | 1 |
| de Mey, C; Lahu, G; Nassr, N | 1 |
| Bethke, TD; Böhmer, G; Gleiter, CH; Hünnemeyer, A; Lahu, G | 1 |
| Bateman, ED; Bredenbröker, D; Brose, M; Calverley, PM; Fabbri, LM; Goehring, UM; Rabe, KF | 1 |
| Bethke, TD; Gleiter, CH; Hartmann, M; Hünnemeyer, A; Lahu, G | 1 |
| Bredenbröker, D; Goehring, UM; Hui, DS; Kuo, HP; Kwa, KH; Lee, SD; Mahayiddin, AA; Roa, CC | 1 |
| Bellamy, JF; Buenestado, A; Devillier, P; Faisy, C; Grassin-Delyle, S; Guitard, F; Israël-Biet, D; Naline, E; Sage, E; Tenor, H | 1 |
| Bredenbröker, D; Brose, M; O'Donnell, DE; Webb, KA | 1 |
| Banerjee, R; Cheng, D; Marynchenko, M; Mocarski, M; Sun, SX; Wu, EQ; Yin, D; Yu, AP | 1 |
| Erdmann, E; Michels, G; Pfister, R | 1 |
| Boulet, LP; Bredenbröker, D; Côté, J; Deschesnes, F; Duong, M; Gauvreau, GM; Killian, KJ; Milot, J; O'Byrne, PM; Schmid-Wirlitsch, C; Strinich, T; Watson, RM | 1 |
| Hirano, Y; Kobayashi, M; Kobayashi, S; Kubo, S; Shimizu, Y; Takahashi, K | 1 |
| Iwata, M; Kobayashi, M; Kubo, S; Miyata, K; Shimizu, Y; Takahashi, K | 1 |
| Hünnemeyer, A; Lahu, G; Nassr, N | 1 |
| Şenyiğit, A; Sezgi, C | 1 |
| Berna, P; Bernardelli, P; Bertrand, CP; Carré, C; Chevalier, E; Coupe, M; Dassaud, M; Dupont, M; Fargeau, H; Fric, M; Lagente, V; Leduc, S; Palazzi, X; Richard, V; Vergne, F | 1 |
| Chuang, PY; Deng, Y; He, JC; Klotman, PE; Liu, R; Mallipattu, SK; Wu, Y; Zhong, Y | 1 |
| Hamilton, LA; Hughes, A; Pinner, NA | 1 |
| Vetter, C | 1 |
| Haran, AC; Mansfield, CN; Salmon, M; Sorensen, EA; Tannheimer, SL; Wright, CD | 1 |
| Hussar, DA | 1 |
| Blasco, LM | 2 |
| Kelly Freeman, ML | 1 |
| Herzog, R; Knebel, NG; Reutter, F; Zech, K | 1 |
| Pham, NT; Reid, DJ | 1 |
| Salmon, M; Tannheimer, SL; Wright, CD | 1 |
| Germer, CT; Roewer, N; Schick, MA; Schlegel, N; Waschke, J; Wollborn, J; Wunder, C | 1 |
| Ray, PE | 1 |
| Hertel, N; Humphreys, S; Jameson, K; Kotchie, RW; Radford, M; Samyshkin, Y | 1 |
| Aoshiba, K; Azuma, A; Mizushima, T; Sato, K; Tanaka, K | 1 |
| Calero, C; Gutiérrez, C; López-Campos, JL | 1 |
| Almagro, P; Ancochea, J; Calle, M; López-Campos, JL; Miravitlles, M; Molina, J; Piñera, P; Quintano, JA; Riesco, JA; Simón, A; Soler-Cataluña, JJ; Soriano, JB; Trigueros, JA | 1 |
| Bredenbröker, D; Brose, M; Fabbri, LM; Göke, B; Rabe, KF; Teichmann, P; Wouters, EF | 1 |
| Beume, R; Dieckmann, A; Hanauer, G; Heuser, A; Kaessner, N; Kley, HP; Knaack, D; Vollert, S; Weiss-Haljiti, C | 1 |
| Calverley, PM; Fabbri, LM; Goehring, UM; Martinez, FJ; Rabe, KF | 1 |
| Kullak-Ublick, GA; Leuppi, JD; Taegtmeyer, AB | 1 |
| Bleyer, M; Braun, A; Fieguth, HG; Förster, C; Fuchs, E; Hohlfeld, JM; Kaup, FJ; Knauf, S; Lauenstein, HD; Neuhaus, V; Pfennig, O; Schlumbohm, C; Seehase, S; Sewald, K; Switalla, S | 1 |
| Greulich, T; Koczulla, AR; Vogelmeier, C | 1 |
| Shmelev, EI; Shmeleva, NM | 1 |
| Basma, H; Fahrid, M; Gunji, Y; Holz, O; Kanaji, N; Liu, X; Magnussen, H; Michalski, J; Muller, KC; Nakanishi, M; Nelson, A; Nogel, S; Rabe, KF; Rennard, SI; Sato, T; Toews, ML; Wang, X | 1 |
| Broadley, KJ; Evans, RL; Ford, WR; Kidd, EJ; Knowles, RG; Nials, AT | 1 |
| Lundquist, LM; Metzger, NL | 1 |
| Bredenbröker, D; Brose, M; Calverley, PMA; Goehring, UM; Martinez, FJ; Rabe, KF; Wedzicha, JA | 1 |
| Lone, NA; Oba, Y | 2 |
| Mukkanti, K; Thappali, SR; Vakkalanka, SK; Varanasi, KV; Veeraraghavan, S | 1 |
| Ehlken, B; Kotchie, R; Magnussen, H; Nowak, D; Wecht, S | 1 |
| Huang, L; Lai, K; Li, X; Liu, A; Luo, Z; Mao, F; Shan, W; Wang, Z; Xie, J | 1 |
| Haefliger, S; Ledderhose, S; Radford, M; Samyshkin, Y; Schlunegger, M | 1 |
| Giembycz, MA; Joshi, T; Moodley, T; Newton, R; Rider, CF; Sharma, P; Wilson, SM; Yan, D | 1 |
| Bateman, ED; Briggs, AH; Kotchie, RW; Mörk, AC; Samyshkin, Y | 1 |
| Bredenbröker, D; Calverley, PMA; Cooke, GE; Goehring, UM; Kowey, PR; Lakkis, H; Mosberg, H; Rabe, KF; Rowe, P; White, WB; Zhu, H | 1 |
| Bundschuh, DS; Eigler, A; Endres, S; Lehr, HA; Rieder, F; Siegmund, B | 1 |
| Biller, H; Hohlfeld, JM; Holz, O; Janssen, O; Krug, N; Lavae-Mokhtari, B; Schaumann, F; Welker, L; Winkler, C | 1 |
| Krug, O; Schänzer, W; Thevis, M | 1 |
| Jenkins, C; Leuppi, J; Osthoff, M | 1 |
| Gu, WJ; Pan, L; Yan, JH | 1 |
| Gavaldà, A; Roberts, RS | 1 |
| Basma, H; Farid, M; Feghali-Bostwick, C; Gunji, Y; Ikari, J; Iwasawa, S; Liu, X; Michalski, JM; Nelson, AJ; Nogel, S; Park, JH; Rennard, SI; Schulte, N; Tenor, H; Toews, ML; Wang, X | 1 |
| Horna, O; Toyas, C | 1 |
| Cortijo, J; Martinez, I; Mata, M; Melero, JA; Tenor, H | 1 |
| Barg, M; Geerts, A; Quednau, R; Tersteegen, A; Wunder, F | 1 |
| Beghè, B; Boschetto, P; Fabbri, LM; Nozzoli, C | 1 |
| White, WB | 1 |
| Tashkin, DP | 2 |
| Buenestado, A; Chaumais, MC; Devillier, P; Grassin-Delyle, S; Longchampt, E; Naline, E; Risse, PA; Tenor, H | 1 |
| Dharmarajan, S; Dinavahi, SS; Nyayapathy, S; Perumal, Y; Viswanadha, S | 1 |
| Bolger, GB; Coricor, GE; Courville, CA; Dransfield, MT; Farris, RF; Lambert, JA; Li, Y; Mazur, MM; McNicholas, CM; Raju, SV; Rowe, SM; Smoot, LH; Tang, LP | 1 |
| Brose, M; Calverley, PM; Dransfield, MT; Goehring, UM; Hanania, NA; Karpel, JP; Rowe, P; Zhu, H | 1 |
| Bai, C; Brose, M; Chen, P; Goehring, UM; Hui, F; Kang, J; Li, H; Richard, F; Wang, H; Yang, J; Zhao, L; Zheng, J; Zhong, N; Zhou, X | 1 |
| Facius, A; Lahu, G | 1 |
| Etori, M; Goto, T; Hirahara, K; Maeda, H; Mikkaichi, T; Mizukami, K; Morimoto, K; Nakamura, S; Sogawa, Y; Suzuki, O; Takagi, N; Tsuchida, H; Yoshino, T | 1 |
| Chong, J; Leung, B; Poole, P | 2 |
| Benipal, H; Kale-Pradhan, P; Lipari, M | 1 |
| Boyd, CM; Fain, K; Li, T; Puhan, MA; Singh, S; Varadhan, R; Weiss, CO; Yu, T | 1 |
| Barnes, NC; Rabe, KF; Saetta, M | 1 |
| Iwasaki, S; Yamakage, M; Zhou, J | 1 |
| Calverley, P | 1 |
| Giembycz, MA; Newton, R | 1 |
| Gail, MH | 1 |
| Diezi, L; Livio, F; Renard, D; Rothuizen, LE | 1 |
| Chou, A; D'Urzo, AD | 1 |
| Arban, R; Cavallini, P; Davies, CH; Davis, TG; Gray, FA; Montanari, D; Negri, M; Poffe, A; Rutter, AR; Schneck, J; Vicentini, E; Wren, PB | 1 |
| Bedert, L; Claes, R; De Backer, J; De Backer, W; Hufkens, A; Parizel, PM; Van Holsbeke, C; Vinchurkar, S; Vos, W | 1 |
| Janez, A; Jensterle, M; Kocjan, T | 1 |
| Song, SD; Tang, HF | 1 |
| Bredenbröker, D; Calverley, PM; Goehring, UM; Rennard, SI; Rowe, P; Sun, SX; Tourkodimitris, S | 1 |
| Karpe, PA; Kumar, S; Lodea, S; Tikoo, K | 1 |
| Alen, J; Boland, S; Boumans, N; Bourin, A; Castermans, K; Defert, O; Leysen, D; Panitti, L; Vanormelingen, J | 1 |
| Sinopal'nikov, AI | 1 |
| Eichlerova, A; Medvedova, I; Mikolka, P; Mokra, D; Mokry, J; Prso, M | 1 |
| Badimon, L; Bendjama, K; Casaní, L; Crespo, J; Cubedo, J; Juan-Babot, O; Lawton, M; Padró, T; Vilahur, G | 1 |
| Diez-Ferrer, M; Dorca, J; Huertas, D; López-Sánchez, M; Manresa, F; Montón, C; Muñoz-Esquerre, M; Pomares, X; Santos, S | 1 |
| Babu, CS; Jabaris, SG; Kumar, RS; Narayanan, S; Sumathy, H; Thanikachalam, S | 1 |
| Page, CP | 1 |
| Bruemmer, D; Diebold, S; Endorf, EB; Findeisen, HM; Hess, K; Kahles, F; Lehrke, M; Makowska, A; Marx, J; Marx, N; Stöhr, R; Tilstam, PV | 1 |
| Brose, M; Calverley, PM; Fabbri, LM; Goehring, UM; Martinez, FJ; Rabe, KF | 1 |
| Freire, J; Qian, X; Tarran, R; Tyrrell, J | 1 |
| Kai, H; Lee, BC; Li, JD; Miyata, M; Susuki-Miyata, S; Xu, H; Yan, C | 1 |
| Amin, A; Ellis, JJ; Howe, A; Moll, K; Sun, SX | 1 |
| Bury, A; Konrad, FM; Ngamsri, KC; Reutershan, J; Schick, MA | 1 |
| Amin, AN; Fu, AZ; Huang, X; Sun, SX | 1 |
| Goto, T; Maeda, H; Nakamura, S; Suzuki, O; Yoshino, T | 1 |
| Janez, A; Jensterle, M; Kocjan, T; Salamun, V; Vrtacnik Bokal, E | 1 |
| Domvri, K; Hatzizisi, O; Kikidaki, V; Kioumis, I; Lampaki, S; Liaka, A; Organtzis, J; Papaioannou, A; Petridis, D; Porpodis, K; Tsirgogianni, K; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Boyd, CM; Puhan, MA; Ter Riet, G; Yu, T | 1 |
| Bailey, WC; Bhatt, SP; Blalock, JE; Dransfield, MT; Gaggar, A; Gautney, J; Handley, G; Jackson, PL; King, RW; Viera, L; Wells, JM; Xu, X | 1 |
| Girish, R; Jabaris, SS; Narayanan, S; Saravana Babu, C; Sugumar, M; Sumathy, H; Thanikachalam, M; Thanikachalam, S | 1 |
| Cortijo, J; Milara, J; Monleon, D; Morcillo, E; Tenor, H | 1 |
| Bateman, ED; Buhl, R; O'Byrne, PM; Rabe, KF | 1 |
| Bardin, P; Bredenbröker, D; Gauvreau, G; Kanniess, F; Rabe, KF | 1 |
| Garnock-Jones, KP | 1 |
| Jardim, JR; Stirbulov, R | 1 |
| Cai, Q; Jain, R; Sun, SX; Tan, H | 1 |
| Droege, CA; Ernst, NE; Mulhall, AM; Panos, RJ; Zafar, MA | 1 |
| Ahidjo, BA; Bishai, WR; Maiga, M; Maiga, MC | 1 |
| Aubier, M; Bateman, ED; Bousquet, J; Bredenbröker, D; O'Byrne, PM | 1 |
| Amore, C; Beume, R; Dell'Elba, G; Di Santo, A; Evangelista, V; Martelli, N; Piccoli, A; Tenor, H; Totani, L | 1 |
| Bardin, P; Bateman, ED; Bredenbröker, D; Busse, W; Chervinsky, P; Meltzer, EO; Ohta, K | 2 |
| Aguiar, RCT; Bhatnagar, H; Holder, KN; Kim, SW; Lin, AP; Moritz, AW; Suhasini, AN; Wang, L | 1 |
| Corman, S; Gao, X; Huang, X; Shorr, AF; Sun, SX; Wan, Y | 1 |
| Baumlin, N; Campos, M; Dennis, JS; Ivonnet, P; Krick, S; Salathe, M; Schmid, A | 1 |
| Kim, JH; Kim, SW; Kim, TJ; Kim, YK; Kwon, SS; Lee, SY; Park, CK; Rhee, CK; Yoon, HK | 1 |
| Calverley, P; Celli, BR; Chambers, M; Clark, JF; Hawkins, N; Scott, DA; Thompson, JC; Woods, B | 1 |
| Bridgeman, MB; Dalal, KS | 1 |
| Blalock, JE; Russell, DW; Wells, JM | 1 |
| Han, H; Lee, JH; Park, HJ; Park, JW; Park, KH; Park, YH; Sim, da W | 1 |
| Calverley, PM; Rabe, KF; Wedzicha, JA | 1 |
| Akkerman, S; Blokland, A; Creemers, P; De Vry, J; Prickaerts, J; Sambeth, A; Uz, T; van Duinen, M; Vanmierlo, T | 1 |
| Branà, MP; Clay, E; Page, C; Patacchini, R; Preti, D; Spina, D; Trevisani, M | 1 |
| Bhongir, RK; Egesten, A; Kasetty, G; Papareddy, P | 1 |
| Liang, BM; Liu, CT; Liu, D; Luo, J; Wang, K | 1 |
| Cho, CS; Kim, JH; Kim, SW; Kim, TJ; Lim, JY; Min, CK; Park, CK; Rhee, CK; Yoon, HK | 1 |
| Al-Sawalha, N; Bond, RA; Forkuo, GS; Gonnella, PA; Joshi, R; Kim, H; Knoll, BJ; Parra, S; Penn, RB; Pera, T; Thanawala, VJ; Valdez, D; Walker, JK | 1 |
| Bateman, ED; Goehring, UM; Richard, F; Watz, H | 1 |
| Bedert, L; Claes, R; De Backer, J; De Backer, W; Hajian, B; Hufkens, A; Parizel, PM; Van Holsbeke, C; Vinchurkar, S; Vos, W | 1 |
| Boyd, CM; Fain, KM; Li, T; Puhan, MA; Singh, S; Yu, T | 1 |
| Gumus, M; Ibiloglu, I; Kapan, M; Kaplan, I; Turkoglu, A; Uslukaya, O; Yazgan, UC | 1 |
| Goehring, UM; Snape, SD; Wigger-Alberti, W | 1 |
| Abdolrasulnia, R; Blackwell, TS; Bordenstein, SR; Brucker, RM; Cheng, DS; Clark, PE; Du, RH; Gleaves, L; Han, W; Polosukhin, VV; Polosukhina, D; Richmond, BW; Zhang, Y | 1 |
| De Maeyer, JH; Lefebvre, RA; Pauwelyn, V; Van Colen, I | 1 |
| Bros, M; Cholaszczyńska, A; Montermann, E; Reske-Kunz, AB | 1 |
| Hodgden, JD; Huser, JM | 1 |
| Calzetta, L; Cazzola, M; Matera, MG; Rogliani, P | 2 |
| Hong, YK; Lee, JS; Lee, SD; Lee, SW; Oh, YM; Park, TS | 1 |
| Ghorbanalipoor, S; Hashimoto, T; Jonkman, MF; Kasprick, A; Koga, H; Ludwig, RJ; Pas, HH; Recke, A; Tenor, H; Vidarsson, G; Zillikens, D | 1 |
| Cseke, A; Ecker, GF; Montanari, F; Wlcek, K | 1 |
| Cai, Q; Dai, X; Shao, N; Yang, M; Yuan, L | 1 |
| Cui, X; Hu, P; Huang, J; Jiang, J; Kuang, Y; Zheng, X | 1 |
| Bast, A; Bootsma, HP; Deneer, V; Drent, M | 1 |
| Anzueto, A; Martinez, FJ; McIvor, A; Pizzichini, E; Rabe, KF; Rennard, SI; Sethi, S; Siddiqui, S; Zhu, H | 1 |
| Alagappan, VK; Anzueto, A; Martinez, FJ; McIvor, A; Miller, CJ; Pizzichini, E; Rabe, KF; Reisner, C; Rekeda, L; Rennard, SI; Sethi, S; Siddiqui, S; Zetterstrand, S | 1 |
| Baeck, C; Federici, M; Kahles, F; Kappel, B; Lebherz, C; Lehrke, M; Marx, N; Möllmann, J; Tacke, F; Werner, C | 1 |
| Abdulrahman, AS; Habib, HS; Khabaz, MN; Murad, HA; Rafeeq, MM; Sulaiman, MI | 1 |
| Bellon, H; Heigl, T; Hoet, P; Lammertyn, E; Mathyssen, C; Pilette, C; Sacreas, A; Vanaudenaerde, BM; Vandermeulen, E; Verleden, GM; Verleden, SE; Vos, R; Vriens, H | 1 |
| Hatipoglu, U; Lau, C; Mehta, AC | 1 |
| Hanauer, G; Lahu, G; Mayer, M; Plock, N; Vollert, S | 1 |
| Chou, CL; Knepper, MA; Umejiego, EN; Wang, Y | 1 |
| Donaldson, GC; Goehring, UM; Mackay, AJ; Nip, TK; Patel, ARC; Prasad, N; Sapsford, RJ; Singh, R; Wedzicha, JA | 1 |
| Anzueto, A; Miravitlles, M | 1 |
| Bass, CR; Meaney, DF; Morales, FN; Morrison, B; Vogel, EW | 1 |
| Bruno, R; Claret, L; Facius, A; Krause, A; Lahu, G | 1 |
| Kong, J; Li, H; Mao, L; Qi, L; Sun, B; Wang, J; Wu, Q; Xie, R; Yang, M; Yang, X; Zhang, Z | 1 |
| Golpe, R; Gómez-Rodríguez, M | 1 |
| Fan, CD; Hao, PD; Li, DW; Liu, X; Mao, LL; Sun, BL; Sun, JY; Yang, MF; Yang, XY; Zhang, HT; Zhang, ZY | 1 |
| Hashim, Z; Khan, A; Nath, A | 1 |
| Bogdanos, DP; Mavropoulos, A; Sakkas, LI | 1 |
| Chen, J; Cheng, Y; Feng, H; Wang, H; Xu, J; Zhong, Q; Zou, Z | 1 |
| Calverley, PMA; Fabbri, LM; Martinez, FJ; Rabe, KF | 1 |
| Kim, JW; Kim, SJ; Kim, YA; Kim, YK; Lee, HY; Lee, SH; Yeo, CD | 1 |
| Berra, G; Gianella, P; Glatz, N; Janssens, JP | 1 |
| Ding, H; Dong, L; He, X; Li, N; Liu, B; Liu, Y | 1 |
| Albert, RK; Anzueto, A; Calverley, PMA; Criner, GJ; Hurst, JR; Krishnan, JA; Miravitlles, M; Papi, A; Rabe, KF; Rigau, D; Sliwinski, P; Tonia, T; Vestbo, J; Wedzicha, JA; Wilson, KC | 1 |
| Blokland, A; Heckman, PRA; Prickaerts, J; Schweimer, JV; Sharp, T | 1 |
| Calkovska, A; Kolomaznik, M; Kosutova, P; Mikolka, P; Mokra, D; Rezakova, S | 1 |
| Blokland, A; Heckman, PRA; Prickaerts, J; Sambeth, A; Uz, T; Van Duinen, MA | 1 |
| Blokland, A; Heckman, PRA; Lahu, G; Prickaerts, J; Sambeth, A; Smit, S; Tsai, M; Uz, T; Van Duinen, MA | 1 |
| Calzetta, L; Cavalli, F; Cazzola, M; Matera, MG; Ora, J; Puxeddu, E; Rogliani, P | 1 |
| Benjamin, JT; Blackwell, TS; Cheng, DS; Du, RH; Gleaves, L; Guo, M; Han, W; McKissack, A; Polosukhin, VV; Richmond, BW; van der Meer, R; Zhang, Y | 1 |
| El-Adawy, SA; El-Ashmawy, NE; El-Bahrawy, HA; Khedr, NF | 1 |
| Kertys, M; Kosutova, P; Medvedova, I; Mikolka, P; Mokra, D; Mokry, J; Urbanova, A | 1 |
| Chen, WY; Fang, ZX; Lu, WF; Lv, XD; Shen, LF; Yang, Q | 1 |
| Gao, Y; Liu, DY; Peng, D; Wang, XJ; Wang, ZG; Zhang, HM; Zhang, YX | 1 |
| Liang, BM; Liu, BC; Liu, CT; Liu, D; Luo, J; Yang, D; Yang, J; Yang, L | 1 |
| Bonnel, D; Eriksson, AH; Legouffe, R; Mortensen, RW; Nielsen, KT; Pamelard, F; Stauber, J | 1 |
| Liu, CL; Liu, PR; Liu, Q; Peng, S; Shi, XW; Yan, HZ; Zhang, Y | 1 |
| Davidsen, JR; Henriksen, DP; Pottegård, A; Salvesen, ØNU | 1 |
| Almatary, AM; El Husseiny, WM; El-Sayed, MA; Elmorsy, MA; Selim, KB | 1 |
| Barreiro, E; Casadevall, C; Gea, J; Pascual-Guardia, S; Puig-Vilanova, E; Salazar-Degracia, A | 1 |
| Aftab, B; Amir, N; Fayyaz, A; Hanif, M; Ijaz, H; Mustafa, MI; Qureshi, J; Rasul, A | 1 |
| Alagappan, VKT; Anzueto, A; Bagul, N; Calverley, PMA; Fabbri, LM; Martinez, FJ; McIvor, A; Pizzichini, E; Purkayastha, D; Rabe, KF; Reisner, C; Rennard, SI; Román, J; Sethi, S; Siddiqui, S; Zetterstrand, S | 1 |
| Kardos, P; Mokros, I; Sauer, R; Vogelmeier, CF | 1 |
| Blokland, A; Heckman, PRA; Prickaerts, J; Van Goethem, NP; Van Hagen, BTJ | 1 |
| Facius, A; Gardiner, P; Lahu, G; Marostica, E; Watz, H | 1 |
| Arancio, O; Gulisano, W; Palmeri, A; Puzzo, D; Tropea, MR | 1 |
| Abdelkhalek, AA; Elkasabgy, NA; Mahmoud, AA | 1 |
| Milani, H; Prickaerts, J; Santiago, A; Schepers, M; Soares, LM; Vanmierlo, T; Weffort de Oliveira, RM | 1 |
| Bailie, M; Chibucos, L; Christensen, PJ; Dils, AJ; Hazama, M; Horowitz, JC; Matsuo, T; Muraki, Y; Nikam, S; Sisson, TH; Subbotina, N; Tohyama, K | 1 |
| Celli, BR | 1 |
| Kertys, M; Mokry, J; Urbanova, A | 1 |
| Chen, Y; Gong, S; Huan, W; Li, C; Meng, F; Wu, F; Zhang, G; Zhang, Y | 1 |
| Chen, X; Chen, Y; Fan, J; Fan, L; Liu, S; Luo, P; Xu, X; Ye, J; You, D; Zhang, X | 1 |
| Amaro, MI; Cabral, LM; de Almeida, GS; de Sousa, VP; Healy, AM; Suzuki, ÉY | 1 |
| Al-Majed, AA; Al-Qahtani, BM; Ansari, MN; Bakheit, AH; Wani, TA; Zargar, S | 1 |
| Davies, A; Gibson, D; Kiff, C; Purkayastha, D; Ruiz, S; Varol, N | 1 |
| Alagappan, VKT; Bagul, N; Baraldo, S; Biondini, D; Göhring, UM; Hanauer, G; Pedersen, F; Purkayastha, D; Rabe, KF; Román, J; Saetta, M; Watz, H | 1 |
| Han, MK | 1 |
| Ficker, JH; Graf, J; Jörres, RA; Lucke, T; Nowak, D; Vogelmeier, CF | 1 |
| Agarwal, S; Iyer, AK; Kashaw, SK; Mishra, M; Sau, S; Singh, P | 1 |
| Barnes, PJ; Davies, CM; Donnelly, LE; Dunne, AE; Fenwick, PS; Kawamatawong, T; Tullett, H | 1 |
| Lee, BC; Li, JD; Susuki-Miyata, S; Yan, C | 1 |
| Alexa, I; Alexa-Stratulat, T; Antohe, I; Antoniu, S; Arghir, O; Grigorescu, C | 1 |
| Ding, H; Li, N; Liu, Y; Wang, P; Zhang, P | 1 |
| Azimova, B; Chen, WH; Jiang, PZ; Liu, WL; Njoya, EM; Peng, T; Qiang, Z; Shi, N; Wang, F; Zhang, GL; Zhou, ZY | 1 |
| Fessler, MB | 1 |
| Davison, C; Farah, Y; Gilleen, J; Kerins, S; Lahu, G; Mehta, MA; Ogrinc, F; Reichenberg, A; Shergill, SS; Tsai, M; Uz, T; Valdearenas, L; Williams, SC | 1 |
| Cui, C; Fu, CX; Guo, CX; Hu, P; Huang, J; Kuang, Y; Pei, Q; Yang, GP; Yang, S; Yang, XY | 1 |
| An, B; Hu, J; Huang, L; Li, X; Li, Z; Pan, T | 1 |
| El-Ashrey, MK; El-Zaher, AA; Fouad, MA; Moussa, BA | 1 |
| Adamkov, M; Balentova, S; Calkovska, A; Kolomaznik, M; Kosutova, P; Mikolka, P; Mokra, D | 1 |
| Feng, H; He, B; He, W; Li, S; Wang, C; Wei, M; Wu, X; Zeng, Z | 1 |
| Deng, K; Wang, G; Wang, L | 1 |
| Al-Sajee, D; Gauvreau, GM; Yin, X | 1 |
| Aloliet, RI; Ansari, MN; Ganaie, MA; Hamad, AM; Imam, F; Khan, TH | 1 |
| Blokland, A; Heckman, PRA; Lahu, G; Prickaerts, J; Sambeth, A; Tsai, M; Uz, T; Van Duinen, MA | 1 |
| Chang, X; Hu, LF; Li, JB; Liu, XY; Ma, XJ; Yin, J | 1 |
| Abdelsalam, RM; Ahmed, LA; El-Khatib, AS; Essam, RM | 1 |
| Carson, KA; Hansel, NN; Laube, BL; Paulin, LM; Sharpless, G | 1 |
| Huang, KL; Lan, CC; Peng, CK; Tzeng, IS; Wu, CP; Wu, YK | 1 |
| Giembycz, MA; Hamed, O; Joshi, R; Joshi, T; Mostafa, MM; Newton, R; Yan, D | 1 |
| Davidson, HE; Pleasants, RA; Radlowski, PA | 1 |
| Bridgewood, C; Civelli, M; Facchinetti, F; Higham, A; Lea, S; Li, J; Metryka, A; Singh, D; Villetti, G | 1 |
| Kang, J; Lee, JS; Lee, SD; Lee, SW; Oh, YM; Park, TS | 1 |
| Akgün, M; Araz, Ö; Erol, HS; Halıcı, Z; Kerget, B; Kerget, F; Özmen, S | 1 |
| Borghuis, T; Burgess, JK; Faiz, A; Mudiyanselage, SNHR; Nikolaev, VO; Schmidt, M; Timens, W; van den Berge, M; Zuo, H | 1 |
| Botros, SS; de Koning, HP; El-Lakkany, NM; Hammam, OA; Sabra, AN; Seif El-Din, SH; William, S | 1 |
| Brankin, P; Bunton, DC; Bylesjo, M; Cheyne, L; Child, H; Cowan, K; Finch, M; Gourlay, EM; Hair, J; Low, C; Lynagh, S; Macluskie, G; Mallinson, D; McNeil, M; Palmer, CNA | 1 |
| Banno, A; Lakshmi, SP; Reddy, AT; Reddy, RC | 1 |
| Bolsius, YG; Havekes, R; Heckman, PRA; Meerlo, P; Prickaerts, J; Raven, F; Roig Kuhn, F | 1 |
| Ansari, MN; Rehman, NU; Samad, A | 1 |
| Chen, Z; Gao, Y; Guo, L; He, X; Huang, L; Huang, YY; Li, Z; Liang, J; Liang, SH; Luo, HB; Wu, D; Wu, R; Yu, S; Zhou, Q | 1 |
| Fortescue, R; Janjua, S; Poole, P | 1 |
| Bonato, J; de Oliveira, RMW; de Souza, STF; Prickaerts, J; Raymundi, AM; Sohn, JMB; Stern, CA | 1 |
| Hu, B; Jiang, H; Liao, L; Tan, M; Xu, X | 1 |
| Garabadu, D; Goyal, A | 1 |
| Ansari, MN; Rastogi, S; Saeedan, AS | 1 |
| Afshari, K; Ashraf-Ganjouei, A; Badripour, A; Bagheri, S; Dehpour, AR; Etemadi, A; Faghani, S; Golbakhsh, M; Haghighi, F; Khavandi, MM; Moradi, K; Nikbakhsh, R | 1 |
| Chen, W; Fu, HR; Gao, YF; Wang, H; Wang, L; Wang, XD; Xu, XY; Xu, Y; Zhang, FF; Zhang, HT; Zhang, JG | 1 |
| Berk, DR; Draelos, ZD; Gooderham, MJ; Kempers, SE; Kircik, LH; Lebwohl, MG; Merritt, C; Navale, L; Osborne, DW; Papp, KA; Smith, K; Stein Gold, L; Trotman, ML; Welgus, H; Zirwas, M | 1 |
| Burghuber, OC; Funk, GC; Gleiss, A; Hartl, S; Kreibich, N; Urban, MH | 1 |
| Chen, RN; Zhu, L | 1 |
| Bindu, M; Murugesan, A; Sugin, LJS; Sunil, KN | 1 |
| Abou Saleh, L; Aragon, IV; Boyd, A; Koloteva, A; McDonough, W; Murphy, JM; Rich, J; Richter, W | 1 |
| Agra, LC; Amaro, MI; Cabral, LM; da Silva, AL; de Almeida, GS; de Sousa, VP; Healy, AM; Rocco, PRM; Simon, A; Suzuki, ÉY | 1 |
| Fu, C; Qiu, F; Qu, H; Zhang, K | 1 |
| Berk, DR; Droege, M; Gooderham, M; Merritt, C; Osborne, DW; Papp, KA; Smith, VH; Thurston, AW; Welgus, H | 1 |
| Ffytche, D; Gilleen, J; Kerins, S; Lahu, G; Mehta, MA; Nottage, J; Ogrinc, F; Shergill, SS; Tsai, M; Uz, T; Valdearenas, L; Williams, SC; Yakub, F | 1 |
| Altınöz, S; Çelebier, M; Dogan, A; Süslü, İ | 1 |
| Duan, L; Jiang, J; Liu, Y; Wang, R; Zhao, J | 1 |
| El Tabaa, MM | 1 |
| Chat, VS; Kearns, DG; Uppal, SK; Wu, JJ | 1 |
| An, TJ; Kim, JH; Kim, SY; Park, CK; Rhee, CK; Yoon, H | 1 |
| Kataoka, S; Nakajima, K; Sano, S; Takaishi, M | 1 |
| Brollo, M; Devillier, P; Grassin-Delyle, S; Naline, E; Salvator, H; Tenor, H | 1 |
| Bodkhe, S; Khan, T; Nikam, M; Patel, K; Sherje, AP; Suvarna, V | 1 |
| Mahil, SK; Smith, CH | 1 |
| Shah, CA | 1 |
| Chen, G; Klein, JD; Ma, F; Rodriguez, EL; Sands, JM; Wang, Y | 1 |
| S, SLJ; V, R | 1 |
| Bhat, A; Chidambaram, SB; Essa, MM; Guillemin, GJ; Heng, B; Lovejoy, DB; Sakharkar, MK; Tan, V | 1 |
| Williams, D | 1 |
| Aguiar, RCT; Ethiraj, P; Holder, KN; Jiang, S; Lin, AP; Myers, J; Qiu, Z; Sasi, B | 1 |
| Bonato, JM; de Mendonça, PSB; Meyer, E; Milani, H; Prickaerts, J; Weffort de Oliveira, RM | 1 |
| Cai, N; Li, M; Li, X; Liu, L; Qin, Y; Wang, H; Xu, B; Xu, J | 1 |
| Du, Y; Liu, J; Wu, P; Yang, Z; Zhang, S | 1 |
| Akhtar, A; Bansal, Y; Bishnoi, M; Kuhad, A; Sah, SP; Saroj, P; Singh, R; Sodhi, RK | 1 |
| Bilen, A; Halici, H; Halici, Z; Keskin, F; Keskin, H; Ozkaraca, M; Tavaci, T; Yuksel, TN | 1 |
| Abdel-Wahab, BA; Albarqi, HA; Ali, FEM; Hassanein, EHM; Walbi, IA | 1 |
| Bayraktutan, Z; Bilen, A; Dincer, B; Halici, Z; Keskin, H; Kose, D; Sirin, B; Toktay, E | 1 |
| Akhtar, M; Hasan, N; Najmi, AK; Parvez, S; Yar, MS; Zameer, S | 1 |
| Gilleen, J; Hawkins, PC; Livingston, NR; Mehta, MA; Shergill, SS; Valdearenas, L; Ye, R | 1 |
| Chung, JS; Kim, DY; Kim, SW; Nam, J; Shin, HJ | 1 |
| Ashour, NH; El Sayed, NS; El-Tanbouly, DM; Khattab, MM | 1 |
| Chen, D; Chen, K; Chen, Z; Huang, B; Liu, Q; Sun, Y | 1 |
| Xiao, J; Xu, W; Zhang, J | 1 |
| Egeberg, A; Gyldenløve, M; Meteran, H; Zachariae, C | 3 |
| Gupta, K; Kumari, A; Pandey, S; Sen, P; Singh, G; Singh, R | 1 |
| Abe, S; Aoshiba, K; Fuchikami, JI; Kawagoe, J; Kikuchi, R; Kono, Y; Koyama, N; Maeda, Y; Nakamura, H; Takahashi, M; Tsuji, T; Yamaguchi, K | 1 |
| Bonato, JM; de Oliveira, RMW; Kunieda, JKC; Milani, H; Prickaerts, J; Schepers, M; Vanmierlo, T; Vilhena, ER | 1 |
| Chen, DD; Le Grange, JM; Zhang, JN; Zheng, XF; Zhou, LQ; Zhu, XL | 1 |
| Baek, JJ; Deveau, CM; Kline, H; Yamamoto, BK | 1 |
| Aguiar, JA; Ask, K; Cao, Q; Doxey, AC; Hirota, JA; Hou, V; Huff, RD; Inman, MD; Kim, Y; Miller, MS; Revill, S; Tiessen, N | 1 |
| Lé, AM; Torres, T | 1 |
| Lea, S; Mathioudakis, AG; Singh, D | 1 |
| Feng, X; Fu, J; Fu, Q; He, H; Hu, Y; Huang, K; Li, L; Peng, J; Shen, A; Tao, X; Xu, R; Yang, X; Yu, X; Zhang, C; Zhang, L | 1 |
| Akhtar, M; Hasan, N; Najmi, AK; Parvez, S; Zameer, S | 1 |
| Agis-Torres, Á; Barahona, MV; Benedito, S; Climent, B; Fernandes, VS; Hernández, M; López-Oliva, ME; Martínez, MP; Navarro-Dorado, J; Prieto, D; Recio, P | 1 |
| Alotaibi, NM; Murad, HA; Shaikh-Omar, A | 1 |
| Al-Abbasi, FA; Almalki, WH; Fuloria, NK; Fuloria, S; Gupta, G; Joshi, N; Kazmi, I; Rajput, SS; Singh, Y; Subramaniyan, V | 1 |
| Egeberg, A; Gyldenløve, M | 1 |
| Cai, N; Chen, K; Li, M; Li, X; Qin, Y; Wang, H; Xu, B; Xu, J | 1 |
| Chen, L; Fu, J; Fu, Q; Hu, Y; Huang, K; Tao, X; Xu, R; Yang, X | 1 |
| Egeberg, A; Gyldenløve, M; Thyssen, JP; Zachariae, C | 1 |
| Karakan, T; Ogus, E; Özer, E; Özgür, BC; Surer, H; Yücetürk, CN | 1 |
| Bhat, A; Bishir, M; Chang, SL; Chidambaram, SB; Pandi-Perumal, SR | 1 |
| Liu, C; Liu, P; Peng, S; Shi, X; Wang, J; Zhang, D; Zhang, Y; Zhuang, L | 1 |
| Egeberg, A; Gyldenløve, M; Ring, HC; Thomsen, SF; Zachariae, C | 1 |
| Cabibbo, M; Cavallaro, G; Craparo, EF; Giammona, G; Scialabba, C | 1 |
| Bai, H; Zeng, S; Zou, M | 1 |
| Deng, J; He, X; He, YM; Huang, Y; Huang, YY; Liu, H; Luo, HB; Wang, Q; Xie, X; Yuan, Y; Zhu, J | 1 |
| Albrecht, L; Bagel, J; Berk, DR; Bhatia, N; Burnett, P; Del Rosso, JQ; Devani, AR; Draelos, ZD; Feng, A; Ferris, LK; Gooderham, MJ; Green, LJ; Hebert, AA; Higham, RC; Jones, T; Kempers, SE; Kircik, LH; Lebwohl, MG; Lomaga, M; Moore, AY; Papp, KA; Pariser, DM; Snyder, S; Stein Gold, L; Yamauchi, PS; Zirwas, M | 1 |
| Cordoro, KM | 1 |
| Feldman, SR; Pixley, JN; Schaetzle, T | 1 |
| Fage, S; Johansen, C | 1 |
| Berk, D; Bhatia, N; Bissonnette, R; Draelos, Z; Droege, M; Eads, K; Elias, M; Ferris, L; Gooderham, M; Guenthner, S; Higham, R; Jones, T; Kempers, S; Kircik, L; Koppel, R; Lee, M; Merritt, C; Navale, L; Saint-Cyr Proulx, E; Welgus, H; Zirwas, M | 1 |
| Gooderham, MJ; Hebert, AA; Lebwohl, MG | 1 |
| Collier, MR; Smith, B; Wu, JJ | 1 |
| Adam, DN; Berk, DR; Burnett, P; Draelos, ZD; Higham, RC; Hong, HC; Krupa, D; Lebwohl, MG; Lynde, CW; Nahm, WK; Papp, KA; Pariser, DM; Stein Gold, L; Stewart, D | 1 |
| Casanova Esquembre, A; Grau Echevarría, A; Labrandero Hoyos, C; Martínez-Doménech, A; Peñuelas Leal, R; Pérez Ferriols, A; Sánchez Carazo, JL; Zaragoza Ninet, V | 1 |
| De la Torre Gomar, FJ; Gimeno Castillo, J; Martínez de Lagrán Álvarez de Arcaya, Z; Menéndez Parrón, A | 1 |
| Page, C; Stolfa, I | 1 |
| Gooderham, M; O'Toole, A | 1 |
103 review(s) available for alpha-aminopyridine and roflumilast
| Article | Year |
|---|---|
Phosphodiesterase 4 inhibitors for the treatment of COPD.
Topics: Aminopyridines; Animals; Benzamides; Bronchodilator Agents; Carboxylic Acids; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2002 |
Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far.
Topics: Aminopyridines; Asthma; Benzamides; Bronchodilator Agents; Carboxylic Acids; Cyclohexanecarboxylic Acids; Cyclopropanes; Drug Interactions; Humans; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2002 |
Roflumilast Altana Pharma.
Topics: Aminopyridines; Animals; Anti-Asthmatic Agents; Benzamides; Bronchoconstriction; Bronchodilator Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclopropanes; Humans; Leukocytes; Phosphodiesterase Inhibitors; Structure-Activity Relationship | 2002 |
[Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Asthma; Benzamides; Bronchodilator Agents; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Lung Diseases; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyridines | 2004 |
[Recent development of new drugs for the treatment of allergic diseases].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Animals; Anti-Allergic Agents; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aprepitant; Benzamides; Cell Adhesion Molecules; Chemokines; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Cytokines; Dendritic Cells; Drug Design; Histamine H1 Antagonists; Humans; Hypersensitivity; Immunoglobulin E; Keratinocytes; Mast Cells; Morpholines; Neurosecretory Systems; Omalizumab; Receptors, Tachykinin; Uracil | 2004 |
Roflumilast: APTA 2217, B9302-107, BY 217, BYK 20869.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Drugs, Investigational; Humans; Lung Diseases, Obstructive; Phosphodiesterase Inhibitors | 2004 |
PDE4 inhibitors in COPD--a more selective approach to treatment.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Benzamides; Bronchodilator Agents; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Nitriles; Phosphodiesterase Inhibitors; Pneumonia; Pulmonary Disease, Chronic Obstructive; Rolipram; Theophylline; Treatment Outcome | 2004 |
PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Enzyme Inhibitors; Humans; Inflammatory Bowel Diseases; Nitriles | 2004 |
Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Amides; Aminopyridines; Benzamides; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Indoles; Inflammation; Lung; Nitriles; Nucleotides, Cyclic; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pulmonary Disease, Chronic Obstructive | 2005 |
PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Carboxylic Acids; Cell Adhesion Molecules; Cell Movement; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2005 |
AWD-12-281 (inhaled) (elbion/GlaxoSmithKline).
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Inhalation; Administration, Topical; Amides; Aminopyridines; Animals; Benzamides; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dermatitis, Atopic; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Indoles; Inflammation; Lipopolysaccharides; Ovalbumin; Phosphodiesterase Inhibitors; Psoriasis; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Diseases; Structure-Activity Relationship | 2005 |
Roflumilast: a selective phosphodiesterase 4 inhibitor.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Humans; Lung Diseases, Obstructive; Molecular Structure; Phosphodiesterase Inhibitors | 2005 |
Phosphodiesterase inhibitors in airways disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Aminopyridines; Animals; Anti-Inflammatory Agents; Asthma; Benzamides; Carboxylic Acids; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 5; Cyclic Nucleotide Phosphodiesterases, Type 7; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Isoenzymes; Nitriles; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pulmonary Disease, Chronic Obstructive | 2006 |
Roflumilast for the treatment of chronic obstructive pulmonary disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Drug Evaluation, Preclinical; Drug Therapy, Combination; Humans; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic | 2006 |
The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Anti-Asthmatic Agents; Asthma; Benzamides; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Drug Costs; Drug Interactions; Humans; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2006 |
Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Humans; Phosphodiesterase Inhibitors; Respiration Disorders; Time Factors | 2006 |
Evaluation of PDE4 inhibition for COPD.
Topics: Aminopyridines; Benzamides; Calcium Channel Blockers; Carboxylic Acids; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Nitriles; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Circulation; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2006 |
PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Diarrhea; Humans; Lung; Nausea; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Respiratory System Agents; Treatment Outcome; Vomiting | 2007 |
Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma.
Topics: Administration, Oral; Aminopyridines; Asthma; Benzamides; Clinical Trials as Topic; Cyclopropanes; Drug Administration Schedule; Humans; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2008 |
[Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Benzamides; Carboxylic Acids; Cyclic AMP; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2008 |
PDE4 inhibitors: a review of current developments (2005 - 2009).
Topics: Aminopyridines; Animals; Benzamides; Clinical Trials as Topic; Cyclopropanes; Drug Design; Humans; Inflammation; Nervous System Diseases; Patents as Topic; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors | 2009 |
Roflumilast in chronic obstructive pulmonary disease: evidence from large trials.
Topics: Administration, Inhalation; Administration, Oral; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Clinical Trials as Topic; Cyclopropanes; Drug Administration Schedule; Forced Expiratory Volume; Humans; Lung; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Severity of Illness Index; Smoking Prevention; Treatment Outcome | 2010 |
The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Topics: Administration, Oral; Aminopyridines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Cyclopropanes; Drug Evaluation, Preclinical; Humans; Inflammation; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2010 |
Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.
Topics: Aminopyridines; Benzamides; Clinical Trials as Topic; Cyclopropanes; Forced Expiratory Volume; Humans; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2010 |
[Diseases of the lung and air passages 2010].
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aminopyridines; Asthma; Benzamides; Cyclopropanes; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Indans; Lung Diseases; Lung Neoplasms; Neoplasm Staging; Phosphodiesterase 4 Inhibitors; Pneumonia, Bacterial; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; Quinolones | 2010 |
Roflumilast for the treatment of chronic obstructive pulmonary disease.
Topics: Aminopyridines; Animals; Benzamides; Cyclopropanes; Humans; Lung; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2010 |
[Roflumilast: a new approach to therapy of chronic obstructive pulmonary disease].
Topics: Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Therapy, Combination; Humans; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Respiratory Function Tests | 2010 |
Roflumilast: in chronic obstructive pulmonary disease.
Topics: Administration, Oral; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Humans; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2010 |
Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.
Topics: Adult; Aminopyridines; Animals; Benzamides; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Respiratory Function Tests; Severity of Illness Index | 2010 |
Roflumilast: clinical benefit in patients suffering from COPD.
Topics: Aminopyridines; Benzamides; Clinical Trials as Topic; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Treatment Outcome | 2010 |
The use of roflumilast in COPD: a primary care perspective.
Topics: Adult; Aminopyridines; Benzamides; Bronchodilator Agents; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Humans; Primary Health Care; Pulmonary Disease, Chronic Obstructive | 2010 |
Roflumilast for COPD.
Topics: Aminopyridines; Animals; Benzamides; Bronchodilator Agents; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2010 |
Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.
Topics: Aminopyridines; Animals; Benzamides; Clinical Trials as Topic; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2011 |
PDE4-inhibitors: a novel, targeted therapy for obstructive airways disease.
Topics: Aminopyridines; Benzamides; Clinical Trials, Phase III as Topic; Cyclic Nucleotide Phosphodiesterases, Type 7; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Lung Diseases, Obstructive; Nitriles; Phosphodiesterase 4 Inhibitors | 2011 |
Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
Topics: Administration, Oral; Aged; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Clinical Trials, Phase III as Topic; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Female; Forced Expiratory Volume; Humans; Lung; Male; Middle Aged; Multicenter Studies as Topic; Patient Selection; Phosphodiesterase 4 Inhibitors; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Risk Factors; Treatment Outcome | 2011 |
[Pharmacological profile of roflumilast].
Topics: Airway Remodeling; Aminopyridines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Cell Division; Cilia; Cyclopropanes; Drug Evaluation, Preclinical; Fibroblasts; Humans; Hypertension, Pulmonary; Macrophages; Mice; Molecular Structure; Mucus; Myocytes, Smooth Muscle; Neutrophils; Nicotiana; Oxidants; Oxidative Stress; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Rats; Smoke | 2010 |
[Clinical profile of roflumilast].
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Aminopyridines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Bronchitis; Bronchodilator Agents; Chronic Disease; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Forced Expiratory Volume; Humans; Mice; Middle Aged; Multicenter Studies as Topic; Muscarinic Antagonists; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Rats; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome; Weight Loss | 2010 |
[Impact of new therapeutic options in COPD].
Topics: Aminopyridines; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Benzamides; Cyclopropanes; Drugs, Investigational; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Smoking Cessation | 2010 |
[Phosphodiesterase 4 inhibitors: a new pharmacologic group in the treatment of chronic inflammation of the airways].
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Cilia; Cyclic AMP; Cyclic GMP; Cyclopropanes; Humans; Inflammation; Isoenzymes; Mucins; Oxidative Stress; Phosphodiesterase 4 Inhibitors; Phosphoric Diester Hydrolases; Pulmonary Circulation; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Second Messenger Systems | 2010 |
[Roflumilast: clinical review of a new option for the treatment of inflammation in COPD].
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Gastrointestinal Diseases; Humans; Inflammation; Multicenter Studies as Topic; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Treatment Outcome; Weight Loss | 2010 |
Roflumilast for severe COPD?
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic | 2011 |
New therapeutic options in the management of COPD - focus on roflumilast.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Therapy, Combination; Humans; Lung; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Risk Assessment; Treatment Outcome | 2011 |
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Topics: Administration, Oral; Aminopyridines; Benzamides; Cyclohexanecarboxylic Acids; Cyclopropanes; Forced Expiratory Volume; Humans; Nitriles; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Randomized Controlled Trials as Topic | 2011 |
[Phosphodiesterase-4 inhibitors: roflumilast].
Topics: Adrenergic beta-2 Receptor Agonists; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Therapy, Combination; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Scopolamine Derivatives; Tiotropium Bromide | 2011 |
[Phosphodiesterase-4 inhibitors: a new target in treatment of COPD].
Topics: Aminopyridines; Benzamides; Bronchodilator Agents; Contraindications; Cyclopropanes; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Forced Expiratory Volume; Humans; Mucociliary Clearance; Oxidative Stress; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Smoking | 2011 |
Pharmacokinetic evaluation of roflumilast.
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Clinical Trials as Topic; Cyclopropanes; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2011 |
[A new alternative treatment in COPD: phosphodiesterase-4 inhibitors].
Topics: Administration, Oral; Aminopyridines; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Cyclopropanes; Humans; Inflammation; Phosphodiesterase 4 Inhibitors; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive | 2011 |
Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Topics: Aminopyridines; Animals; Benzamides; Cyclopropanes; Forced Expiratory Volume; Humans; Lung; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Treatment Outcome | 2012 |
Roflumilast: a novel treatment for chronic obstructive pulmonary disease.
Topics: Aminopyridines; Benzamides; Bronchitis, Chronic; Cyclopropanes; Forced Expiratory Volume; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2012 |
Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2012 |
A review of the advances in chronic obstructive pulmonary disease treatment.
Topics: Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Humans; Indans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Randomized Controlled Trials as Topic; Scopolamine Derivatives; Tiotropium Bromide | 2012 |
Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Topics: Aged; Aminopyridines; Benzamides; Cyclopropanes; Disease Progression; Female; Humans; Lung; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Risk Assessment; Treatment Outcome | 2013 |
Chronic obstructive pulmonary disease--a treatable disease.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Aminopyridines; Benzamides; Breathing Exercises; Bronchodilator Agents; Cyclopropanes; Disease Progression; Humans; Muscarinic Antagonists; Noninvasive Ventilation; Oxygen Inhalation Therapy; Pneumonectomy; Pulmonary Disease, Chronic Obstructive; Smoking Cessation | 2013 |
Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Forced Expiratory Volume; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Vital Capacity | 2014 |
Phosphodiesterase-4 inhibitors: a review of current developments (2010 - 2012).
Topics: Administration, Oral; Aminopyridines; Animals; Benzamides; Cyclopropanes; Drug Approval; Drug Delivery Systems; Drug Design; Drug Industry; Humans; Patents as Topic; Phosphodiesterase 4 Inhibitors; Thalidomide | 2013 |
Roflumilast : the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD.
Topics: Aminopyridines; Animals; Benzamides; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2014 |
Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD.
Topics: Acute Disease; Administration, Oral; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Smoking | 2014 |
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Topics: Administration, Oral; Aminopyridines; Benzamides; Cyclohexanecarboxylic Acids; Cyclopropanes; Forced Expiratory Volume; Humans; Nitriles; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Randomized Controlled Trials as Topic | 2013 |
Roflumilast in the management of chronic obstructive pulmonary disease.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Drug Approval; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Spirometry; United States; United States Food and Drug Administration | 2013 |
Current drug treatment, chronic and acute.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aminopyridines; Anti-Bacterial Agents; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Therapy, Combination; Evidence-Based Medicine; Forced Expiratory Volume; Humans; Muscarinic Antagonists; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2014 |
How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Aminopyridines; Benzamides; Cyclopropanes; Drug Therapy, Combination; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2014 |
[Pharmacovigilance update].
Topics: Aminopyridines; Antibodies, Monoclonal, Murine-Derived; Azithromycin; Benzamides; Carbamates; Cyclopropanes; Humans; Nitrofurantoin; Oligopeptides; Pharmacovigilance; Phenylenediamines; Pyridines; Rituximab; Zolpidem | 2014 |
[Progress in PDE4 targeted therapy for inflammatory diseases].
Topics: Aminopyridines; Aminoquinolines; Arthritis; Asthma; Benzamides; Cyclopropanes; Dermatitis; Humans; Inflammation; Inflammatory Bowel Diseases; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Sulfones; Thalidomide; Thiazoles | 2014 |
Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials.
Topics: Aged; Aminopyridines; Benzamides; Cyclopropanes; Dyspnea; Female; Forced Expiratory Volume; Humans; Lung; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Recovery of Function; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2014 |
[Novel trends in pharmacotherapy of chronic obstructive pulmonary disease--prevention of exacerbations (focus on roflumilast)].
Topics: Aminopyridines; Benzamides; Bronchitis, Chronic; Controlled Clinical Trials as Topic; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2014 |
Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents; Asthma; Benzamides; Bronchodilator Agents; Clinical Trials as Topic; Cyclopropanes; Humans; Molecular Targeted Therapy; Naphthyridines; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Theophylline | 2014 |
Roflumilast: A Review in COPD.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Drug Tolerance; Humans; Pulmonary Disease, Chronic Obstructive | 2015 |
Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
Topics: Aminopyridines; Animals; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Delivery Systems; Drug Design; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests | 2015 |
Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis.
Topics: Albuterol; Aminopyridines; Beclomethasone; Benzamides; Benzyl Alcohols; Bronchodilator Agents; Budesonide; Chlorobenzenes; Cyclopropanes; Fluticasone-Salmeterol Drug Combination; Formoterol Fumarate; Glucocorticoids; Humans; Indans; Ipratropium; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Quinolones; Survival Rate; Theophylline; Tiotropium Bromide; Triamcinolone | 2015 |
Disease phenotyping in chronic obstructive pulmonary disease: the neutrophilic endotype.
Topics: Aminopyridines; Azithromycin; Benzamides; Cyclopropanes; Humans; Neutrophils; Phenotype; Pulmonary Disease, Chronic Obstructive | 2016 |
Roflumilast: a review of its use in the treatment of COPD.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Forced Expiratory Volume; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Secondary Prevention; Symptom Flare Up | 2016 |
Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Benzamides; Cyclopropanes; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Prevalence; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Risk Factors; Severity of Illness Index; Treatment Outcome | 2016 |
Clinical Question: In adults with COPD does roflumilast reduce the frequency of exacerbations compDared to standard therapies aIone?
Topics: Adult; Aminopyridines; Benzamides; Cyclopropanes; Disease Progression; Humans; Patient Acuity; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests | 2016 |
The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.
Topics: Aminopyridines; Animals; Benzamides; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Humans; Phenotype; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Research Design | 2016 |
Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Drug Therapy, Combination; Gastrointestinal Diseases; Humans; Medication Adherence; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis.
Topics: Aminopyridines; Benzamides; Chi-Square Distribution; Cyclopropanes; Disease Progression; Forced Expiratory Volume; Humans; Lung; Odds Ratio; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Recovery of Function; Severity of Illness Index; Spirometry; Treatment Outcome; Vital Capacity | 2016 |
What is the role of roflumilast in chronic obstructive pulmonary disease?
Topics: Aminopyridines; Benzamides; Cyclic AMP; Cyclopropanes; Forced Expiratory Volume; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic | 2017 |
Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives.
Topics: Aminopyridines; Autoimmune Diseases; Benzamides; Boron Compounds; Cyclopropanes; Eye Diseases; Humans; Immunologic Factors; Intestinal Diseases; Phosphodiesterase 4 Inhibitors; Skin Diseases; Thalidomide | 2017 |
[New therapeutic options in pulmonary diseases in 2016 : focus on asthma, COPD and idiopathic pulmonary fibrosis (IPF)].
Topics: Aminopyridines; Asthma; Benzamides; Cyclopropanes; Humans; Idiopathic Pulmonary Fibrosis; Lung Diseases; Pulmonary Disease, Chronic Obstructive; Pulmonary Medicine; Therapies, Investigational | 2017 |
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Topics: Administration, Oral; Aminopyridines; Benzamides; Cyclohexanecarboxylic Acids; Cyclopropanes; Disease Progression; Forced Expiratory Volume; Humans; Nitriles; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Randomized Controlled Trials as Topic | 2017 |
Effect of roflumilast on chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2018 |
Efficacy and safety of phosphodiesterase 4 inhibitors in patients with asthma: A systematic review and meta-analysis.
Topics: Aminopyridines; Asthma; Benzamides; Bronchodilator Agents; Cyclopropanes; Forced Expiratory Volume; Headache; Humans; Nausea; Peak Expiratory Flow Rate; Phosphodiesterase 4 Inhibitors | 2018 |
Mini Review: Chronic obstructive pulmonary disease, its new drug treatments and strategies: A review.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Humans; Indans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2018 |
Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap.
Topics: Airway Remodeling; Aminopyridines; Asthma; Benzamides; Cyclopropanes; Forced Expiratory Volume; Humans; Interleukin-17; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2018 |
Roflumilast in patients with advanced chronic obstructive pulmonary disease: towards a better-targeted use.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Disease Progression; Hospitalization; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic | 2019 |
[The application of roflumilast in the tre atment of bronchial asthma].
Topics: Aminopyridines; Asthma; Benzamides; Cyclopropanes; Humans | 2019 |
Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Bronchodilator Agents; Budesonide; Cyclopropanes; Fluticasone; Formoterol Fumarate; Humans; Ipratropium; Muscarinic Antagonists; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Recurrence; Salmeterol Xinafoate; Theophylline; Tiotropium Bromide | 2016 |
An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma.
Topics: Aminopyridines; Asthma; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Humans; Inflammation; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2019 |
Optimizing Drug Therapies in Patients with COPD in the US Nursing Home Setting.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aged; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Female; Humans; Nursing Homes; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; United States | 2019 |
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.
Topics: Administration, Oral; Aminopyridines; Benzamides; Cyclohexanecarboxylic Acids; Cyclopropanes; Diarrhea; Disease Progression; Forced Expiratory Volume; Humans; Middle Aged; Nitriles; Peak Expiratory Flow Rate; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Randomized Controlled Trials as Topic; Thiazoles; Vital Capacity | 2020 |
[Research progress of roflumilast in the treatment of bronchial asthma].
Topics: Aminopyridines; Anti-Asthmatic Agents; Asthma; Benzamides; Cyclopropanes; Humans; Lung | 2020 |
Roflumilast: A potential drug for the treatment of cognitive impairment?
Topics: Aminopyridines; Animals; Benzamides; Cognitive Dysfunction; Cyclopropanes; Humans; Memory; Phosphodiesterase 4 Inhibitors | 2020 |
New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19.
Topics: Aminopyridines; Benzamides; COVID-19 Drug Treatment; Cyclopropanes; Humans; Neprilysin; Pandemics; SARS-CoV-2 | 2020 |
Topical Agents Currently in Phase II or Phase III Trials for Atopic Dermatitis.
Topics: Administration, Cutaneous; Aminopyridines; Benzamides; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Dermatitis, Atopic; Dermatologic Agents; Humans; Nitriles; Pyrazoles; Pyrimidines; Resorcinols; Severity of Illness Index; Skin Cream; Stilbenes; Treatment Outcome | 2020 |
Current insights on clinical efficacy of roflumilast for treatment of COPD, asthma and ACOS.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents; Asthma; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Respiratory System; Treatment Outcome | 2020 |
Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19.
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; COVID-19; COVID-19 Drug Treatment; Cyclopropanes; Cytokines; Inflammation Mediators; Pandemics; Phosphodiesterase 4 Inhibitors | 2021 |
The Role of the Pharmacist in Optimizing Outcomes With Roflumilast, a PDE4 Inhibitor for the Treatment of COPD.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Pharmacists; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life | 2022 |
New Topical Therapies for Psoriasis.
Topics: Administration, Topical; Aminopyridines; Amygdalin; Benzamides; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclopropanes; Dermatologic Agents; Humans; Interleukin-2; MicroRNAs; Nitriles; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Pyrazoles; Pyrimidines; Resorcinols; Stilbenes | 2022 |
Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease.
Topics: Administration, Inhalation; Aminopyridines; Animals; Benzamides; Cyclic AMP; Cyclopropanes; Humans; Inflammation; Isoquinolines; para-Aminobenzoates; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyrimidinones; Sulfonamides | 2021 |
Effects of Roflumilast on Patients with Chronic Obstructive Pulmonary Disease Treated with Inhaled Corticosteroid/Long-Acting
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Diarrhea; Disease Progression; Headache; Humans; Pulmonary Disease, Chronic Obstructive | 2022 |
A Review of Topical Roflumilast for the Treatment of Plaque Psoriasis.
Topics: Adrenal Cortex Hormones; Aminopyridines; Clinical Trials as Topic; Dermatologic Agents; Humans; Immunoglobulin A; Psoriasis; Severity of Illness Index; Treatment Outcome | 2023 |
Oral roflumilast as a therapeutic option for psoriasis, what role does it have? Case report and literature review.
Topics: Administration, Oral; Aminopyridines; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Pulmonary Disease, Chronic Obstructive | 2023 |
Topical Roflumilast for Plaque Psoriasis.
Topics: Adolescent; Adult; Aminopyridines; Benzamides; Emollients; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis | 2023 |
84 trial(s) available for alpha-aminopyridine and roflumilast
| Article | Year |
|---|---|
The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Female; Headache; Humans; Male; Nasal Provocation Tests; Phosphodiesterase Inhibitors; Rhinitis, Allergic, Seasonal | 2001 |
The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Aminopyridines; Analysis of Variance; Asthma, Exercise-Induced; Benzamides; Confidence Intervals; Cross-Over Studies; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Double-Blind Method; Humans; Lipopolysaccharides; Male; Phosphodiesterase Inhibitors; Tumor Necrosis Factor-alpha | 2002 |
Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Adult; Allergens; Aminopyridines; Asthma; Benzamides; Cross-Over Studies; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Phosphodiesterase Inhibitors | 2005 |
Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Aminopyridines; Anti-Inflammatory Agents; Asthma; Beclomethasone; Benzamides; Child; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Probability; Respiratory Function Tests; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2006 |
Efficacy and safety of roflumilast in the treatment of asthma.
Topics: Adolescent; Adult; Aged; Aminopyridines; Anti-Asthmatic Agents; Asthma; Benzamides; Child; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lung; Male; Middle Aged; Phosphodiesterase Inhibitors; Respiratory Function Tests | 2006 |
Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge.
Topics: Administration, Oral; Adolescent; Adult; Allergens; Aminopyridines; Benzamides; Bronchial Hyperreactivity; Bronchial Provocation Tests; Cross-Over Studies; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Forced Expiratory Volume; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Pilot Projects; Treatment Outcome | 2007 |
Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects.
Topics: Adult; Aminopyridines; Anti-Anxiety Agents; Benzamides; Cyclopropanes; Drug Interactions; Humans; Male; Midazolam; Phosphodiesterase Inhibitors | 2007 |
Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Adult; Aminopyridines; Area Under Curve; Benzamides; Cross-Over Studies; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dietary Fats; Fasting; Female; Food-Drug Interactions; Half-Life; Headache; Humans; Male; Phosphodiesterase Inhibitors | 2006 |
Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Interactions; Humans; Male; Phosphodiesterase Inhibitors | 2006 |
Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor.
Topics: Administration, Oral; Aminopyridines; Analysis of Variance; Area Under Curve; Benzamides; Chromatography, High Pressure Liquid; Cross-Over Studies; Cyclopropanes; Dose-Response Relationship, Drug; Drug Tolerance; Female; Humans; Linear Models; Male; Mass Spectrometry; Phosphodiesterase Inhibitors; Time Factors | 2007 |
Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Aluminum Hydroxide; Aminopyridines; Antacids; Benzamides; Cross-Over Studies; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Drug Interactions; Female; Humans; Magnesium Hydroxide; Male; Middle Aged; Phosphodiesterase Inhibitors | 2007 |
Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
Topics: Aged; Aminopyridines; Benzamides; Cohort Studies; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Female; Health Status; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Respiratory Function Tests; Severity of Illness Index; Treatment Outcome | 2007 |
Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis.
Topics: Adult; Aged; Aminopyridines; Analysis of Variance; Area Under Curve; Benzamides; Cyclopropanes; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies | 2007 |
Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD.
Topics: Aged; Aminopyridines; Benzamides; Biomarkers; Cell Count; Cross-Over Studies; Cyclopropanes; Double-Blind Method; Eosinophils; Female; Forced Expiratory Volume; Humans; Male; Microcirculation; Middle Aged; Neutrophils; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Sputum | 2007 |
Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Adult; Aminopyridines; Anti-Anxiety Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzamides; Cross-Over Studies; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C19; Female; Fluvoxamine; Half-Life; Humans; Male; Middle Aged; Mixed Function Oxygenases; Phosphodiesterase Inhibitors; Tablets; Time Factors | 2007 |
A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
Topics: Aged; Aminopyridines; Benzamides; Cost-Benefit Analysis; Cyclopropanes; Double-Blind Method; Female; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quality of Life | 2007 |
The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Inhalation; Adult; Aminopyridines; Anti-Inflammatory Agents; Area Under Curve; Benzamides; Budesonide; Cross-Over Studies; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Drug Interactions; Humans; Male | 2007 |
Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial.
Topics: Administration, Oral; Adult; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchoalveolar Lavage; Cyclopropanes; Endotoxins; Eosinophils; Female; Humans; Inflammation; Lung; Lymphocytes; Macrophages; Male; Neutrophils; Phosphodiesterase Inhibitors; Young Adult | 2008 |
Single-dose pharmacokinetics of roflumilast in children and adolescents.
Topics: Adolescent; Aminopyridines; Anti-Asthmatic Agents; Area Under Curve; Benzamides; Child; Chromatography, High Pressure Liquid; Cross-Over Studies; Cyclopropanes; Dose-Response Relationship, Drug; Electrocardiography; Female; Half-Life; Humans; Male; Phosphodiesterase Inhibitors; Tandem Mass Spectrometry | 2008 |
Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide.
Topics: Adult; Aminopyridines; Antifungal Agents; Benzamides; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Female; Humans; Ketoconazole; Male; Phosphodiesterase 4 Inhibitors; Young Adult | 2008 |
The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.
Topics: Acetates; Administration, Oral; Adolescent; Adult; Aminopyridines; Anti-Asthmatic Agents; Benzamides; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Humans; Leukotriene Antagonists; Male; Middle Aged; Phosphodiesterase Inhibitors; Quinolines; Sulfides | 2009 |
Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide.
Topics: Administration, Oral; Adult; Aminopyridines; Anti-Bacterial Agents; Area Under Curve; Benzamides; Cross-Over Studies; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Erythromycin; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Young Adult | 2009 |
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
Topics: Administration, Oral; Adrenergic beta-Agonists; Aged; Aminopyridines; Analysis of Variance; Benzamides; Cholinergic Antagonists; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Regression Analysis; Severity of Illness Index; Smoking; Treatment Outcome; Vital Capacity | 2009 |
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
Topics: Administration, Inhalation; Administration, Oral; Aged; Albuterol; Aminopyridines; Analysis of Variance; Benzamides; Bronchodilator Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Regression Analysis; Salmeterol Xinafoate; Scopolamine Derivatives; Severity of Illness Index; Smoking; Tiotropium Bromide; Treatment Outcome; Vital Capacity | 2009 |
Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide.
Topics: Administration, Oral; Adult; Aminopyridines; Benzamides; Cyclopropanes; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP3A; Drug Interactions; Enoxacin; Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Young Adult | 2011 |
High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast.
Topics: Administration, Oral; Adult; Aminopyridines; Area Under Curve; Benzamides; Biological Availability; Cross-Over Studies; Cyclopropanes; Humans; Male; Phosphodiesterase 4 Inhibitors | 2011 |
Absence of pharmacokinetic interaction between roflumilast and digoxin in healthy adults.
Topics: Adult; Aminopyridines; Anti-Arrhythmia Agents; Benzamides; Cross-Over Studies; Cyclopropanes; Digoxin; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Phosphodiesterase 4 Inhibitors; Young Adult | 2012 |
Supra-therapeutic doses of roflumilast have no effect on cardiac repolarization in healthy subjects.
Topics: Adolescent; Adult; Aminopyridines; Benzamides; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Heart Conduction System; Heart Rate; Humans; Male; Middle Aged; Young Adult | 2011 |
Lack of pharmacokinetic and pharmacodynamic interactions of roflumilast with (R, S)-warfarin in healthy adult subjects.
Topics: Adult; Aminopyridines; Anticoagulants; Benzamides; Cyclopropanes; Double-Blind Method; Drug Interactions; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Stereoisomerism; Warfarin | 2011 |
No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study.
Topics: Adult; Aminopyridines; Benzamides; Blood Glucose; Bronchodilator Agents; Cardiac Output; Cyclopropanes; Drug Interactions; Electrocardiography; Ethanolamines; Formoterol Fumarate; Heart; Heart Rate; Humans; Male; Phosphodiesterase 4 Inhibitors; Potassium | 2011 |
Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults.
Topics: Adolescent; Adult; Aminopyridines; Area Under Curve; Benzamides; Blood Pressure; Body Temperature; Bronchodilator Agents; Cross-Over Studies; Cyclopropanes; Cytochrome P-450 CYP1A2; Drug Interactions; Female; Half-Life; Heart Rate; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Quality Control; Theophylline; Therapeutic Equivalency; Young Adult | 2011 |
Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Dyspnea; Female; Humans; Lung; Male; Middle Aged; Placebos; Pulmonary Disease, Chronic Obstructive; Regression Analysis | 2011 |
Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study.
Topics: Administration, Oral; Adult; Aminopyridines; Area Under Curve; Benzamides; Case-Control Studies; Creatinine; Cyclopropanes; Female; Half-Life; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Prospective Studies; Renal Insufficiency; Severity of Illness Index | 2011 |
Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anti-Inflammatory Agents; Asian People; Benzamides; Cyclopropanes; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Treatment Outcome; Vital Capacity | 2011 |
Physiological effects of roflumilast at rest and during exercise in COPD.
Topics: Aged; Airway Resistance; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Administration Schedule; Dyspnea; Exercise; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Physical Endurance; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Rest; Severity of Illness Index | 2012 |
Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects.
Topics: Adolescent; Adult; Allergens; Aminopyridines; Asthma; Benzamides; Cross-Over Studies; Cyclopropanes; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pneumonia; Pulmonary Eosinophilia; Young Adult | 2011 |
Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus.
Topics: Adult; Aged; Aminopyridines; Area Under Curve; Benzamides; Blood Glucose; Body Weight; C-Peptide; Cyclopropanes; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glycated Hemoglobin; Glycerol; Homeostasis; Humans; Insulin; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Sample Size | 2012 |
Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
Topics: Adrenal Cortex Hormones; Adult; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Poisson Distribution; Pulmonary Disease, Chronic Obstructive; Respiratory Therapy; Severity of Illness Index; Treatment Outcome | 2012 |
Efficacy of roflumilast in the COPD frequent exacerbator phenotype.
Topics: Aged; Aminopyridines; Benzamides; Cyclopropanes; Diarrhea; Disease Progression; Double-Blind Method; Endpoint Determination; Female; Humans; Incidence; Male; Middle Aged; Phenotype; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Treatment Outcome; Weight Loss | 2013 |
[Roflumilast in combination with long-acting bronchodilators in the management of patients with severe and very severe COPD. A cost-effectiveness analysis for Germany].
Topics: Aminopyridines; Benzamides; Bronchodilator Agents; Cost-Benefit Analysis; Cyclopropanes; Drug Combinations; Female; Germany; Health Care Costs; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Prevalence; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2013 |
Cardiovascular safety in patients receiving roflumilast for the treatment of COPD.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Benzamides; Cardiovascular Diseases; Cyclopropanes; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Prevalence; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Switzerland; Treatment Outcome | 2013 |
Low-dose endotoxin inhalation in healthy volunteers--a challenge model for early clinical drug development.
Topics: Administration, Inhalation; Adolescent; Adult; Aminopyridines; Benzamides; Cyclopropanes; Dose-Response Relationship, Drug; Drug Design; Endotoxins; Female; Healthy Volunteers; Humans; Lipopolysaccharides; Male; Middle Aged; Monocytes; Neutrophils; Phosphodiesterase 4 Inhibitors; Pneumonia; Reproducibility of Results; Research Design; Sputum; Young Adult | 2013 |
Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study.
Topics: Aged; Aminopyridines; Asian People; Benzamides; Cyclopropanes; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Treatment Outcome; White People | 2014 |
Implementing lessons learned from previous bronchial biopsy trials in a new randomized controlled COPD biopsy trial with roflumilast.
Topics: Aminopyridines; Benzamides; Biomarkers; Biopsy; Cyclopropanes; Double-Blind Method; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2014 |
The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Cholinergic Agents; Cyclopropanes; Exercise Tolerance; Humans; Lung; Phenotype; Phosphodiesterase 4 Inhibitors; Plethysmography; Pulmonary Disease, Chronic Obstructive; Spirometry; Treatment Outcome | 2014 |
Phosphodiesterase 4 inhibition as a potential new therapeutic target in obese women with polycystic ovary syndrome.
Topics: Adult; Aminopyridines; Benzamides; Body Weight; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Insulin; Menstrual Cycle; Metformin; Molecular Targeted Therapy; Obesity; Phosphodiesterase 4 Inhibitors; Polycystic Ovary Syndrome; Sex Hormone-Binding Globulin; Testosterone | 2014 |
Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Aminopyridines; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Bronchodilator Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Glucocorticoids; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Treatment Outcome; Vital Capacity | 2015 |
Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study.
Topics: Adult; Aminopyridines; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Female; Glucagon-Like Peptide-1 Receptor; Humans; Liraglutide; Metformin; Obesity; Phosphodiesterase 4 Inhibitors; Polycystic Ovary Syndrome; Weight Loss | 2015 |
A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease.
Topics: Aged; Aminopyridines; Benzamides; Bronchitis, Chronic; Cyclopropanes; Double-Blind Method; Epoxide Hydrolases; Exercise Tolerance; Female; Forced Expiratory Volume; Glycine; Humans; Inflammation; Male; Middle Aged; Neutrophils; Phosphodiesterase 4 Inhibitors; Proline; Prolyl Oligopeptidases; Pulmonary Disease, Chronic Obstructive; Quality of Life; Serine Endopeptidases; Signal Transduction; Spirometry; Sputum; Treatment Outcome; Vital Capacity | 2015 |
Roflumilast for asthma: Efficacy findings in mechanism of action studies.
Topics: Adolescent; Adult; Aged; Aminopyridines; Asthma; Benzamides; Cross-Over Studies; Cyclopropanes; Double-Blind Method; Forced Expiratory Volume; Humans; Middle Aged; Phosphodiesterase 4 Inhibitors; Sputum; Young Adult | 2015 |
Roflumilast for asthma: Efficacy findings in non-placebo-controlled comparator and dosing studies.
Topics: Acetates; Adolescent; Adult; Aged; Aminopyridines; Asthma; Beclomethasone; Benzamides; Child; Cyclopropanes; Double-Blind Method; Forced Expiratory Volume; Humans; Middle Aged; Phosphodiesterase 4 Inhibitors; Quinolines; Sulfides; Young Adult | 2015 |
Roflumilast for asthma: Efficacy findings in placebo-controlled studies.
Topics: Adolescent; Adult; Aged; Aminopyridines; Asthma; Beclomethasone; Benzamides; Child; Cyclopropanes; Double-Blind Method; Forced Expiratory Volume; Humans; Middle Aged; Phosphodiesterase 4 Inhibitors; Quality of Life; Young Adult | 2015 |
Roflumilast for asthma: Safety findings from a pooled analysis of ten clinical studies.
Topics: Adolescent; Adult; Aged; Aminopyridines; Asthma; Benzamides; Child; Cyclopropanes; Humans; Middle Aged; Phosphodiesterase 4 Inhibitors; Young Adult | 2015 |
Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma.
Topics: Acetates; Aged; Aged, 80 and over; Aminopyridines; Anti-Asthmatic Agents; Asthma; Benzamides; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Leukocyte Count; Leukotriene Antagonists; Male; Middle Aged; Quinolines; Risk Factors; Severity of Illness Index; Spirometry; Sulfides; Treatment Outcome | 2016 |
Functional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS/LABA/LAMA.
Topics: Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Pulmonary Ventilation; Respiratory Function Tests; Severity of Illness Index; Tissue Distribution; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aminopyridines; Benzamides; Chronic Disease; Cyclopropanes; Dermatologic Agents; Female; Humans; Male; Middle Aged; Ointments; Phosphodiesterase 4 Inhibitors; Psoriasis; Skin Tests; Treatment Outcome; Young Adult | 2016 |
Efficacy and Safety of Roflumilast in Korean Patients with COPD.
Topics: Aged; Aminopyridines; Asian People; Benzamides; Cyclopropanes; Double-Blind Method; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Republic of Korea; Respiratory Function Tests; Treatment Outcome | 2016 |
Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Aminopyridines; Benzamides; Bronchitis, Chronic; Bronchodilator Agents; Budesonide, Formoterol Fumarate Drug Combination; Cyclopropanes; Disease Progression; Double-Blind Method; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Humans; Lung; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Research Design; Severity of Illness Index; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vital Capacity | 2016 |
Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Bronchitis, Chronic; Bronchodilator Agents; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Respiratory Therapy; Severity of Illness Index | 2016 |
Pharmacokinetic/Pharmacodynamic Modeling of the PDE4 Inhibitor TAK-648 in Type 2 Diabetes: Early Translational Approaches for Human Dose Prediction.
Topics: Adult; Aminopyridines; Animals; Area Under Curve; Benzamides; Cyclopropanes; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Male; Mice; Middle Aged; Models, Biological; Phosphodiesterase 4 Inhibitors; Translational Research, Biomedical | 2017 |
Randomized Double-Blind Controlled Trial of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease.
Topics: Aged; Aged, 80 and over; Aminopyridines; Benzamides; Cyclopropanes; Disease Progression; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Leukocyte Count; London; Male; Middle Aged; Neutrophils; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Sputum; Treatment Outcome | 2017 |
Modeling and Simulation of Pivotal Clinical Trials Using Linked Models for Multiple Endpoints in Chronic Obstructive Pulmonary Disease With Roflumilast.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Benzamides; Clinical Trials as Topic; Computer Simulation; Cyclopropanes; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Models, Biological; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2017 |
Effect of roflumilast in patients with severe COPD and a history of hospitalisation.
Topics: Aged; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Cyclopropanes; Female; Forced Expiratory Volume; Hospitalization; Humans; Male; Middle Aged; Phenotype; Phosphodiesterase 4 Inhibitors; Prognosis; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Regression Analysis; Respiration Disorders; Treatment Outcome | 2017 |
Acute administration of roflumilast enhances sensory gating in healthy young humans in a randomized trial.
Topics: Adolescent; Adult; Aminopyridines; Animals; Benzamides; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Electroencephalography; Evoked Potentials, Auditory; Female; Humans; Male; Nausea; Phosphodiesterase 4 Inhibitors; Sensory Gating; Vomiting; Young Adult | 2018 |
Acute administration of roflumilast enhances immediate recall of verbal word memory in healthy young adults.
Topics: Adolescent; Adult; Aminopyridines; Benzamides; Cross-Over Studies; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Electroencephalography; Evoked Potentials; Female; Healthy Volunteers; Humans; Male; Mental Recall; Phosphodiesterase 4 Inhibitors; Protein Kinases; Surveys and Questionnaires; Verbal Learning; Young Adult | 2018 |
Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study.
Topics: Administration, Inhalation; Administration, Oral; Aged; Albuterol; Aminopyridines; Benzamides; Cyclopropanes; Drug Therapy, Combination; Exercise Tolerance; Female; Glucocorticoids; Glycopyrrolate; Humans; Lung Volume Measurements; Male; Middle Aged; Muscarinic Antagonists; Phosphodiesterase 4 Inhibitors; Pilot Projects; Pregnenediones; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2018 |
Effect and safety of roflumilast for chronic obstructive pulmonary disease in Chinese patients.
Topics: Aged; Aminopyridines; Asian People; Benzamides; Cyclopropanes; Double-Blind Method; Drug Monitoring; Female; Humans; Male; Middle Aged; Outcome and Process Assessment, Health Care; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Respiratory Function Tests; Surveys and Questionnaires | 2018 |
Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aminopyridines; Benzamides; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Treatment Outcome | 2018 |
Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA.
Topics: Aged; Aged, 80 and over; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Therapy, Combination; Female; Forced Expiratory Volume; Germany; Health Status; Humans; Lung; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quality of Life; Severity of Illness Index; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2018 |
Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Double-Blind Method; Drug Monitoring; Drug Tolerance; Humans; Models, Biological; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2018 |
Design and characterization of emulsified spray dried alginate microparticles as a carrier for the dually acting drug roflumilast.
Topics: A549 Cells; Administration, Inhalation; Adult; Alginates; Aminopyridines; Benzamides; beta-Cyclodextrins; Bronchodilator Agents; Cell Survival; Cross-Over Studies; Cyclopropanes; Cytokines; Drug Carriers; Drug Design; Drug Liberation; Female; Glucuronic Acid; Glycerophosphates; Hexuronic Acids; Humans; Lung; Male; Middle Aged; Particle Size; Phosphodiesterase 4 Inhibitors; Spirometry | 2018 |
Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
Topics: Aged; Aminopyridines; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Benzamides; Biopsy; Bronchodilator Agents; CD8-Positive T-Lymphocytes; Cyclopropanes; Double-Blind Method; Eosinophils; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Mucous Membrane; Pulmonary Disease, Chronic Obstructive; Respiratory System | 2018 |
An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients.
Topics: Adult; Aminopyridines; Animals; Benzamides; Brain; Cognition; Cognition Disorders; Cross-Over Studies; Cyclopropanes; Double-Blind Method; Female; Humans; Male; Memory, Episodic; Memory, Short-Term; Middle Aged; Phosphodiesterase 4 Inhibitors; Prefrontal Cortex; Schizophrenia | 2021 |
Pharmacokinetics of single- and multiple-dose roflumilast: an open-label, three-way crossover study in healthy Chinese volunteers.
Topics: Adolescent; Adult; Aminopyridines; Benzamides; China; Cross-Over Studies; Cyclopropanes; Dose-Response Relationship, Drug; Female; Healthy Volunteers; Humans; Male; Middle Aged; Molecular Structure; Tablets; Young Adult | 2018 |
Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study.
Topics: Aged; Aged, 80 and over; Aminopyridines; Benzamides; Cognition; Cross-Over Studies; Cyclic AMP; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Healthy Aging; Humans; Memory; Mental Recall; Middle Aged; Phosphodiesterase 4 Inhibitors; Stimulation, Chemical; Verbal Behavior | 2019 |
Mucociliary Clearance in Former Tobacco Smokers with Both Chronic Obstructive Pulmonary Disease and Chronic Bronchitis and the Effect of Roflumilast.
Topics: Aged; Aminopyridines; Benzamides; Bronchitis, Chronic; Cross-Over Studies; Cyclopropanes; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Mucociliary Clearance; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Reproducibility of Results; Tobacco Smoking | 2019 |
Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD.
Topics: Age Factors; Aged; Aminopyridines; Benzamides; Cyclopropanes; Female; Humans; Male; Medication Adherence; Phosphodiesterase 4 Inhibitors; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Risk Factors; Seoul; Single-Blind Method; Time Factors; Treatment Outcome | 2019 |
Trial of Roflumilast Cream for Chronic Plaque Psoriasis.
Topics: Administration, Topical; Adult; Aminopyridines; Benzamides; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Female; Humans; Least-Squares Analysis; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Skin Cream | 2020 |
Effects of roflumilast on arterial stiffness in COPD (ELASTIC): A randomized trial.
Topics: Aged; Aminopyridines; Benzamides; Biomarkers; Cyclopropanes; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Intention to Treat Analysis; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Treatment Outcome; Vascular Stiffness | 2021 |
Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.
Topics: Adult; Aged; Aminopyridines; Benzamides; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Skin Cream; Treatment Outcome | 2020 |
The effects of roflumilast, a phosphodiesterase type-4 inhibitor, on EEG biomarkers in schizophrenia: A randomised controlled trial.
Topics: Adult; Aminopyridines; Benzamides; Cognition; Cognitive Dysfunction; Cross-Over Studies; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Double-Blind Method; Drug Monitoring; Electroencephalography; Evoked Potentials; Female; Humans; Male; Mental Processes; Phosphodiesterase 4 Inhibitors; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome | 2021 |
Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia.
Topics: Adult; Aged; Aminopyridines; Benzamides; Cognitive Dysfunction; Cross-Over Studies; Cyclopropanes; Dorsolateral Prefrontal Cortex; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Phosphodiesterase 4 Inhibitors; Prefrontal Cortex; Schizophrenia | 2021 |
The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study.
Topics: Aminopyridines; Benzamides; Dermatitis, Atopic; Double-Blind Method; Emollients; Humans; Proof of Concept Study; Severity of Illness Index; Treatment Outcome | 2023 |
Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial.
Topics: Aminopyridines; Benzamides; Double-Blind Method; Emollients; Humans; Psoriasis; Severity of Illness Index; Treatment Outcome | 2023 |
286 other study(ies) available for alpha-aminopyridine and roflumilast
| Article | Year |
|---|---|
Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; CD4-Positive T-Lymphocytes; Cyclic Nucleotide Phosphodiesterases, Type 1; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Cytokines; Dendritic Cells; Eosinophils; Humans; Immunosuppressive Agents; In Vitro Techniques; Luminescent Measurements; Lymphocyte Activation; Monocytes; Neutrophils; Phosphodiesterase Inhibitors; Pyridazines; Tumor Necrosis Factor-alpha | 2001 |
In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Aminopyridines; Animals; Anti-Asthmatic Agents; Benzamides; Bronchoconstriction; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dose-Response Relationship, Drug; Guinea Pigs; Lipopolysaccharides; Lung Diseases, Obstructive; Male; Ovalbumin; Phosphodiesterase Inhibitors; Rats; Rats, Inbred BN; Rats, Sprague-Dawley; Trachea; Tumor Necrosis Factor-alpha | 2001 |
Lack of DNA binding in the rat nasal mucosa and other tissues of the nasal toxicants roflumilast, a phosphodiesterase 4 inhibitor, and a metabolite, 4-amino-3,5-dichloropyridine, in contrast to the nasal carcinogen 2,6-dimethylaniline.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Aniline Compounds; Animals; Benzamides; Carcinogens; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; DNA; DNA Adducts; Hydroxybenzoates; Male; Molecular Structure; Mutagenicity Tests; Mutagens; Nasal Mucosa; Phosphorus Radioisotopes; Pyridines; Rats; Rats, Wistar | 2002 |
Inhibition of phosphodiesterase 4 in allergic rhinitis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Humans; Phosphodiesterase Inhibitors; Rhinitis, Allergic, Seasonal | 2002 |
Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma.
Topics: Aminopyridines; Animals; Anti-Asthmatic Agents; Asthma; Benzamides; Bronchi; Cyclopropanes; Dexamethasone; Disease Models, Animal; Immunohistochemistry; Inflammation; Mice; Mice, Inbred BALB C | 2003 |
Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Amides; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Cytokines; Humans; Indoles; Interleukin-2; Interleukin-4; Interleukin-5; Leukocytes, Mononuclear; Nitriles; Phosphodiesterase Inhibitors; Polyps; Tumor Necrosis Factor-alpha | 2004 |
[Selective phosphodiesterase 4 inhibition. Controlling inflammation--also in patients with COPD].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dose-Response Relationship, Drug; Forced Expiratory Volume; Humans; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2004 |
The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adolescent; Adult; Aminopyridines; Benzamides; Cell Adhesion; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Endothelial Cells; Endothelium, Vascular; Female; Humans; In Vitro Techniques; Leukocyte Elastase; Male; Matrix Metalloproteinase 9; Neutrophils; Peroxidase; Phosphodiesterase Inhibitors; Tumor Necrosis Factor-alpha | 2005 |
Synthesis and potential anti-inflammatory activity of some tetrahydrophthalazinones.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Drug Design; Drug Evaluation, Preclinical; Humans; Lipopolysaccharides; Molecular Structure; Phosphodiesterase Inhibitors; Phthalazines; Pulmonary Disease, Chronic Obstructive; Rolipram; Stereoisomerism; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2004 |
Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenylyl Cyclases; Aminopyridines; Benzamides; Biotransformation; Blotting, Western; Cell Line; Chlorides; Colforsin; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Cystic Fibrosis Transmembrane Conductance Regulator; Enzyme Activation; Humans; Iodine Radioisotopes; Isoquinolines; Phosphodiesterase Inhibitors; Sulfonamides | 2005 |
Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke.
Topics: Administration, Oral; Aminopyridines; Animals; Benzamides; Bronchoalveolar Lavage Fluid; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Goblet Cells; Hyperplasia; Interleukin-10; Macrophages; Male; Mice; Mice, Inbred C57BL; Phosphodiesterase Inhibitors; Pulmonary Emphysema; Smoking | 2005 |
Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation.
Topics: Aminopyridines; Animals; Benzamides; Cells, Cultured; Cyclopropanes; Electrophoretic Mobility Shift Assay; Enzyme Activation; Interleukin-1; JNK Mitogen-Activated Protein Kinases; Lipopolysaccharides; Macrophages, Peritoneal; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Nitrites; p38 Mitogen-Activated Protein Kinases; Phosphodiesterase Inhibitors; Toxicity Tests; Tumor Necrosis Factor-alpha | 2005 |
Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Aminopyridines; Animals; Benzamides; Bronchial Spasm; Bronchoalveolar Lavage Fluid; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Disease Models, Animal; Immunization; Male; Neutrophils; Nitriles; Ovalbumin; Phosphodiesterase Inhibitors; Pneumonia; Pyridines; Rats; Respiratory Hypersensitivity; Rolipram; Serotonin; Treatment Outcome; Tumor Necrosis Factor-alpha | 2006 |
Roflumilast for chronic obstructive pulmonary disease.
Topics: Aminopyridines; Attitude of Health Personnel; Benzamides; Cyclopropanes; Humans; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Treatment Failure | 2005 |
Roflumilast for chronic obstructive pulmonary disease.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2005 |
Roflumilast for chronic obstructive pulmonary disease.
Topics: Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Forced Expiratory Flow Rates; Humans; Inflammation; Pulmonary Disease, Chronic Obstructive; Smoking | 2005 |
Roflumilast for chronic obstructive pulmonary disease.
Topics: Aminopyridines; Attitude of Health Personnel; Benzamides; Cyclopropanes; Forced Expiratory Volume; Humans; Pulmonary Disease, Chronic Obstructive; Reproducibility of Results | 2005 |
Roflumilast for chronic obstructive pulmonary disease.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Aminopyridines; Benzamides; Cyclopropanes; Forced Expiratory Volume; Humans; Pulmonary Disease, Chronic Obstructive | 2005 |
The inhibitory effects of roflumilast on lipopolysaccharide-induced nitric oxide production in RAW264.7 cells are mediated by heme oxygenase-1 and its product carbon monoxide.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Animals; Benzamides; Blotting, Western; Carbon Monoxide; Cell Line; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Enzyme-Linked Immunosorbent Assay; Heme Oxygenase (Decyclizing); Lipopolysaccharides; Macrophages; Mice; Nitric Oxide; Organometallic Compounds; Tumor Necrosis Factor-alpha | 2005 |
Roflumilast inhibition of pulmonary leukotriene production and bronchoconstriction in ovalbumin-sensitized and -challenged Guinea pigs.
Topics: Allergens; Aminopyridines; Animals; Benzamides; Bronchoalveolar Lavage Fluid; Bronchoconstriction; Cyclopropanes; Cysteine; Disease Models, Animal; Guinea Pigs; Leukotriene B4; Leukotrienes; Male; Ovalbumin; Phosphodiesterase Inhibitors; SRS-A | 2005 |
Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Apoptosis; Benzamides; Cell Proliferation; Cells, Cultured; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 1; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; DNA; Gene Expression; Humans; Iloprost; Intracellular Membranes; Metalloproteases; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphodiesterase Inhibitors; Pulmonary Artery | 2006 |
Phosphodiesterase 4 inhibition with roflumilast: a new approach to pulmonary disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Aminopyridines; Anti-Inflammatory Agents; Asthma; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Humans; Lung Diseases; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pulmonary Ventilation; Randomized Controlled Trials as Topic | 2006 |
Phosphodiesterase type 4 inhibitors for asthma: a real breakthrough or just expensive theophylline?
Topics: Aminopyridines; Asthma; Benzamides; Cyclopropanes; Humans; Phosphodiesterase Inhibitors; Randomized Controlled Trials as Topic; Theophylline | 2006 |
Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Cytokines; Humans; Inflammation; Interleukin-8; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Phosphodiesterase Inhibitors; Pyridines | 2006 |
A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Aminopyridines; Benzamides; Bronchi; Cells, Cultured; Collagen Type I; Connective Tissue Growth Factor; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Extracellular Matrix Proteins; Fibronectins; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Lung; Middle Aged; Myocytes, Smooth Muscle; RNA, Messenger | 2006 |
A reporter gene assay for screening of PDE4 subtype selective inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Benzamides; Cell Line; Cloning, Molecular; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Cytoplasm; Dose-Response Relationship, Drug; Humans; Immunohistochemistry; Isoenzymes; Kinetics; Luciferases; Phosphodiesterase Inhibitors; Recombinant Fusion Proteins; Regulatory Sequences, Nucleic Acid; Rolipram; Transfection; U937 Cells | 2007 |
L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Animals; Apoenzymes; Ascaris suum; Asthma; Benzamides; Bronchoconstriction; Carboxylic Acids; Cognition Disorders; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Guinea Pigs; Humans; Inhibitory Concentration 50; Injections, Intraperitoneal; Interferon-gamma; Male; Molecular Structure; Nitriles; Ovalbumin; Polymerase Chain Reaction; Quinolines; Rats; Sensitivity and Specificity; Sheep | 2007 |
Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Inhalation; Aminopyridines; Animals; Anti-Allergic Agents; Benzamides; Bronchoalveolar Lavage Fluid; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Lung; Ovalbumin; Peak Expiratory Flow Rate; Phosphodiesterase Inhibitors; Pulmonary Edema; Rats; Rats, Inbred BN; Respiratory Hypersensitivity; Time Factors; Vital Capacity | 2007 |
Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Apoptosis; Benzamides; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Dexamethasone; Gene Expression Regulation, Leukemic; Hematopoietic System; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitriles; Phosphodiesterase Inhibitors; Receptors, Glucocorticoid; Rolipram | 2007 |
Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability.
Topics: Aminopyridines; Animals; Benzamides; Capillary Permeability; CD11b Antigen; Cell Adhesion; Cell Adhesion Molecules; Cell Communication; Cell Line; Cells, Cultured; Cyclopropanes; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Leukocytes; Lipopolysaccharides; Male; Mesenteric Veins; Neutrophils; Phosphodiesterase Inhibitors; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Selectins; Tumor Necrosis Factor-alpha | 2007 |
Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and mice.
Topics: Aminopyridines; Animals; Antidiarrheals; Benzamides; Cold Temperature; Cyclopropanes; Defecation; Gastrointestinal Motility; Irritable Bowel Syndrome; Loperamide; Male; Mice; Mice, Inbred C57BL; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Rats; Rats, Sprague-Dawley; Restraint, Physical; Rolipram; Stress, Psychological | 2008 |
PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways.
Topics: Aminopyridines; Animals; Apoptosis; Base Sequence; Benzamides; Cell Line; Cells, Cultured; Cyclic AMP-Dependent Protein Kinases; Cyclopropanes; Guanine Nucleotide Exchange Factors; Myocytes, Cardiac; Nitric Oxide; Nitric Oxide Donors; Nitroprusside; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; rap1 GTP-Binding Proteins; Rats; RNA, Small Interfering; Rolipram; Signal Transduction | 2008 |
Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma.
Topics: Aminopyridines; Animals; Anti-Asthmatic Agents; Asthma; Benzamides; Bronchi; Chronic Disease; Cyclopropanes; Cytokines; Dexamethasone; Disease Models, Animal; Female; Humans; Inflammation; Mice; Mice, Inbred BALB C; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Specific Pathogen-Free Organisms | 2008 |
Anti-inflammatory modulation of chronic airway inflammation in the murine house dust mite model.
Topics: Aminopyridines; Androstadienes; Animals; Anti-Inflammatory Agents; Asthma; Benzamides; Bronchoalveolar Lavage; Cyclopropanes; Dermatophagoides pteronyssinus; Dexamethasone; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluticasone; Glucocorticoids; Inflammation; Mice; Mice, Inbred BALB C; Phosphodiesterase Inhibitors; Prednisolone | 2008 |
Development and characterisation of a novel and rapid lung eosinophil influx model in the rat.
Topics: Alum Compounds; Aminopyridines; Animals; Anti-Inflammatory Agents; Asthma; Benzamides; Bronchoalveolar Lavage Fluid; Budesonide; Cyclopropanes; Dibenzazepines; Disease Models, Animal; Eosinophils; Histamine H1 Antagonists; Imidazoles; Ketotifen; Lung; Mice; Mice, Inbred BALB C; Ovalbumin; Phosphodiesterase Inhibitors; Prednisolone; Rats; Rats, Inbred BN | 2008 |
The selective MMP-12 inhibitor, AS111793 reduces airway inflammation in mice exposed to cigarette smoke.
Topics: Aminopyridines; Animals; Benzamides; Bronchoalveolar Lavage Fluid; Chemokine CXCL1; Cyclopropanes; Inflammation; Interleukin-6; Lipopolysaccharides; Male; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Protease Inhibitors; Respiratory System; Smoking | 2008 |
Curative effects of phosphodiesterase 4 inhibitors cilomilast, roflumilast, and rolipram in dermatitis mouse model.
Topics: Aminopyridines; Animals; Benzamides; Carboxylic Acids; Cyclohexanecarboxylic Acids; Cyclopropanes; Dermatitis; Dermatitis, Contact; Disease Models, Animal; Eosinophil Peroxidase; Interleukin-4; Male; Mice; Mice, Inbred BALB C; Nitriles; Peroxidase; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Picryl Chloride; Rolipram | 2008 |
Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors.
Topics: Aminopyridines; Animals; Benzamides; Chemistry, Pharmaceutical; Crystallography, X-Ray; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Drug Design; Humans; Leukocytes, Mononuclear; Models, Biological; Models, Chemical; Phosphodiesterase 4 Inhibitors; Pyrazoles; Pyridines; Pyrrolidinones; Rats; Rolipram; Tumor Necrosis Factor-alpha | 2008 |
Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice.
Topics: Aminopyridines; Animals; B-Lymphocytes; Benzamides; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclopropanes; Dendritic Cells; Dose-Response Relationship, Drug; Immunity, Innate; Immunohistochemistry; Lung; Male; Mice; Mice, Inbred C57BL; Models, Animal; Neutrophils; Peroxidase; Phosphodiesterase Inhibitors; Pulmonary Emphysema; T-Lymphocytes; Tobacco Smoke Pollution | 2008 |
Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury.
Topics: Aminopyridines; Animals; Benzamides; Bleomycin; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Cyclopropanes; Disease Models, Animal; Lung; Lung Injury; Male; Mice; Mice, Inbred C57BL; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Fibrosis; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Effects of the phosphodiesterase type 4 inhibitor roflumilast on early and late allergic response and airway hyperresponsiveness in Aspergillus-fumigatus-sensitized mice.
Topics: Aminopyridines; Animals; Antigens, Fungal; Aspergillus fumigatus; Asthma; Benzamides; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Cyclopropanes; Disease Models, Animal; Eosinophils; Female; Leukocyte Count; Lymphocytes; Methacholine Chloride; Mice; Mice, Inbred BALB C; Neutrophils; Phosphodiesterase 4 Inhibitors; Pneumonia; Respiratory Hypersensitivity; Respiratory Mechanics | 2009 |
PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts.
Topics: Adult; Aminopyridines; Benzamides; Cells, Cultured; Chemotaxis; Collagen; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclooxygenase 1; Cyclooxygenase 2; Cyclopropanes; Dinoprostone; Drug Synergism; Fibroblasts; Fibronectins; Humans; Lung; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Fibrosis; Rolipram; Transforming Growth Factor beta1 | 2009 |
Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats.
Topics: Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Hypertension, Pulmonary; Hypoxia; Male; Monocrotaline; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Rats; Rats, Wistar | 2009 |
The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in
Topics: Aminopyridines; Animals; Benzamides; Carboxylic Acids; Cyclohexanecarboxylic Acids; Cyclopropanes; Ferrets; Humans; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Neutrophils; Nitriles; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pica; Piperazines; Pyridines; Rats; Rats, Inbred Lew; Receptors, Adrenergic, alpha-2; Rolipram; Tumor Necrosis Factor-alpha; Vomiting | 2009 |
Phosphodiesterase-4 inhibition in COPD.
Topics: Aminopyridines; Benzamides; Bronchodilator Agents; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Drug Therapy, Combination; Humans; Patient Selection; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Research Design; Treatment Outcome | 2009 |
Roflumilast increases Clara cell secretory protein in cigarette smoke-exposed mice.
Topics: Aminopyridines; Animals; Benzamides; Blotting, Western; Bronchoalveolar Lavage Fluid; Cyclopropanes; Down-Regulation; Immunoenzyme Techniques; Male; Mice; Mice, Inbred AKR; Mitogen-Activated Protein Kinases; Phosphodiesterase Inhibitors; Proliferating Cell Nuclear Antigen; Pulmonary Disease, Chronic Obstructive; Smoking; Statistics, Nonparametric; Uteroglobin | 2009 |
Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects.
Topics: Adult; Aminopyridines; Area Under Curve; Benzamides; Chromatography, High Pressure Liquid; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Male; Metabolic Clearance Rate; Phosphodiesterase Inhibitors; Rifampin | 2009 |
The role of the phosphodiesterase-4 inhibitor, roflumilast, in chronic obstructive pulmonary disease.
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchitis; Cyclopropanes; Forced Expiratory Volume; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2010 |
Effect of cyclic AMP-elevating agents on airway ciliary beat frequency in central and lateral airways in rat precision-cut lung slices.
Topics: Aminopyridines; Animals; Benzamides; Colforsin; Cyclic AMP; Cyclopropanes; Dissection; Enzyme Inhibitors; Female; In Vitro Techniques; Lung; Mucociliary Clearance; Phosphodiesterase 4 Inhibitors; Prostaglandins; Rats; Rats, Wistar; Rolipram; Terbutaline; Time Factors | 2010 |
New evidence in pulmonary and preventive medicine.
Topics: Adrenergic beta-Agonists; Albuterol; Aminopyridines; Benzamides; Breast Neoplasms; Bronchodilator Agents; Cyclopropanes; Disease Progression; Early Detection of Cancer; Evidence-Based Medicine; Female; Humans; Papillomavirus Vaccines; Preventive Medicine; Primary Prevention; Pulmonary Disease, Chronic Obstructive; Salmeterol Xinafoate; Scopolamine Derivatives; Secondary Prevention; Tiotropium Bromide; Uterine Cervical Neoplasms | 2010 |
No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine.
Topics: Adult; Aminopyridines; Benzamides; Cimetidine; Cross-Over Studies; Cyclopropanes; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Humans; Male; Phosphodiesterase 4 Inhibitors | 2011 |
Exposing rodents to a combination of tobacco smoke and lipopolysaccharide results in an exaggerated inflammatory response in the lung.
Topics: Adrenal Cortex Hormones; Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; Bronchoalveolar Lavage Fluid; Budesonide; Cyclopropanes; Disease Models, Animal; Inflammation Mediators; Lipopolysaccharides; Lung; Male; Mucus; Neutrophil Infiltration; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pneumonia; Pulmonary Edema; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Time Factors; Tobacco Smoke Pollution | 2010 |
Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.
Topics: Adult; Aged; Aminopyridines; Area Under Curve; Benzamides; Cyclopropanes; Female; Humans; Male; Middle Aged; Models, Biological; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2010 |
The divergent opinions of regulatory authorities on roflumilast are puzzling but we need new drugs for treating chronic obstructive pulmonary disease.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Drug Approval; Drug Design; Europe; Humans; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; United States; United States Food and Drug Administration | 2010 |
Inhibition of cyclooxygenase-2 prevents adverse effects induced by phosphodiesterase type 4 inhibitors in rats.
Topics: Acute Lung Injury; Aminopyridines; Animals; Benzamides; Bronchoalveolar Lavage Fluid; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cyclopropanes; Diclofenac; Disease Models, Animal; Humans; Inflammation; Lipopolysaccharides; Male; Neutrophil Infiltration; Phosphodiesterase 4 Inhibitors; Pyrazoles; Rats; Rats, Wistar | 2011 |
Roflumilast.
Topics: Aminopyridines; Animals; Benzamides; Cyclopropanes; Humans; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic | 2010 |
Chronopharmacology of roflumilast: a comparative pharmacokinetic study of morning versus evening administration in healthy adults.
Topics: Administration, Oral; Adult; Aminopyridines; Area Under Curve; Benzamides; Chromatography, High Pressure Liquid; Circadian Rhythm; Cyclopropanes; Drug Administration Schedule; Drug Tolerance; Humans; Intestinal Absorption; Safety; Therapeutic Equivalency | 2010 |
Topical effects of roflumilast on 1-chloro-2,4-dinitrobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice.
Topics: Aminopyridines; Animals; Benzamides; Body Weight; Cell Line; Cell Proliferation; Cyclic AMP; Cyclopropanes; Dermatitis, Atopic; Dinitrochlorobenzene; Down-Regulation; Female; Humans; Immunoglobulin E; Interleukin-1alpha; Irritants; Local Lymph Node Assay; Lymph Nodes; Mice; Mice, Inbred BALB C; Phosphodiesterase 4 Inhibitors; Skin; Th1 Cells | 2010 |
ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity.
Topics: Adrenergic alpha-2 Receptor Antagonists; Aminopyridines; Animals; Benzamides; Blood Cells; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Enzyme Inhibitors; Ferrets; Interleukin-4; Lipopolysaccharides; Macrophages, Alveolar; Naphthyridines; Nitriles; Pneumonia; Rats; Tumor Necrosis Factor-alpha; Vomiting | 2011 |
[Introduction. COPD treatment].
Topics: Aminopyridines; Benzamides; Cyclopropanes; Forecasting; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2010 |
[Pulmonary medicine. Two new drugs for the treatment of COPD].
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Cyclopropanes; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2011 |
[New drugs in chronic obstructive pulmonary disease].
Topics: Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Therapy, Combination; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2011 |
The differential impact of PDE4 subtypes in human lung fibroblasts on cytokine-induced proliferation and myofibroblast conversion.
Topics: Aminopyridines; Benzamides; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Cytokines; Fibroblast Growth Factor 2; Fibroblasts; Gene Expression Profiling; Humans; Interleukin-1beta; Isoenzymes; Lung; Myofibroblasts; Phosphodiesterase 4 Inhibitors; Pulmonary Fibrosis; Pyridines; RNA, Small Interfering; Transfection; Transforming Growth Factor beta | 2011 |
[Introduction].
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2011 |
Roflumilast (Daliresp) for COPD.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2011 |
Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide.
Topics: Aminopyridines; Benzamides; Cells, Cultured; Chemokines; Cyclopropanes; Dinoprostone; Epoprostenol; Female; Humans; Lipopolysaccharides; Macrophages, Alveolar; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Phosphoric Diester Hydrolases; Tumor Necrosis Factor-alpha | 2012 |
Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.
Topics: Aminopyridines; Benzamides; Bronchodilator Agents; Cost-Benefit Analysis; Cyclopropanes; Drug Combinations; Health Services; Health Status; Humans; Markov Chains; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Reproducibility of Results; Scopolamine Derivatives; Severity of Illness Index; Time Factors; Tiotropium Bromide | 2011 |
Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor.
Topics: Aminopyridines; Animals; Anti-Asthmatic Agents; Benzamides; Bronchial Hyperreactivity; Bronchoconstriction; Cyclohexanecarboxylic Acids; Cyclopropanes; Disease Models, Animal; Eosinophils; Female; Guinea Pigs; In Vitro Techniques; Lung; Male; Naphthyridines; Nitriles; Ovalbumin; Phosphodiesterase 4 Inhibitors; Rats; Trachea | 2012 |
Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor.
Topics: Adult; Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; Bronchoalveolar Lavage Fluid; Cells, Cultured; Chemokine CXCL1; Cyclohexanecarboxylic Acids; Cyclopropanes; Glucocorticoids; Humans; Lipopolysaccharides; Male; Naphthyridines; Neutrophils; Nitriles; Phosphodiesterase 4 Inhibitors; Pneumonia; Prednisolone; Rats; Rats, Wistar; Superoxides; Tumor Necrosis Factor-alpha | 2012 |
Lack of involvement of type 7 phosphodiesterase in an experimental model of asthma.
Topics: Aminopyridines; Animals; Asthma; Benzamides; Bronchoalveolar Lavage Fluid; Cyclic Nucleotide Phosphodiesterases, Type 7; Cyclopropanes; Cytokines; Disease Models, Animal; Female; Immunoglobulin E; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout | 2012 |
[COPD and diabetes mellitus. Does pulmonary medication modify blood glucose metabolism?].
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Blood Glucose; Cholinergic Antagonists; Cyclopropanes; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Insulin Resistance; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2011 |
Roflumilast enhances the renal protective effects of retinoids in an HIV-1 transgenic mouse model of rapidly progressive renal failure.
Topics: AIDS-Associated Nephropathy; Aminopyridines; Animals; Benzamides; Benzoates; Cell Differentiation; CREB-Binding Protein; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclopropanes; Cytoprotection; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Kidney Tubules; Male; Mice; Mice, Transgenic; Phosphodiesterase 4 Inhibitors; Phosphorylation; Proteinuria; Receptors, Retinoic Acid; Renal Insufficiency; Retinoic Acid Receptor alpha; Signal Transduction; Tetrahydronaphthalenes; Time Factors | 2012 |
[New goals in COPD treatment. From symptom control to prevention of exacerbations].
Topics: Aminopyridines; Benzamides; Cyclopropanes; Disease Progression; Humans; Long-Term Care; Phosphodiesterase 4 Inhibitors; Prognosis; Pulmonary Disease, Chronic Obstructive | 2011 |
Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Cyclopropanes; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ethanolamines; Formoterol Fumarate; Glucocorticoids; Humans; Inflammation; Inhibitory Concentration 50; Leukocytes, Mononuclear; Lipopolysaccharides; Male; Phosphodiesterase 4 Inhibitors; Salmeterol Xinafoate; Tumor Necrosis Factor-alpha | 2012 |
New drugs 2012 part I.
Topics: Aminopyridines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Benzazepines; Benzimidazoles; Benzofurans; Ceftaroline; Cephalosporins; Cyclopropanes; Drug Approval; Drug Combinations; Humans; Imidazoles; Indoles; Isoindoles; Linagliptin; Lurasidone Hydrochloride; Macrolides; Oxadiazoles; Piperazines; Proline; Purines; Quinazolines; Thiazoles; United States; Vilazodone Hydrochloride | 2012 |
If roflumilast inhibits the innate immunity in the stable patient, what about infection?
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Immunity, Innate; Immunocompromised Host; Opportunistic Infections; Phosphodiesterase 4 Inhibitors | 2013 |
Clinical Considerations for Roflumilast: A New Treatment for COPD.
Topics: Administration, Oral; Aminopyridines; Benzamides; Bronchitis, Chronic; Cyclic AMP; Cyclopropanes; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2012 |
Sensitive quantification of roflumilast and roflumilast N-oxide in human plasma by LC-MS/MS employing parallel chromatography and electrospray ionisation.
Topics: Aminopyridines; Benzamides; Chromatography, High Pressure Liquid; Cyclopropanes; Humans; Linear Models; Liquid-Liquid Extraction; Male; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2012 |
Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts.
Topics: Actins; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Cells, Cultured; Chemokine CCL5; Chemokine CXCL10; Connective Tissue Growth Factor; Cyclopropanes; Endothelin-1; Fibroblasts; Fibronectins; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Indans; Inflammation; Lung; Phosphodiesterase 4 Inhibitors; Pulmonary Fibrosis; Quinolones; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2012 |
Phosphodiesterase-4 inhibition as a therapeutic approach to treat capillary leakage in systemic inflammation.
Topics: Aminopyridines; Animals; Benzamides; Capillaries; Capillary Permeability; Cyclic AMP; Cyclopropanes; Endothelium, Vascular; Inflammation; Lipopolysaccharides; Male; Microcirculation; Phosphodiesterase 4 Inhibitors; Rats; Rats, Sprague-Dawley; Rolipram; Vascular Diseases | 2012 |
Can we cure HIV-1-associated nephropathy in transgenic mice?
Topics: AIDS-Associated Nephropathy; Aminopyridines; Animals; Benzamides; Benzoates; Cyclopropanes; Female; HIV Infections; HIV-1; Kidney Tubules; Male; Phosphodiesterase 4 Inhibitors; Renal Insufficiency; Tetrahydronaphthalenes | 2012 |
Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Algorithms; Aminopyridines; Benzamides; Bronchodilator Agents; Cost-Benefit Analysis; Cyclopropanes; Decision Support Techniques; Drug Costs; Drug Therapy, Combination; Health Care Costs; Humans; Markov Chains; Models, Economic; Muscarinic Antagonists; Outcome and Process Assessment, Health Care; Phosphodiesterase 4 Inhibitors; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Severity of Illness Index; State Medicine; Time Factors; Treatment Outcome; United Kingdom | 2012 |
Alternatives to indicating roflumilast and the chronic obstructive pulmonary disease classification.
Topics: Aminopyridines; Autoimmunity; Benzamides; Bronchodilator Agents; Cholinergic Antagonists; Comorbidity; Cyclopropanes; Drug Synergism; Humans; Immunocompromised Host; Infection Control; Inflammation; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Smoking; Tumor Necrosis Factor-alpha | 2012 |
Superiority of PC-SOD to other anti-COPD drugs for elastase-induced emphysema and alteration in lung mechanics and respiratory function in mice.
Topics: Administration, Inhalation; Airway Resistance; Aminopyridines; Androstadienes; Animals; Benzamides; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Bronchodilator Agents; Cyclopropanes; Fluticasone; Forced Expiratory Volume; Ipratropium; Lung; Mice; Pancreatic Elastase; Phosphatidylcholines; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Respiratory Physiological Phenomena; Superoxide Dismutase; Superoxides; Vital Capacity | 2012 |
The potential role of racecadotril in the treatment of diarrhea associated with roflumilast.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aminopyridines; Antidiarrheals; Benzamides; Child; Cyclic AMP; Cyclopropanes; Diarrhea; Humans; Neprilysin; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Thiorphan | 2012 |
Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery.
Topics: Adrenal Cortex Hormones; alpha 1-Antitrypsin; Aminopyridines; Anti-Bacterial Agents; Asthma; Benzamides; Bronchitis; Bronchodilator Agents; Chronic Disease; Comorbidity; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Expectorants; Humans; Phenotype; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Respiratory System Agents; Severity of Illness Index; Spain; Theophylline | 2012 |
The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice.
Topics: Administration, Oral; Aminopyridines; Animals; Benzamides; Blood Glucose; Cyclopropanes; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Female; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Mice; Mice, Mutant Strains; Phosphodiesterase 4 Inhibitors | 2012 |
LPS-induced lung inflammation in marmoset monkeys - an acute model for anti-inflammatory drug testing.
Topics: Aged; Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; Bronchoalveolar Lavage Fluid; Callithrix; Cyclopropanes; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Immunosuppressive Agents; Inflammation; Inflammation Mediators; Lipopolysaccharides; Lung; Lung Diseases; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Tumor Necrosis Factor-alpha | 2012 |
[Chronic obstructive pulmonary disease : new pharmacotherapeutic options].
Topics: Adrenal Cortex Hormones; Aminopyridines; Benzamides; Cholinergic Antagonists; Cyclopropanes; Humans; Pulmonary Disease, Chronic Obstructive | 2012 |
[Current anti-inflammatory therapy in patients with chronic obstructive pulmonary disease].
Topics: Aminopyridines; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Humans; Leukocytes; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2012 |
Attenuation of inhibitory prostaglandin E2 signaling in human lung fibroblasts is mediated by phosphodiesterase 4.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Aminopyridines; Benzamides; Cells, Cultured; Chemotaxis; Colforsin; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dinoprostone; Fibroblasts; Fibronectins; Gene Expression; Humans; Iloprost; Isoenzymes; Lung; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Receptors, Epoprostenol; Receptors, Prostaglandin; Receptors, Prostaglandin E, EP2 Subtype; Rolipram; Second Messenger Systems | 2012 |
A comparison of antiasthma drugs between acute and chronic ovalbumin-challenged guinea-pig models of asthma.
Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Aminopyridines; Androstadienes; Animals; Anti-Asthmatic Agents; Asthma; Benzamides; Bronchial Hyperreactivity; Chronic Disease; Cyclopropanes; Disease Models, Animal; Fluticasone; Guinea Pigs; Histamine; Inflammation; Male; Ovalbumin; Sulfides; Time Factors | 2012 |
Simultaneous quantitation of IC87114, roflumilast and its active metabolite roflumilast N-oxide in plasma by LC-MS/MS: application for a pharmacokinetic study.
Topics: Adenine; Aminopyridines; Animals; Benzamides; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Linear Models; Male; Quinazolines; Rats; Rats, Wistar; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2012 |
Roflumilast: doubtful efficacy but clear harms in COPD.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Disease Progression; Drug Approval; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2013 |
Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: dual β₂-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Salmeterol Xinafoate | 2013 |
Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.
Topics: Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Cohort Studies; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Glucocorticoids; Hospitalization; Humans; Life Expectancy; Male; Markov Chains; Middle Aged; Models, Econometric; Muscarinic Antagonists; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Severity of Illness Index; Switzerland | 2013 |
Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary di
Topics: Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Cells, Cultured; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; Epithelial Cells; Ethanolamines; Female; Formoterol Fumarate; Glucocorticoids; Humans; Male; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Respiratory Mucosa; Transcription, Genetic; Treatment Outcome | 2013 |
Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom.
Topics: Age Factors; Aged; Aminopyridines; Benzamides; Bronchitis; Bronchodilator Agents; Chronic Disease; Clinical Trials as Topic; Cost-Benefit Analysis; Cyclopropanes; Delayed-Action Preparations; Female; Health Services; Humans; Male; Markov Chains; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Respiratory Function Tests; United Kingdom | 2014 |
The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice.
Topics: Aminopyridines; Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Benzamides; Colitis; Colon; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dextran Sulfate; Disease Models, Animal; Female; Interferon-gamma; Intestinal Mucosa; Lectins, C-Type; Mice; Naphthyridines; Phosphodiesterase 3 Inhibitors; Phosphodiesterase 4 Inhibitors; Spleen; Tumor Necrosis Factor-alpha | 2013 |
Monitoring phosphodiesterase-4 inhibitors using liquid chromatography/(tandem) mass spectrometry in sports drug testing.
Topics: Aminopyridines; Benzamides; Chromatography, Liquid; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Limit of Detection; Nitriles; Phosphodiesterase 4 Inhibitors; Rolipram; Spectrometry, Mass, Electrospray Ionization; Substance Abuse Detection; Tandem Mass Spectrometry | 2013 |
Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2.
Topics: Aminopyridines; Benzamides; Cells, Cultured; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dinoprostone; Fibroblasts; Humans; Lung; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Receptors, Prostaglandin E, EP2 Subtype; RNA, Messenger; Signal Transduction; Vascular Endothelial Growth Factor A | 2013 |
[Intractable diarrhoea and severe weight loss by roflumilast].
Topics: Aged; Aminopyridines; Animals; Anorexia; Benzamides; Bronchitis; Comorbidity; Cyclopropanes; Diarrhea; Drug Evaluation, Preclinical; Female; Gastrointestinal Tract; Hallucinations; Hospitalization; Humans; Patient Readmission; Phosphodiesterase Inhibitors; Polypharmacy; Product Surveillance, Postmarketing; Pulmonary Disease, Chronic Obstructive; Sleep Apnea Syndromes; Vomiting; Weight Loss | 2013 |
Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cells.
Topics: Aminopyridines; Antioxidants; Axonemal Dyneins; Benzamides; Biomarkers; Bronchi; Cell Count; Cell Differentiation; Chloride Channels; Cilia; Cyclopropanes; Cytokines; Epithelial Cells; Forkhead Transcription Factors; Goblet Cells; Humans; Metaplasia; Mucin 5AC; Oxidative Stress; Reactive Oxygen Species; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; RNA, Messenger; Tubulin; Viral Load; Virus Replication | 2013 |
Phenotype/endotype-driven therapy in COPD: potential economic implications.
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchitis, Chronic; Bronchodilator Agents; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Costs; Forced Expiratory Volume; Humans; Lung; Patient Selection; Phenotype; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Treatment Outcome | 2013 |
Characterization of the cellular activity of PDE 4 inhibitors using two novel PDE 4 reporter cell lines.
Topics: Aminopyridines; Animals; Benzamides; CHO Cells; Cricetulus; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide-Gated Cation Channels; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Models, Biological; Nitriles; Phosphodiesterase 4 Inhibitors; Pyridines; Receptors, Adrenergic, beta-1; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
Identifying and treating COPD in cardiac patients.
Topics: Aminopyridines; Benzamides; Cardiovascular Diseases; Cyclopropanes; Electrocardiography; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Pulmonary Disease, Chronic Obstructive; Registries | 2013 |
Cardiovascular safety of roflumilast.
Topics: Aminopyridines; Benzamides; Cardiovascular Diseases; Cyclopropanes; Female; Humans; Male; Pulmonary Disease, Chronic Obstructive | 2013 |
Response.
Topics: Aminopyridines; Benzamides; Cardiovascular Diseases; Cyclopropanes; Female; Humans; Male; Pulmonary Disease, Chronic Obstructive | 2013 |
Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.
Topics: Aminopyridines; Benzamides; Chemokines; Cyclopropanes; Humans; In Vitro Techniques; Lipopolysaccharides; Lung; Tumor Necrosis Factor-alpha | 2013 |
Combined inhibition of PDE4 and PI3Kδ modulates the inflammatory component involved in the progression of chronic obstructive pulmonary disease.
Topics: Adenine; Aminopyridines; Benzamides; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Cyclopropanes; Disease Progression; Humans; Lipopolysaccharides; Macrophages; Matrix Metalloproteinase 9; Neutrophils; Nicotiana; Phosphodiesterase 4 Inhibitors; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pulmonary Alveoli; Pulmonary Disease, Chronic Obstructive; Quinazolines; Smoke; U937 Cells | 2014 |
Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis.
Topics: Aminophenols; Aminopyridines; Animals; Benzamides; Bronchi; Bronchitis, Chronic; Cells, Cultured; Cyclic AMP; Cyclopropanes; Cystic Fibrosis Transmembrane Conductance Regulator; Diarrhea; Dose-Response Relationship, Drug; Epithelial Cells; Humans; Intestinal Secretions; Intestine, Small; Membrane Potentials; Mice; Mucociliary Clearance; Phosphodiesterase 4 Inhibitors; Quinolones; Smoke; Smoking; Time Factors | 2014 |
Application of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerability.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Logistic Models; Models, Biological; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2013 |
Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice.
Topics: Administration, Ophthalmic; Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Gastric Emptying; Heterocyclic Compounds, 2-Ring; Humans; Leukocyte Disorders; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Neutrophil Infiltration; Neutrophils; Phenylacetates; Phosphodiesterase 4 Inhibitors; Pneumonia; Tumor Necrosis Factor-alpha | 2013 |
Benefits and harms of roflumilast in moderate to severe COPD.
Topics: Aged; Aminopyridines; Benzamides; Cyclopropanes; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Placebos; Pulmonary Disease, Chronic Obstructive; Risk Assessment | 2014 |
Phosphodiesterase 4 inhibitor roflumilast improves the bronchodilative effect of sevoflurane in sensitized airways.
Topics: Airway Resistance; Aminopyridines; Anesthetics, Inhalation; Animals; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; Guinea Pigs; Male; Methyl Ethers; Muscle, Smooth; Organ Culture Techniques; Phosphodiesterase 4 Inhibitors; Random Allocation; Sevoflurane; Treatment Outcome | 2014 |
Using absolute risks to assess the risks and benefits of treatment.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2014 |
New therapy for managing moderate to severe chronic obstructive pulmonary disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Therapy, Combination; Forced Expiratory Volume; Humans; Multicenter Studies as Topic; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Salmeterol Xinafoate; Scopolamine Derivatives; Severity of Illness Index; Tiotropium Bromide | 2014 |
GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.
Topics: Aminopyridines; Animals; Anti-Anxiety Agents; Behavior, Animal; Benzamides; Callithrix; Cerebral Cortex; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Drug Evaluation, Preclinical; Ferrets; Inflammation; Isoenzymes; Macaca fascicularis; Male; Nootropic Agents; Oxadiazoles; Phosphodiesterase 4 Inhibitors; Pica; Rats; Rolipram; Thiazoles | 2014 |
Calorie restriction mimicking effects of roflumilast prevents diabetic nephropathy.
Topics: Adenylate Kinase; Aminopyridines; Animals; Benzamides; Blood Glucose; Blood Urea Nitrogen; Caloric Restriction; Creatinine; Cyclopropanes; Diabetic Nephropathies; In Situ Nick-End Labeling; Male; Rats; Rats, Sprague-Dawley; Sirtuin 1 | 2014 |
Novel Roflumilast analogs as soft PDE4 inhibitors.
Topics: Aminopyridines; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dose-Response Relationship, Drug; Humans; Hydrolysis; Molecular Structure; Phosphodiesterase 4 Inhibitors; Structure-Activity Relationship | 2014 |
Influence of roflumilast on airway reactivity and apoptosis in ovalbumin-sensitized Guinea pigs.
Topics: Administration, Inhalation; Administration, Oral; Airway Resistance; Aminopyridines; Animals; Apoptosis; Benzamides; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Cyclopropanes; Guinea Pigs; Histamine; Leukocytes, Mononuclear; Lung; Male; Muscle Contraction; Muscle, Smooth; Ovalbumin; Phosphodiesterase 4 Inhibitors; Plethysmography, Whole Body; Primary Cell Culture; Tissue Culture Techniques | 2015 |
Roflumilast-induced Local Vascular Injury Is Associated with a Coordinated Proteome and Microparticle Change in the Systemic Circulation in Pigs.
Topics: Aminopyridines; Animals; Benzamides; Biomarkers; Blood Proteins; Cell-Derived Microparticles; Cyclopropanes; Female; Interleukin-6; Phosphodiesterase 4 Inhibitors; Proteome; Proteomics; Swine; Vascular System Injuries | 2015 |
Roflumilast added to triple therapy in patients with severe COPD: a real life study.
Topics: Adrenergic beta-Agonists; Aged; Aminopyridines; Benzamides; Cyclopropanes; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Male; Middle Aged; Muscarinic Antagonists; Phosphodiesterase 4 Inhibitors; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Registries; Severity of Illness Index; Treatment Outcome | 2015 |
Effects of rolipram and roflumilast, phosphodiesterase-4 inhibitors, on hypertension-induced defects in memory function in rats.
Topics: Aminopyridines; Animals; Benzamides; Blood Pressure; Brain; Cognition; Corticosterone; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Gene Expression Regulation, Enzymologic; Hypertension; Male; Maze Learning; Memory; Phosphodiesterase 4 Inhibitors; Rats; Rats, Wistar; Recognition, Psychology; RNA, Messenger; Rolipram | 2015 |
PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner.
Topics: Aminopyridines; Animals; Benzamides; Cell Adhesion; Cell Line; Cell Proliferation; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Femoral Artery; Gene Expression Regulation; Guanine Nucleotide Exchange Factors; Histones; Humans; Mice; Monocytes; Myocytes, Smooth Muscle; Neointima; Phosphodiesterase 4 Inhibitors; Rats; Signal Transduction; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1; Vascular System Injuries | 2015 |
Dual anti-inflammatory agents prevent COPD exacerbations.
Topics: Aminopyridines; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Cyclopropanes; Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2015 |
COPD: improving prevention and care.
Topics: Aminopyridines; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Cyclopropanes; Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Pregnancy; Pulmonary Disease, Chronic Obstructive | 2015 |
Roflumilast combined with adenosine increases mucosal hydration in human airway epithelial cultures after cigarette smoke exposure.
Topics: Adenosine; Adrenergic beta-Agonists; Aminopyridines; Analgesics; Benzamides; Bronchi; Cyclic AMP; Cyclopropanes; HEK293 Cells; Humans; Isoproterenol; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Respiratory Mucosa; Smoking | 2015 |
Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.
Topics: Aminopyridines; Animals; Benzamides; Catalytic Domain; Cell Line; Cyclic AMP; Cyclic AMP-Dependent Protein Kinase Catalytic Subunits; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Haemophilus influenzae; Humans; Inflammation; Mice; Mice, Inbred C57BL; Phosphorylation; Protein Binding; Pulmonary Disease, Chronic Obstructive; RNA, Small Interfering; Transcription Factor RelA; Up-Regulation | 2015 |
Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Aminopyridines; Benzamides; Chi-Square Distribution; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Costs; Female; Health Resources; Hospital Costs; Hospitalization; Humans; Linear Models; Male; Medicare Part C; Middle Aged; Models, Economic; Multivariate Analysis; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Retrospective Studies; Time Factors; Treatment Outcome; United States | 2015 |
The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
Topics: Aminopyridines; Animals; Benzamides; Capillary Permeability; Chemokines; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Cytoskeleton; Disease Models, Animal; Enzyme Activation; Epithelial Cells; Gene Expression; Male; Mice; Neutrophil Infiltration; Neutrophils; Phosphodiesterase 4 Inhibitors; Pneumonia; Protein Transport; Rolipram; Time Factors | 2015 |
Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease.
Topics: Aged; Aged, 80 and over; Aminopyridines; Benzamides; Chi-Square Distribution; Cyclopropanes; Databases, Factual; Female; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Patient Readmission; Phosphodiesterase 4 Inhibitors; Propensity Score; Pulmonary Disease, Chronic Obstructive; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; United States | 2015 |
The role of phosphodiesterase 4B in IL-8/LTB4-induced human neutrophil chemotaxis evaluated with a phosphodiesterase 4B inhibitor.
Topics: Adult; Aminopyridines; Benzamides; Chemotaxis; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Dose-Response Relationship, Drug; Female; Humans; Interleukin-8; Leukocytes, Mononuclear; Leukotriene B4; Lipopolysaccharides; Male; Neutrophils; Nitriles; Phosphodiesterase 4 Inhibitors; Tumor Necrosis Factor-alpha | 2015 |
Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients.
Topics: Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Flow Cytometry; Fluticasone; Forced Expiratory Volume; Greece; Humans; Lung; Muscarinic Antagonists; Phagocytosis; Phosphodiesterase 4 Inhibitors; Pilot Projects; Pulmonary Disease, Chronic Obstructive; Recovery of Function; Salmeterol Xinafoate; Spirometry; Time Factors; Tiotropium Bromide; Treatment Outcome; Vital Capacity | 2015 |
Quantitative benefit-harm assessment for setting research priorities: the example of roflumilast for patients with COPD.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Data Collection; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Research; Research Design; Risk Assessment | 2015 |
Phosphodiesterase-4 inhibitors ameliorates cognitive deficits in deoxycorticosterone acetate induced hypertensive rats via cAMP/CREB signaling system.
Topics: Adrenergic alpha-2 Receptor Agonists; Aminopyridines; Animals; Antihypertensive Agents; Benzamides; Brain-Derived Neurotrophic Factor; Clonidine; Cognition Disorders; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclopropanes; Desoxycorticosterone Acetate; Disease Models, Animal; Hippocampus; Hypertension; Male; Memory; Nootropic Agents; Phosphodiesterase 4 Inhibitors; Rats; Rats, Wistar; Rolipram | 2015 |
Roflumilast Prevents the Metabolic Effects of Bleomycin-Induced Fibrosis in a Murine Model.
Topics: Aminopyridines; Animals; Benzamides; Bleomycin; Cyclopropanes; Disease Models, Animal; Lung; Magnetic Resonance Spectroscopy; Male; Metabolome; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis | 2015 |
Roflumilast for asthma: Weighing the evidence.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aminopyridines; Asthma; Benzamides; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors | 2015 |
Roflumilast in COPD: a Brazilian perspective.
Topics: Aminopyridines; Benzamides; Brazil; Cyclopropanes; Disease Progression; Humans; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2015 |
Roflumilast: Who Is Using It and How It Affects Health Care Resource Utilization and Costs.
Topics: Aged; Aminopyridines; Benzamides; Cyclopropanes; Female; Health Care Costs; Health Resources; Humans; Insurance Claim Review; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Retrospective Studies; United States | 2015 |
Roflumilast, a Type 4 Phosphodiesterase Inhibitor, Shows Promising Adjunctive, Host-Directed Therapeutic Activity in a Mouse Model of Tuberculosis.
Topics: Aminopyridines; Animals; Antitubercular Agents; Benzamides; Cyclopropanes; Disease Models, Animal; Female; Interferon-gamma; Interleukin-1beta; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Phosphodiesterase 4 Inhibitors; Survival Analysis; Tuberculosis, Pulmonary; Tumor Necrosis Factor-alpha | 2015 |
Roflumilast inhibits leukocyte-platelet interactions and prevents the prothrombotic functions of polymorphonuclear leukocytes and monocytes.
Topics: Aminopyridines; Animals; Benzamides; Blood Platelets; Cardiovascular Diseases; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Extracellular Traps; Fibrinogen; Humans; Leukocytes; Macrophage-1 Antigen; Mice; Microscopy, Confocal; Monocytes; Neutrophils; P-Selectin; Phosphatidylinositol 3-Kinases; Phosphodiesterase 4 Inhibitors; Phosphorylation; Platelet Adhesiveness; Pulmonary Disease, Chronic Obstructive; Risk; Thromboplastin; Thrombosis | 2016 |
A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.
Topics: Aminopyridines; Animals; B-Lymphocytes; Benzamides; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Transgenic; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Phosphodiesterase 4 Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Signal Transduction; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2016 |
A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world.
Topics: Aged; Ambulatory Care; Aminopyridines; Benzamides; Cost of Illness; Cyclopropanes; Disease Progression; Female; Hospitalization; Humans; Longitudinal Studies; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Retrospective Studies; Symptom Flare Up; United States | 2015 |
Roflumilast partially reverses smoke-induced mucociliary dysfunction.
Topics: Albuterol; Aminopyridines; Benzamides; Biosensing Techniques; Bronchi; Cells, Cultured; Chlorides; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclopropanes; Cystic Fibrosis Transmembrane Conductance Regulator; Epithelial Cells; Fluorescence Resonance Energy Transfer; Formoterol Fumarate; Humans; Mucociliary Clearance; Phosphodiesterase 4 Inhibitors; RNA, Messenger; Second Messenger Systems; Smoke; Smoking; Time Factors; Transfection | 2015 |
Effect of roflumilast on airway remodelling in a murine model of chronic asthma.
Topics: Airway Remodeling; Allergens; Aminopyridines; Animals; Anti-Asthmatic Agents; Asthma; Benzamides; Bronchoalveolar Lavage Fluid; Chronic Disease; Cyclopropanes; Cytokines; Disease Models, Animal; Female; Goblet Cells; Humans; Hydroxyproline; Immunoglobulin E; Lung; Mice; Mice, Inbred BALB C; Pulmonary Fibrosis; Respiratory Hypersensitivity; T-Lymphocyte Subsets | 2016 |
Respiratory medications.
Topics: Administration, Inhalation; Aminopyridines; Androstadienes; Asthma; Beclomethasone; Benzamides; Cyclopropanes; Humans; Indans; Maleates; Nasal Sprays; Powders; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Tract Diseases; Rhinitis, Allergic | 2016 |
Roflumilast Ameliorates Airway Hyperresponsiveness Caused by Diet-Induced Obesity in a Murine Model.
Topics: Adiponectin; Aminopyridines; Animals; Benzamides; Cell Proliferation; Cyclopropanes; Cytokines; Diet; Disease Models, Animal; Leptin; Mice, Inbred C57BL; Models, Biological; Obesity; Ovalbumin; Pulmonary Fibrosis; Reactive Oxygen Species; Respiratory Hypersensitivity; T-Lymphocytes | 2016 |
The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses.
Topics: Aminopyridines; Animals; Benzamides; Cyclopropanes; Donepezil; Indans; Male; Memory; Mice; Mice, Inbred C57BL; Nootropic Agents; Phosphodiesterase 4 Inhibitors; Piperidines; Rats, Wistar; Recognition, Psychology; Rolipram; Scopolamine; Spatial Memory; Vomiting | 2016 |
Ozone-Induced Hypertussive Responses in Rabbits and Guinea Pigs.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antitussive Agents; Benzamides; Bronchoconstriction; Bronchodilator Agents; Capsaicin; Citric Acid; Cough; Cyclopropanes; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Guinea Pigs; Male; Neutrophil Infiltration; Oxidants, Photochemical; Ozone; Propylene Glycols; Rabbits; Transient Receptor Potential Channels | 2016 |
Roflumilast Increases Bacterial Load and Dissemination in a Model of Pseudomononas Aeruginosa Airway Infection.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bacterial Load; Benzamides; Bronchoalveolar Lavage Fluid; Chemokines; Colony Count, Microbial; Cyclopropanes; Cytokines; Female; Leukocyte Count; Lung; Mice; Mice, Inbred BALB C; Neutrophils; Pseudomonas Infections; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Infections | 2016 |
Effect of roflumilast, novel phosphodiesterase-4 inhibitor, on lung chronic graft-versus-host disease in mice.
Topics: Aminopyridines; Animals; Benzamides; Blotting, Western; Bone Marrow Transplantation; Cell Transplantation; Chemokine CCL2; Chemokine CCL3; Cyclopropanes; Female; Gene Expression; Graft vs Host Disease; Interleukin-1beta; Interleukin-6; Lung; Lymphocyte Count; Mice, Inbred BALB C; Phosphodiesterase 4 Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Spleen; T-Lymphocytes, Regulatory; Transforming Growth Factor beta1; Transplantation, Homologous | 2016 |
Phosphodiesterase 4 Inhibitors Attenuate the Asthma Phenotype Produced by β2-Adrenoceptor Agonists in Phenylethanolamine N-Methyltransferase-Knockout Mice.
Topics: Adrenergic beta-2 Receptor Agonists; Aminopyridines; Animals; Asthma; Benzamides; Bronchial Hyperreactivity; Cyclopropanes; Drug Therapy, Combination; Eosinophils; Formoterol Fumarate; Inflammation; Lung; Mice; Mice, Knockout; Mucus; Phenotype; Phenylethanolamine N-Methyltransferase; Phosphodiesterase 4 Inhibitors | 2016 |
Evidence selection for a prescription drug's benefit-harm assessment: challenges and recommendations.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Drug Evaluation; Humans; Prescription Drugs; Research Design; Risk Assessment | 2016 |
The effects of roflumilast on the pancreas and remote organs in a cerulein-induced experimental acute pancreatitis model in rats.
Topics: Acute Disease; Aminopyridines; Amylases; Animals; Benzamides; Ceruletide; Cyclopropanes; Disease Models, Animal; Inflammation Mediators; Interleukin-1beta; Interleukin-6; Lung; Male; Oxidative Stress; Pancreas; Pancreatitis; Rats, Wistar; Tumor Necrosis Factor-alpha | 2016 |
Airway bacteria drive a progressive COPD-like phenotype in mice with polymeric immunoglobulin receptor deficiency.
Topics: Aging; Airway Remodeling; Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Disease Models, Animal; Gene Expression Regulation; Host-Pathogen Interactions; Humans; Immunity, Innate; Immunoglobulin A, Secretory; Leukocyte Elastase; Lung; Matrix Metalloproteinase 12; Mice; Mice, Inbred C57BL; Mice, Knockout; Microbiota; NF-kappa B; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Receptors, Polymeric Immunoglobulin; Respiratory Mucosa | 2016 |
Synergistic effect between 5-HT4 receptor agonist and phosphodiesterase 4-inhibitor in releasing acetylcholine in pig gastric circular muscle in vitro.
Topics: Acetylcholine; Aminopyridines; Animals; Azabicyclo Compounds; Benzamides; Benzofurans; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dose-Response Relationship, Drug; Drug Synergism; Gastrointestinal Motility; Male; Muscle Contraction; Muscle, Smooth; Phosphodiesterase 4 Inhibitors; Receptors, Serotonin, 5-HT4; Serotonin 5-HT4 Receptor Agonists; Stomach; Sus scrofa | 2016 |
The phosphodiesterase 4 inhibitor roflumilast augments the Th17-promoting capability of dendritic cells by enhancing IL-23 production, and impairs their T cell stimulatory activity due to elevated IL-10.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; Cells, Cultured; Cyclopropanes; Dendritic Cells; Hypersensitivity; Interleukin-10; Interleukin-23; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Phosphodiesterase 4 Inhibitors; Th17 Cells; Th2 Cells | 2016 |
PDE4 Inhibition as Potential Treatment of Epidermolysis Bullosa Acquisita.
Topics: Aminopyridines; Animals; Antigen-Antibody Complex; Autoantibodies; Autoantigens; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Disease Models, Animal; Epidermis; Epidermolysis Bullosa Acquisita; Humans; Mice; Mice, Inbred C57BL; Neutrophils; Phosphodiesterase 4 Inhibitors | 2016 |
Virtual Screening of DrugBank Reveals Two Drugs as New BCRP Inhibitors.
Topics: Aminopyridines; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzamides; Cell Line, Tumor; Cisapride; Cyclopropanes; Drug Evaluation, Preclinical; Humans; Inhibitory Concentration 50; Logistic Models; Neoplasm Proteins; Probability; Reproducibility of Results; ROC Curve; User-Computer Interface | 2017 |
Simultaneous determination of roflumilast and its metabolite in human plasma by LC-MS/MS: Application for a pharmacokinetic study.
Topics: Aminopyridines; Benzamides; Chromatography, High Pressure Liquid; Cyclopropanes; Humans; Limit of Detection; Phosphodiesterase 4 Inhibitors; Reproducibility of Results; Solid Phase Extraction; Tandem Mass Spectrometry | 2016 |
Repositioning 'old' drugs to treat rare diseases: arguing from the mechanism of action.
Topics: Administration, Oral; Aminopyridines; Benzamides; Cyclopropanes; Drug Repositioning; Evidence-Based Medicine; Female; Histiocytosis, Langerhans-Cell; Humans; Middle Aged; Orphan Drug Production; Phosphodiesterase 4 Inhibitors; Rare Diseases; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism.
Topics: Aminopyridines; Animals; Benzamides; Cyclic AMP-Dependent Protein Kinases; Cyclopropanes; Diet, High-Fat; Energy Metabolism; Glucose; Insulin Resistance; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Signal Transduction; Weight Gain | 2017 |
Co-inhalation of roflumilast, rather than formoterol, with fluticasone more effectively improves asthma in asthmatic mice.
Topics: Administration, Inhalation; Aminopyridines; Animals; Anti-Asthmatic Agents; Asthma; Benzamides; Bronchoalveolar Lavage Fluid; Cyclopropanes; Disease Models, Animal; Drug Therapy, Combination; Female; Fluticasone; Formoterol Fumarate; Immunoglobulin E; Interleukin-4; Interleukin-5; Mice; Mice, Inbred BALB C; Tumor Necrosis Factor-alpha | 2017 |
Interleukin-1α induced release of interleukin-8 by human bronchial epithelial cells in vitro: assessing mechanisms and possible treatment options.
Topics: Acetates; Acetylcysteine; Aminopyridines; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Azithromycin; Benzamides; Bronchi; Cell Line; Cyclopropanes; Dapsone; Dexamethasone; Dose-Response Relationship, Drug; Epithelial Cells; Fluoroquinolones; Humans; Interleukin-1alpha; Interleukin-8; MAP Kinase Signaling System; Moxifloxacin; Neutrophils; Phosphorylation; Pyridones; Quinolines; Sulfides; Theophylline; Treatment Outcome | 2017 |
Roflumilast and aquaporin-2 regulation in rat renal inner medullary collecting duct.
Topics: 1-Methyl-3-isobutylxanthine; Aminopyridines; Animals; Aquaporin 2; Benzamides; Capillary Permeability; Cyclopropanes; Dose-Response Relationship, Drug; Kidney Medulla; Kidney Tubules, Collecting; Male; Phosphodiesterase 4 Inhibitors; Phosphorylation; Protein Transport; Rats; Rats, Sprague-Dawley; Vasopressins; Water | 2017 |
A new two-step algorithm for the treatment of COPD.
Topics: Adrenal Cortex Hormones; Algorithms; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Cyclopropanes; Humans; Macrolides; Muscarinic Antagonists; Phenotype; Pulmonary Disease, Chronic Obstructive; Pulmonary Medicine | 2017 |
Phosphodiesterase-4 inhibition restored hippocampal long term potentiation after primary blast.
Topics: Aminopyridines; Animals; Animals, Newborn; Benzamides; Blast Injuries; Cell Death; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Disease Models, Animal; Disks Large Homolog 4 Protein; Gene Expression Regulation; Glycine; Guanylate Kinases; Hippocampus; In Vitro Techniques; Long-Term Potentiation; Membrane Proteins; Papaverine; Phosphodiesterase 4 Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Time Factors | 2017 |
Roflumilast Reduces Cerebral Inflammation in a Rat Model of Experimental Subarachnoid Hemorrhage.
Topics: Aminopyridines; Animals; Apoptosis; Benzamides; Blood-Brain Barrier; Brain; Brain Edema; Cyclopropanes; Inflammation; Inflammation Mediators; Permeability; Phosphodiesterase 4 Inhibitors; Rats; Subarachnoid Hemorrhage | 2017 |
Intolerance to roflumilast in real-life clinical practice.
Topics: Aged; Aged, 80 and over; Aminopyridines; Benzamides; Cyclopropanes; Female; Gastrointestinal Diseases; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pulmonary Disease, Chronic Obstructive; Retrospective Studies; Sleep Initiation and Maintenance Disorders | 2017 |
The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice.
Topics: Alcohol Drinking; Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Ethanol; Male; Mice; Mice, Inbred C57BL; Motor Activity; Phosphodiesterase 4 Inhibitors; Rolipram | 2017 |
Is Concomitant Use of Theophylline and Roflumilast Really Contraindicated?
Topics: Aminopyridines; Benzamides; Cyclopropanes; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Theophylline | 2017 |
Roflumilast reverses polymicrobial sepsis-induced liver damage by inhibiting inflammation in mice.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents; Bacterial Load; Benzamides; Cyclopropanes; Cytokines; Inflammation; Liver; Liver Diseases; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Sepsis; STAT3 Transcription Factor; Survival Analysis | 2017 |
Roflumilast treatment inhibits lung carcinogenesis in benzo(a)pyrene-induced murine lung cancer model.
Topics: Aminopyridines; Animals; Benzamides; Benzo(a)pyrene; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Lung Neoplasms; Mice; Neovascularization, Pathologic | 2017 |
Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast.
Topics: Aminopyridines; Animals; Benzamides; Cyclopropanes; Dietary Fats; Female; Gene Expression; Interleukin-1beta; Interleukin-6; Muscle, Smooth; NF-kappa B; Obesity; Phosphodiesterase 4 Inhibitors; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics | 2017 |
Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline.
Topics: Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Cyclopropanes; Disease Progression; Fluoroquinolones; Humans; Macrolides; Muscarinic Antagonists; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Secondary Prevention; Societies, Medical; United States | 2017 |
Phosphodiesterase 4 inhibition affects both the direct and indirect pathway: an electrophysiological study examining the tri-phasic response in the substantia nigra pars reticulata.
Topics: Action Potentials; Aminopyridines; Analysis of Variance; Animals; Benzamides; Cyclopropanes; Dose-Response Relationship, Drug; Electric Stimulation; Electrocardiography; Male; Motor Cortex; Neural Pathways; Pars Reticulata; Phosphodiesterase 4 Inhibitors; Rats; Rats, Wistar | 2018 |
Effects of roflumilast, a phosphodiesterase-4 inhibitor, on the lung functions in a saline lavage-induced model of acute lung injury.
Topics: Acute Lung Injury; Administration, Intravenous; Aminopyridines; Animals; Benzamides; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Cyclopropanes; Disease Models, Animal; Female; Lung; Male; Phosphodiesterase 4 Inhibitors; Rabbits; Sodium Chloride; Treatment Outcome | 2017 |
Bacterial-derived Neutrophilic Inflammation Drives Lung Remodeling in a Mouse Model of Chronic Obstructive Pulmonary Disease.
Topics: Airway Remodeling; Aminopyridines; Animals; Bacillus; Benzamides; Cyclopropanes; Disease Models, Animal; Mice, Inbred C57BL; Mice, Mutant Strains; Neutrophils; Pneumonia, Bacterial; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Receptors, Cell Surface | 2018 |
Roflumilast, type 4 phosphodiesterase inhibitor, attenuates inflammation in rats with ulcerative colitis via down-regulation of iNOS and elevation of cAMP.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; Colitis, Ulcerative; Colon; Cyclic AMP; Cyclopropanes; Dextran Sulfate; Disease Models, Animal; Down-Regulation; Humans; Male; Nitric Oxide; Nitric Oxide Synthase Type II; Phosphodiesterase 4 Inhibitors; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha; Up-Regulation | 2018 |
Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs.
Topics: Aminopyridines; Animals; Benzamides; Biomarkers; Cyclopropanes; Guinea Pigs; Inflammation Mediators; Lung; Male; Organ Culture Techniques; Ovalbumin; Phosphodiesterase 4 Inhibitors; Phosphodiesterase 5 Inhibitors; Random Allocation; Respiratory Hypersensitivity; Tadalafil; Treatment Outcome | 2017 |
MALDI imaging facilitates new topical drug development process by determining quantitative skin distribution profiles.
Topics: Acetamides; Administration, Topical; Aminopyridines; Benzamides; Cyclopropanes; Drug Discovery; Humans; Nitriles; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Skin; Skin Absorption; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2018 |
Phosphodiesterase 4 Inhibitor Roflumilast Protects Rat Hippocampal Neurons from Sevoflurane Induced Injury via Modulation of MEK/ERK Signaling Pathway.
Topics: Aminopyridines; Animals; Apoptosis; Benzamides; Cell Survival; Cells, Cultured; Cyclopropanes; Hippocampus; MAP Kinase Signaling System; Methyl Ethers; Neurons; Neuroprotective Agents; Phosphodiesterase 4 Inhibitors; Rats; Rats, Wistar; Sevoflurane | 2018 |
Roflumilast Usage from 2010 to 2016: A Danish Nationwide Drug Utilization Study.
Topics: Adolescent; Adult; Aged; Aminopyridines; Benzamides; Cyclopropanes; Denmark; Drug Utilization; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Practice Patterns, Physicians'; Pulmonary Disease, Chronic Obstructive; Registries; Young Adult | 2018 |
Design, synthesis, and molecular modeling of heterocyclic bioisostere as potent PDE4 inhibitors.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Heterocyclic Compounds; Humans; Models, Molecular; Molecular Structure; Phosphodiesterase 4 Inhibitors; Structure-Activity Relationship | 2018 |
The phosphodiesterase-4 inhibitor roflumilast reverts proteolysis in skeletal muscle cells of patients with COPD cachexia.
Topics: Aminopyridines; Autophagy; Benzamides; Biomarkers; Case-Control Studies; Cross-Sectional Studies; Cyclopropanes; Female; Humans; Male; Middle Aged; Muscle Fibers, Skeletal; Muscle Proteins; Muscle Weakness; Muscle, Skeletal; Phosphodiesterase 4 Inhibitors; Proteolysis; Pulmonary Disease, Chronic Obstructive | 2018 |
The mediating role of phosphodiesterase type 4 in the dopaminergic modulation of motor impulsivity.
Topics: Aminopyridines; Animals; Benzamides; Brain; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dextroamphetamine; Dopamine; Dopamine Uptake Inhibitors; Impulsive Behavior; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphodiesterase 4 Inhibitors; Rats, Wistar | 2018 |
Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Protein Precursor; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 5; Cyclopropanes; Disease Models, Animal; Female; Humans; Male; Memory; Mice, Transgenic; Nootropic Agents; Phosphodiesterase Inhibitors; Random Allocation; Vardenafil Dihydrochloride | 2018 |
Roflumilast promotes memory recovery and attenuates white matter injury in aged rats subjected to chronic cerebral hypoperfusion.
Topics: Aging; Aminopyridines; Animals; Arginase; Benzamides; Brain Ischemia; Chronic Disease; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Hippocampus; Male; Maze Learning; Memory Disorders; Microglia; Neurodegenerative Diseases; Neuroprotective Agents; Nootropic Agents; Optic Tract; Random Allocation; Rats, Wistar; White Matter | 2018 |
Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury.
Topics: Alveolar Epithelial Cells; Aminopyridines; Animals; Benzamides; Cells, Cultured; Chemokines; Cyclic AMP; Cyclopropanes; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fibroblasts; Humans; Isoquinolines; Mice, Inbred C57BL; Mice, Transgenic; Phosphodiesterase 4 Inhibitors; Pulmonary Fibrosis; Pulmonary Surfactant-Associated Protein D; Pyridines; Tumor Necrosis Factor-alpha | 2018 |
Improving Our Aim: Targeting Therapy with Roflumilast in Patients with Severe and Very Severe Chronic Obstructive Pulmonary Disease.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic | 2018 |
Determination of Phosphodiesterase Inhibitors Tadalafil, Roflumilast and Roflumilast N-Oxide Using LC-MS in Guinea Pig Plasma.
Topics: Aminopyridines; Animals; Benzamides; Chromatography, High Pressure Liquid; Cyclopropanes; Guinea Pigs; Linear Models; Male; Phosphodiesterase Inhibitors; Reproducibility of Results; Sensitivity and Specificity; Tadalafil; Tandem Mass Spectrometry | 2018 |
Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP/PKA/CREB-FtMt signalling axis.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Cyclopropanes; Down-Regulation; Drug Resistance, Neoplasm; Female; Ferritins; G1 Phase; Humans; Mitochondrial Proteins; Ovarian Neoplasms; Resting Phase, Cell Cycle; Signal Transduction | 2018 |
Development of a new formulation of roflumilast for pulmonary drug delivery to treat inflammatory lung conditions.
Topics: Administration, Inhalation; Aminopyridines; Anti-Inflammatory Agents; Benzamides; Cell Line, Tumor; Cyclopropanes; Drug Compounding; Drug Delivery Systems; Dry Powder Inhalers; Humans; Lung Neoplasms; Powders | 2018 |
Spectroscopic and molecular modeling studies of binding interaction between bovine serum albumin and roflumilast.
Topics: Aminopyridines; Animals; Benzamides; Binding Sites; Cattle; Cyclopropanes; Models, Molecular; Molecular Structure; Serum Albumin, Bovine; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet | 2018 |
Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK.
Topics: Administration, Inhalation; Aged; Aminopyridines; Benzamides; Bronchitis, Chronic; Bronchodilator Agents; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Hospitalization; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; United Kingdom | 2018 |
Roflumilast for eosinophilic chronic obstructive pulmonary disease?
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Cyclopropanes; Humans; Pulmonary Disease, Chronic Obstructive | 2018 |
Medical Treatment of COPD.
Topics: Adrenal Cortex Hormones; Aminopyridines; Benzamides; Biomimetics; Bronchodilator Agents; Cholinergic Antagonists; Cyclopropanes; Germany; Guideline Adherence; Humans; Medical Overuse; Practice Patterns, Physicians'; Pulmonary Disease, Chronic Obstructive; Theophylline; Treatment Outcome | 2018 |
Exploring the Role of Water Molecules in the Ligand Binding Domain of PDE4B and PDE4D: Virtual Screening Based Molecular Docking of Some Active Scaffolds.
Topics: Aminopyridines; Benzamides; Binding Sites; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Phosphodiesterase 4 Inhibitors; Thermodynamics; Water | 2019 |
Direct Inhibitory Effect of the PDE4 Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive Pulmonary Disease.
Topics: Aminopyridines; Benzamides; Calcium; CD11b Antigen; Chemokine CXCL1; Chemotaxis, Leukocyte; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Guanine Nucleotide Exchange Factors; Humans; Leukotriene B4; Neutrophils; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Rolipram | 2019 |
Dexamethasone Inhibits Synergistic Induction of PDE4B Expression by Roflumilast and Bacterium NTHi.
Topics: Aminopyridines; Animals; Benzamides; Cell Line; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dexamethasone; Disease Models, Animal; Epithelial Cells; Gene Expression Regulation, Bacterial; Haemophilus influenzae; Humans; Inflammation; Lung; Pulmonary Disease, Chronic Obstructive | 2018 |
The phosphodiesterase type 4 inhibitor roflumilast suppresses inflammation to improve diabetic bladder dysfunction rats.
Topics: Aminopyridines; Animals; Benzamides; Cyclopropanes; Cystitis; Diabetes Complications; Diabetes Mellitus, Experimental; Female; Inflammation; Interleukin-1beta; Interleukin-6; NF-kappa B; Phosphodiesterase 4 Inhibitors; Rats; Rats, Sprague-Dawley; Treatment Outcome; Tumor Necrosis Factor-alpha; Urodynamics | 2019 |
Inhibition of TPL2 by interferon-α suppresses bladder cancer through activation of PDE4D.
Topics: Aminopyridines; Animals; Antiviral Agents; Benzamides; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclooxygenase 2; Cyclopropanes; Disease Models, Animal; Drug Synergism; Enzyme Activation; Female; HEK293 Cells; Humans; Interferon-alpha; MAP Kinase Kinase Kinases; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Proto-Oncogene Proteins; Urinary Bladder Neoplasms | 2018 |
Drugging the Mighty Neutrophil in Chronic Obstructive Pulmonary Disease.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Neutrophils; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2019 |
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Aminopyridines; Animals; Benzamides; Clioquinol; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Drug Design; Humans; Ligands; Mice; Rats; Rolipram | 2019 |
Roflumilast analogs with improved metabolic stability, plasma protein binding, and pharmacokinetic profile.
Topics: Aminopyridines; Animals; Benzamides; Blood Proteins; Chromatography, High Pressure Liquid; Cyclopropanes; Humans; Liver; Male; Phosphodiesterase 4 Inhibitors; Protein Binding; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry | 2019 |
Reduction of lung inflammation, oxidative stress and apoptosis by the PDE4 inhibitor roflumilast in experimental model of acute lung injury.
Topics: Acute Lung Injury; Aminopyridines; Animals; Apoptosis; Benzamides; Bronchoalveolar Lavage Fluid; Cyclopropanes; Disease Models, Animal; Female; Male; Oxidative Stress; Phosphodiesterase 4 Inhibitors; Pneumonia; Rabbits | 2018 |
Roflumilast ameliorates cognitive impairment in APP/PS1 mice via cAMP/CREB/BDNF signaling and anti-neuroinflammatory effects.
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Animals; Benzamides; Brain-Derived Neurotrophic Factor; Cognitive Dysfunction; Cyclic AMP; Cyclopropanes; Disease Models, Animal; Male; Memory; Mice, Transgenic; Nootropic Agents; Phosphodiesterase 4 Inhibitors | 2019 |
Roflumilast, a phosphodiesterase 4 inhibitor, attenuates cadmium-induced renal toxicity via modulation of NF-κB activation and induction of NQO1 in rats.
Topics: Aminopyridines; Animals; Benzamides; Cadmium Chloride; Catalase; Creatinine; Cyclopropanes; Glutathione; Kidney; Kidney Diseases; Male; NAD(P)H Dehydrogenase (Quinone); NF-kappa B; Phosphodiesterase 4 Inhibitors; Rats, Wistar; Superoxide Dismutase; Urea | 2019 |
Influence of roflumilast on sepsis mice through the JAK/STAT signaling pathway.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; Bronchoalveolar Lavage Fluid; Cyclopropanes; Disease Models, Animal; Female; Janus Kinases; Lung; Male; Mice; Phosphodiesterase 4 Inhibitors; Sepsis; Signal Transduction; STAT3 Transcription Factor | 2019 |
Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: Modulation of cAMP/CREB/TLR4 inflammatory and fibrogenic pathways.
Topics: Aminopyridines; Animals; Benzamides; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclic Nucleotide Phosphodiesterases, Type 1; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Liver Cirrhosis; Male; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Rats; Rats, Wistar; Signal Transduction; Toll-Like Receptor 4; Vinca Alkaloids | 2019 |
Phosphodiesterase-4 Inhibitor Roflumilast Attenuates Pulmonary Air Emboli-Induced Lung Injury.
Topics: Acute Lung Injury; Aminopyridines; Animals; Benzamides; Capillary Permeability; Cyclopropanes; Cytokines; Disease Models, Animal; Embolism, Air; Humans; Lung; Male; NF-kappa B; Perfusion; Phosphodiesterase 4 Inhibitors; Rats; Signal Transduction | 2019 |
Impact of Phosphodiesterase 4 Inhibition on the Operational Efficacy, Response Maxima, and Kinetics of Indacaterol-Induced Gene Expression Changes in BEAS-2B Airway Epithelial Cells: A Global Transcriptomic Analysis.
Topics: Adrenergic beta-2 Receptor Agonists; Aminopyridines; Aminoquinolines; Benzamides; Cell Line; Cyclopropanes; Drug Synergism; Epithelial Cells; Gene Expression Profiling; Gene Expression Regulation; Humans; Indans; Lung; Oligonucleotide Array Sequence Analysis; Phosphodiesterase 4 Inhibitors; Quinolones; Salmeterol Xinafoate; Sulfones | 2019 |
The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Benzamides; Chemokine CCL2; Chemokine CCL4; Cyclopropanes; Female; Humans; Macrophages, Alveolar; Male; Middle Aged; para-Aminobenzoates; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Sulfonamides; Tumor Necrosis Factor-alpha | 2019 |
Evaluation of the Roflumilast Effect Supplemented with Linezolid in Pleural Empyema in Rats Caused by Intrapleural Staphylococcus aureus Inoculation.
Topics: Aminopyridines; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Benzamides; Cyclopropanes; Drug Therapy, Combination; Empyema, Pleural; Linezolid; Lung; Male; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus | 2020 |
Cigarette smoke exposure alters phosphodiesterases in human structural lung cells.
Topics: Adult; Aminopyridines; Benzamides; Cyclopropanes; Female; Gene Expression; Humans; Lung; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Phosphoric Diester Hydrolases; Pulmonary Disease, Chronic Obstructive; RNA, Messenger; Smoke; Smoking; Tobacco Products | 2020 |
The phosphodiesterase-4 inhibitor roflumilast impacts Schistosoma mansoni ovipositing in vitro but displays only modest antischistosomal activity in vivo.
Topics: Aminopyridines; Animals; Anthelmintics; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 1; Cyclopropanes; Dose-Response Relationship, Drug; Female; Inhibitory Concentration 50; Male; Mice; Microscopy, Electron, Scanning; Oviposition; Phosphodiesterase 4 Inhibitors; Praziquantel; Schistosoma mansoni | 2020 |
Application of pharmacogenomics and bioinformatics to exemplify the utility of human ex vivo organoculture models in the field of precision medicine.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Exome Sequencing; Fluticasone; Formoterol Fumarate; Genomics; Humans; Lung; MicroRNAs; Models, Biological; Organ Culture Techniques; Pharmacogenomic Variants; Precision Medicine; Pulmonary Disease, Chronic Obstructive; State Medicine | 2019 |
Glucocorticoid Receptor α Mediates Roflumilast's Ability to Restore Dexamethasone Sensitivity in COPD.
Topics: Aminopyridines; Benzamides; Cells, Cultured; Cyclopropanes; Dexamethasone; Drug Resistance; Epithelial Cells; Glucocorticoids; Humans; Inflammation Mediators; Interleukin-8; Lung; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Receptors, Glucocorticoid; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Up-Regulation | 2020 |
Phosphodiesterase inhibitors roflumilast and vardenafil prevent sleep deprivation-induced deficits in spatial pattern separation.
Topics: Aminopyridines; Animals; Benzamides; Cyclopropanes; Hippocampus; Male; Memory Disorders; Mice; Phosphodiesterase 4 Inhibitors; Sleep Deprivation; Spatial Memory; Vardenafil Dihydrochloride | 2020 |
In Silico, Ex Vivo and In Vivo Studies of Roflumilast as a Potential Antidiarrheal and Antispasmodic agent: Inhibition of the PDE-4 Enzyme and Voltage-gated Ca++ ion Channels.
Topics: Aminopyridines; Animals; Antidiarrheals; Benzamides; Binding Sites; Calcium Channel Blockers; Carbachol; Castor Oil; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Diarrhea; Isoproterenol; Jejunum; Mice; Molecular Docking Simulation; Papaverine; Parasympatholytics; Phosphodiesterase 4 Inhibitors; Protein Binding; Protein Interaction Domains and Motifs; Protein Structure, Secondary; Rabbits; Verapamil | 2020 |
Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.
Topics: Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dementia, Vascular; Dogs; Drug Design; Humans; Male; Mice, Inbred C57BL; Molecular Structure; Phosphodiesterase 4 Inhibitors; Protein Binding; Rolipram; Structure-Activity Relationship; Vomiting; Xanthones | 2020 |
Persistence of the extinction of fear memory requires late-phase cAMP/PKA signaling in the infralimbic cortex.
Topics: Aminopyridines; Animals; Benzamides; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclopropanes; Extinction, Psychological; Fear; Male; Memory; Memory Consolidation; Phosphodiesterase 4 Inhibitors; Prefrontal Cortex; Rats, Wistar; Signal Transduction | 2020 |
Roflumilast, a Phosphodiesterases-4 (PDE4) Inhibitor, Alleviates Sepsis‑induced Acute Kidney Injury.
Topics: Acute Kidney Injury; Aminopyridines; Animals; Apoptosis; Benzamides; Blood Urea Nitrogen; Creatinine; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Cytokines; Female; Hepatitis A Virus Cellular Receptor 1; Inflammation; Kidney; Lipocalin-2; Mice; Mice, Inbred BALB C; NF-kappa B; Phosphodiesterase 4 Inhibitors; Sepsis | 2020 |
Roflumilast attenuates cognitive deficits in estrogen insufficient rats.
Topics: Aminopyridines; Animals; Benzamides; Cognition; Cognitive Dysfunction; Cyclic AMP; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Estrogen Receptor alpha; Estrogens; Female; Ovariectomy; Phenols; Phosphodiesterase 4 Inhibitors; Pyrazoles; Rats; Rats, Wistar | 2020 |
Roflumilast counteracts DMH-induced preneoplastic colon damage in albino Wistar rats.
Topics: 1,2-Dimethylhydrazine; Aminopyridines; Animals; Anti-Inflammatory Agents; Antioxidants; Benzamides; Catalase; Colon; Colonic Neoplasms; Cyclopropanes; Glutathione Reductase; Hydrogen Sulfide; Lipoxygenase; Male; Nitric Oxide; Oxidative Stress; Phosphodiesterase 4 Inhibitors; Precancerous Conditions; Prostaglandin-Endoperoxide Synthases; Rats, Wistar; Superoxide Dismutase | 2020 |
Inhibition of phosphodiesterase IV enzyme improves locomotor and sensory complications of spinal cord injury via altering microglial activity: Introduction of Roflumilast as an alternative therapy.
Topics: Agnosia; Aminopyridines; Animals; Benzamides; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Disease Models, Animal; Humans; Male; Microglia; Neurogenic Inflammation; Phosphodiesterase 4 Inhibitors; Rats; Spinal Cord; Spinal Cord Injuries; Tabes Dorsalis | 2020 |
The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer's Disease: A Preclinical Study in APP/PS1 Transgenic Mice.
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Protein Precursor; Animals; Behavior, Animal; Benzamides; Cerebral Cortex; Cyclopropanes; Depression; Disease Models, Animal; Hippocampus; Maze Learning; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Phosphodiesterase 4 Inhibitors; Presenilin-1; Recognition, Psychology | 2020 |
PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice.
Topics: Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Disease Models, Animal; Female; Gastroparesis; Mice; Mice, Nude; Phosphodiesterase 4 Inhibitors; Pyridines; Pyrimidinones; Rolipram | 2020 |
Effects of a novel roflumilast and formoterol fumarate dry powder inhaler formulation in experimental allergic asthma.
Topics: Administration, Inhalation; Aminopyridines; Animals; Asthma; Benzamides; Cyclopropanes; Dry Powder Inhalers; Formoterol Fumarate; Mice; Particle Size; Powders | 2020 |
Simultaneous quantification and pharmacokinetic evaluation of roflumilast and its N-oxide in cynomolgus monkey plasma by LC-MS/MS method.
Topics: Administration, Oral; Aminopyridines; Animals; Benzamides; Chromatography, Liquid; Cyclopropanes; Linear Models; Macaca fascicularis; Male; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2021 |
Electrochemical Behavior and Square-Wave Stripping Voltammetric Determination of Roflumilast in Pharmaceutical Dosage Forms.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Drug Compounding; Electrochemical Techniques; Electrodes; Mercury; Molecular Structure; Particle Size; Silver; Silver Compounds | 2021 |
Roflumilast prevents lymphotoxin α (TNF-β)-induced inflammation activation and degradation of type 2 collagen in chondrocytes.
Topics: Aminopyridines; Benzamides; Cell Line; Chondrocytes; Collagen Type II; Cyclopropanes; Cytokines; Extracellular Matrix; Humans; Inflammation; Lymphotoxin-alpha; Phosphodiesterase 4 Inhibitors; Receptors, Tumor Necrosis Factor, Type II; Signal Transduction | 2020 |
The effect and associated mechanism of action of phosphodiesterase 4 (PDE4) inhibitor on CD4+ lymphocyte proliferation.
Topics: Aminopyridines; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2021 |
Phosphodiesterase-4 inhibitors reduce the expression of proinflammatory mediators by human epidermal keratinocytes independent of intracellular cAMP elevation.
Topics: Aminopyridines; Benzamides; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Cyclic AMP; Cyclopropanes; Down-Regulation; Humans; Inflammation Mediators; Interleukin-18; Interleukin-1alpha; Interleukin-8; Keratinocytes; MAP Kinase Signaling System; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide; Tumor Necrosis Factor-alpha | 2020 |
Clinical relevance of the relaxant effects of roflumilast on human bronchus: potentiation by a long-acting beta-2-agonist.
Topics: Aminopyridines; Benzamides; Bronchi; Bronchodilator Agents; Cyclopropanes; Female; Formoterol Fumarate; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2021 |
In chronic plaque psoriasis, roflumilast cream safely increased likelihood of clear or almost clear state at 6 weeks.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Psoriasis; Treatment Outcome | 2020 |
Can roflumilast become steroid-sparing alternative in the treatment of COVID-19?
Topics: Adrenal Cortex Hormones; Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; COVID-19 Drug Treatment; Cyclopropanes; Cytokine Release Syndrome; Cytokines; Humans; Immune System; Immunity, Innate; Inflammation; Models, Theoretical; Phosphodiesterase 4 Inhibitors; Risk; Steroids; Thalidomide | 2020 |
Adrenomedullin Inhibits Osmotic Water Permeability in Rat Inner Medullary Collecting Ducts.
Topics: Adrenomedullin; Aminopyridines; Animals; Aquaporin 2; Benzamides; Cell Membrane; Cyclic AMP; Cyclopropanes; Kidney Medulla; Osmosis; Permeability; Phosphorylation; Protein Kinase C; Rats; RNA, Messenger; Signal Transduction; Water | 2020 |
Roflumilast, a cAMP-Specific Phosphodiesterase-4 Inhibitor, Reduces Oxidative Stress and Improves Synapse Functions in Human Cortical Neurons Exposed to the Excitotoxin Quinolinic Acid.
Topics: Aminopyridines; Benzamides; Brain-Derived Neurotrophic Factor; Cyclic AMP Response Element-Binding Protein; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Humans; Neurons; Neurotoxins; Oxidative Stress; Phosphodiesterase 4 Inhibitors; Quinolinic Acid; Synapses | 2020 |
Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression.
Topics: Aminopyridines; Animals; B7-H1 Antigen; Benzamides; Cell Line, Tumor; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Gene Expression Regulation, Neoplastic; Humans; Immune Tolerance; Lymphocyte Activation; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Knockout; Phosphodiesterase 4 Inhibitors; Signal Transduction | 2021 |
Roflumilast protects against spatial memory impairments and exerts anti-inflammatory effects after transient global cerebral ischemia.
Topics: Aminopyridines; Animals; Benzamides; Brain Ischemia; Cyclopropanes; Doublecortin Protein; Hippocampus; Ischemic Attack, Transient; Rats; Spatial Memory | 2021 |
Roflumilast prevents ischemic stroke-induced neuronal damage by restricting GSK3β-mediated oxidative stress and IRE1α/TRAF2/JNK pathway.
Topics: Aminopyridines; Animals; Apoptosis; Benzamides; Brain Ischemia; Cyclopropanes; Endoribonucleases; Glycogen Synthase Kinase 3 beta; Inositol; Ischemic Stroke; MAP Kinase Signaling System; Neurons; Oxidative Stress; Rats; Reperfusion Injury; Stroke; TNF Receptor-Associated Factor 2 | 2021 |
Roflumilast Attenuates Doxorubicin-Induced Cardiotoxicity by Targeting Inflammation and Cellular Senescence in Cardiomyocytes Mediated by SIRT1.
Topics: Aminopyridines; Animals; Benzamides; Cells, Cultured; Cellular Senescence; Cyclopropanes; Doxorubicin; Inflammation; Myocytes, Cardiac; Rats; Sirtuin 1 | 2021 |
Neuroprotective effects of roflumilast against quinolinic acid-induced rat model of Huntington's disease through inhibition of NF-κB mediated neuroinflammatory markers and activation of cAMP/CREB/BDNF signaling pathway.
Topics: Aminopyridines; Animals; Benzamides; Brain-Derived Neurotrophic Factor; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Huntington Disease; Inflammation; Male; Neuroprotective Agents; NF-kappa B; Nitrosative Stress; Oxidative Stress; Quinolinic Acid; Rats; Rats, Wistar; Signal Transduction | 2021 |
Neuroprotective effect of roflumilast under cerebral ischaemia/reperfusion injury in juvenile rats through NLRP-mediated inflammatory response inhibition.
Topics: Aminopyridines; Animals; Benzamides; Brain; Cyclopropanes; Male; Neuroprotective Agents; Rats; Reperfusion Injury | 2021 |
Roflumilast protects from cisplatin-induced testicular toxicity in male rats and enhances its cytotoxicity in prostate cancer cell line. Role of NF-κB-p65, cAMP/PKA and Nrf2/HO-1, NQO1 signaling.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cisplatin; Cyclic AMP-Dependent Protein Kinases; Cyclopropanes; Heme Oxygenase (Decyclizing); Male; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; NF-kappa B; Prostatic Neoplasms; Rats; Rats, Wistar; Signal Transduction | 2021 |
Roflumilast as a Potential Therapeutic Agent for Cecal Ligation and Puncture-Induced Septic Lung Injury.
Topics: Aminopyridines; Animals; Benzamides; Cecum; Cyclopropanes; Disease Models, Animal; Ligation; Lung; Lung Injury; NF-kappa B; Punctures; Rats; Sepsis | 2022 |
Roflumilast and tadalafil improve learning and memory deficits in intracerebroventricular Aβ1-42 rat model of Alzheimer's disease through modulations of hippocampal cAMP/cGMP/BDNF signaling pathway.
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Animals; Benzamides; Brain-Derived Neurotrophic Factor; Cyclic AMP; Cyclic GMP; Cyclopropanes; Cytokines; Gene Expression Regulation; Hippocampus; Male; Memory Disorders; Morris Water Maze Test; Oxidative Stress; Peptide Fragments; Random Allocation; Rats; Rats, Wistar; Tadalafil; Vasodilator Agents | 2021 |
Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cisplatin; Cyclopropanes; Cytarabine; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methylprednisolone; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphodiesterase 4 Inhibitors; Pilot Projects | 2022 |
Roflumilast ameliorates cognitive deficits in a mouse model of amyloidogenesis and tauopathy: Involvement of nitric oxide status, Aβ extrusion transporter ABCB1, and reversal by PKA inhibitor H89.
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cognitive Dysfunction; Cyclopropanes; Disease Models, Animal; Hippocampus; Isoquinolines; Male; Mice; Nitric Oxide; Phosphodiesterase 4 Inhibitors; Protein Kinase Inhibitors; Streptozocin; Sulfonamides; Tauopathies | 2021 |
Inhibitory effect of roflumilast on experimental periodontitis.
Topics: Alveolar Bone Loss; Aminopyridines; Animals; Benzamides; Cyclopropanes; Gingiva; Inflammation; Interleukin-1beta; Interleukin-6; NF-kappa B; Periodontitis; Rats; Rats, Wistar; RNA, Messenger; Tumor Necrosis Factor-alpha; X-Ray Microtomography | 2022 |
Roflumilast Suppresses Adipogenic Differentiation
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Aminopyridines; AMP-Activated Protein Kinases; Animals; Anti-Obesity Agents; Benzamides; Cell Differentiation; Cyclopropanes; Diet, High-Fat; Gene Expression Regulation, Enzymologic; Lipolysis; Male; Mice; Mice, Inbred C57BL; Obesity; Phosphodiesterase 4 Inhibitors | 2021 |
Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy.
Topics: Administration, Oral; Aminopyridines; Benzamides; Cyclopropanes; Double-Blind Method; Humans; Psoriasis; Severity of Illness Index; Treatment Outcome | 2021 |
Roflumilast improves resolution of sepsis-induced acute kidney injury by retarding late phase renal interstitial immune cells infiltration and leakage in urinary sediments.
Topics: Acute Kidney Injury; Aminopyridines; Animals; Benzamides; Cyclopropanes; Disease Models, Animal; Kidney; Rats; Sepsis | 2022 |
Differential effects of dexamethasone and roflumilast on asthma in mice with or without short cigarette smoke exposure.
Topics: Aminopyridines; Animals; Asthma; Benzamides; Bronchoalveolar Lavage Fluid; Cyclopropanes; Dexamethasone; Disease Models, Animal; Lung; Mice; Mice, Inbred BALB C; Ovalbumin; Smoking | 2021 |
Positive effects of roflumilast on behavior, neuroinflammation, and white matter injury in mice with global cerebral ischemia.
Topics: Aminopyridines; Animals; Arginase; Behavior, Animal; Benzamides; Brain Ischemia; Calcium-Binding Proteins; Cognitive Dysfunction; Cyclopropanes; Hippocampus; Mice; Microfilament Proteins; Microglia; Neuroinflammatory Diseases; Neuroprotective Agents; Phosphodiesterase 4 Inhibitors; Recovery of Function; Treatment Outcome; White Matter | 2021 |
Impacts of anti-inflammatory phosphodiesterase inhibitors on a murine model of chronic pulmonary inflammation.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; Cyclopropanes; Disease Models, Animal; Histone Deacetylase 2; Interleukin-8; Lung; Male; Mice, Inbred C57BL; Nicotiana; Pentoxifylline; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Reactive Oxygen Species; Smoke; Smoking; Theophylline; Tumor Necrosis Factor-alpha | 2021 |
Roflumilast treatment during forced abstinence reduces relapse to methamphetamine seeking and taking.
Topics: Aminopyridines; Amphetamine-Related Disorders; Animals; Benzamides; Central Nervous System Stimulants; Cyclopropanes; Drug-Seeking Behavior; Extinction, Psychological; Male; Methamphetamine; Phosphodiesterase 4 Inhibitors; Rats; Recurrence; Self Administration | 2022 |
Potentiation of long-acting β
Topics: Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Benzothiazoles; Budesonide; Cell Line; Chemokines; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; Epithelial Cells; Formoterol Fumarate; Glucocorticoids; Humans; Lung; Multidrug Resistance-Associated Proteins; Nitriles; Phosphodiesterase 4 Inhibitors; Rolipram; Second Messenger Systems; Triazoles | 2021 |
Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: therapeutic role of roflumilast.
Topics: Aminopyridines; Animals; Aorta; Becaplermin; Benzamides; CD36 Antigens; Cell Proliferation; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Hepatocytes; Hypertension; Insulin; Liver; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Myocytes, Smooth Muscle; Nanoparticles; Non-alcoholic Fatty Liver Disease; Phosphodiesterase 4 Inhibitors; Polymers; RNA, Small Interfering; Sirtuin 1; Transforming Growth Factor beta1 | 2022 |
Rapid improvement of idiopathic aphthous ulcers with oral roflumilast therapy.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Recurrence; Stomatitis, Aphthous | 2022 |
Roflumilast Reduces Pathological Symptoms of Sporadic Alzheimer's Disease in Rats Produced by Intracerebroventricular Streptozotocin by Inhibiting NF-κB/BACE-1 Mediated Aβ Production in the Hippocampus and Activating the cAMP/BDNF Signalling Pathway.
Topics: Alzheimer Disease; Aminopyridines; Animals; Benzamides; Brain-Derived Neurotrophic Factor; Cyclopropanes; Disease Models, Animal; Glycogen Synthase Kinase 3 beta; Hippocampus; Maze Learning; Memory Disorders; NF-kappa B; Rats; Streptozocin | 2022 |
In vitro inhibition of phosphodiesterase type 4 enhances rat corpus cavernosum nerve-mediated relaxation induced by gasotransmitters.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dose-Response Relationship, Drug; Gasotransmitters; Hydrogen Sulfide; Male; Muscle Relaxation; Nitroarginine; Penis; Peripheral Nerves; Rats, Wistar; Tadalafil | 2022 |
Rectal roflumilast improves trinitrobenzenesulfonic acid-induced chronic colitis in rats.
Topics: Aminopyridines; Animals; Benzamides; Colitis; Cyclopropanes; Disease Models, Animal; Mice; Peroxidase; Rats; Trinitrobenzenesulfonic Acid; Tumor Necrosis Factor-alpha | 2022 |
A European pharmacotherapeutic agent roflumilast exploring integrated preclinical and clinical evidence for SARS CoV-2 mediated inflammation to organ damage.
Topics: Aged; Aminopyridines; Benzamides; COVID-19 Drug Treatment; Cyclopropanes; Humans; Inflammation; Phosphodiesterase 4 Inhibitors; SARS-CoV-2 | 2022 |
Killing all the birds with one drug - is oral roflumilast a novel treatment option for psoriasis?
Topics: Aminopyridines; Chronic Disease; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Pulmonary Disease, Chronic Obstructive | 2022 |
Roflumilast, a cyclic nucleotide phosphodiesterase 4 inhibitor, protects against cerebrovascular endothelial injury following cerebral ischemia/reperfusion by activating the Notch1/Hes1 pathway.
Topics: Aminopyridines; Animals; Benzamides; Blood-Brain Barrier; Brain Ischemia; Cerebral Infarction; Cyclopropanes; Endothelial Cells; Humans; Ischemic Stroke; Nucleotides, Cyclic; Phosphodiesterase 4 Inhibitors; Rats; Receptor, Notch1; Reperfusion; Reperfusion Injury; Transcription Factor HES-1 | 2022 |
Roflumilast-Mediated Phosphodiesterase 4D Inhibition Reverses Diabetes-Associated Cardiac Dysfunction and Remodeling: Effects Beyond Glucose Lowering.
Topics: Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Diabetes Mellitus, Type 2; Glucose; Heart Diseases; Humans; Hyperglycemia; Insulins; Mice; MicroRNAs; Phosphodiesterase 4 Inhibitors | 2022 |
Rapid clearing of refractory nummular dermatitis with oral roflumilast therapy.
Topics: Administration, Oral; Aminopyridines; Benzamides; Cyclopropanes; Eczema; Humans | 2022 |
The protective effect of roflumilast and ibuprofen on testicular ischemia reperfusion injury: An experimental study.
Topics: Aminopyridines; Animals; Benzamides; Cyclopropanes; Humans; Ibuprofen; Male; Rats; Reperfusion Injury; Spermatic Cord Torsion; Testis; Thyrotropin | 2022 |
Roflumilast, a Phosphodiesterase-4 Inhibitor, Ameliorates Sleep Deprivation-Induced Cognitive Dysfunction in C57BL/6J Mice.
Topics: Aminopyridines; Amyloid beta-Peptides; Animals; Benzamides; Brain-Derived Neurotrophic Factor; Cognitive Dysfunction; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Hippocampus; Mice; Mice, Inbred C57BL; Phosphodiesterase 4 Inhibitors; Sleep Deprivation; Synapsins | 2022 |
Suppression of phosphodiesterase IV enzyme by roflumilast ameliorates cognitive dysfunction in aged rats after sevoflurane anaesthesia via PKA-CREB and MEK/ERK pathways.
Topics: Aminopyridines; Anesthesia; Animals; Benzamides; Cognitive Dysfunction; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Hippocampus; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Phosphodiesterase Inhibitors; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Sevoflurane | 2022 |
Considerable improvement in hidradenitis suppurativa with oral roflumilast therapy.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Hidradenitis Suppurativa; Humans | 2022 |
Inhalable Formulation Based on Lipid-Polymer Hybrid Nanoparticles for the Macrophage Targeted Delivery of Roflumilast.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Macrophages; Mannose; Nanoparticles; Particle Size; Phosphatidylethanolamines; Polyethylene Glycols; Polymers | 2022 |
Discovery of novel PDE4 inhibitors targeting the M-pocket from natural mangostanin with improved safety for the treatment of Inflammatory Bowel Diseases.
Topics: Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dextran Sulfate; Dipyridamole; Dogs; Inflammatory Bowel Diseases; Mice; Phosphodiesterase 4 Inhibitors | 2022 |
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pruritus; Psoriasis; Randomized Controlled Trials as Topic; Skin Cream | 2022 |
Roflumilast for Chronic Plaque Psoriasis.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis | 2022 |
Roflumilast.
Topics: Aminopyridines; Benzamides; Cyclopropanes; Humans | 2022 |
Long-term clearance of severe plaque psoriasis with oral roflumilast.
Topics: Administration, Oral; Aminopyridines; Benzamides; Cyclopropanes; Humans; Psoriasis; Severity of Illness Index | 2023 |
Topical roflumilast (Zoryve) for plaque psoriasis.
Topics: Administration, Cutaneous; Administration, Topical; Aminopyridines; Benzamides; Cyclopropanes; Dermatologic Agents; Humans; Psoriasis; Severity of Illness Index; Treatment Outcome | 2023 |
Severe and therapeutic challenging oral erosive lichen planus treated with oral roflumilast.
Topics: Aminopyridines; Benzamides; Humans; Lichen Planus; Lichen Planus, Oral | 2023 |
Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis-Reply.
Topics: Administration, Cutaneous; Aminopyridines; Benzamides; Chronic Disease; Cyclopropanes; Double-Blind Method; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Skin Cream; Treatment Outcome | 2023 |
Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis.
Topics: Administration, Cutaneous; Aminopyridines; Benzamides; Chronic Disease; Cyclopropanes; Double-Blind Method; Humans; Phosphodiesterase 4 Inhibitors; Psoriasis; Severity of Illness Index; Skin Cream; Treatment Outcome | 2023 |
Refractory Behçet disease succesfully treated with roflumilast.
Topics: Aminopyridines; Behcet Syndrome; Benzamides; Cyclopropanes; Humans | 2023 |
Phosphodiesterase inhibitors and lung diseases.
Topics: Aminopyridines; Humans; Lung Diseases; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive | 2023 |